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ABSTRACT
Assessing the Cost-Effectiveness of Tumor Necrosis Factor Inhibitors and
Prescribing Practices of Rheumatologists in Patients with Rheumatoid Arthritis

Khalid M. Kamal

Three new tumor necrosis factor (TNF) inhibitors, adalimumab, etanercept, and
infliximab, have been approved for use in patients with active RA. The goals of the
study were two fold: 1) to perform a cost-effectiveness analysis of the three TNF
inhibitors in patients with RA that inadequately respond to MTX alone and 2) to assess
the current prescribing patterns, laboratory monitoring practices, and perceived barriers
of rheumatologists in prescribing these agents in patients with RA. Phase I involved
the development of a Markov simulation model to estimate the health effects and costs
associated with five treatment strategies in patients with RA that inadequately respond
to MTX alone: (1) adalimumab plus MTX, (2) etanercept plus MTX, (3) infliximab
plus MTX, (4) leflunomide plus MTX, and (5) standard therapy of MTX. A
hypothetical cohort of 10,000 55-year old women was evaluated using Monte Carlo
simulation. The study was conducted from a societal perspective. The main outcome
measures were net gains in quality-adjusted life expectancy and incremental costeffectiveness ratios, (ICERs) in dollars per quality adjusted life year (QALY) gained.
Costs and effects were discounted at 3%. Etanercept plus MTX was the most costeffective treatment with an ICER of $49,724/QALY. Leflunomide plus MTX was the
second most cost-effective option with an ICER of $52,833/QALY. One-way and
probabilistic sensitivity analyses indicated that the conclusions were relatively stable to
variations in model assumptions. In phase II, a survey was mailed to a randomly
selected national sample of rheumatologists, of which 22.3% responded. The survey
findings indicated that TNF inhibitor use was not restricted to moderate and severe
patients with RA. Also, TNF inhibitor plus one disease modifying anti-rheumatic drug
was the treatment of choice in patients with severe RA that inadequately respond to
MTX alone. Costs to the patient and insurance coverage were perceived as major
barriers in prescribing TNF inhibitors. One-fourth of the rheumatologists reported not
using any monitoring guidelines for the TNF inhibitors indicating a need to revise
monitoring guidelines or perhaps implement new guidelines for TNF inhibitors.
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CHAPTER ONE

INTRODUCTION

Clinical features of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease that
affects joints and other tissues. The disease is characterized by inflammation of
synovial tissues, joint swelling, stiffness and pain, which may progress to joint and
bone erosion. Rheumatoid arthritis generally follows one of three routes of disease
progression: progressive, intermittent, or malignant. Around 70% of cases are
progressive in nature, which follow a chronic pattern with periods of exacerbation and
remission and significant functional limitation. Another 25% of cases are intermittent
in nature and are characterized by brief attacks of inflammation with partial or
complete remissions. The remaining 5% have a malignant form of the disease with
extra-articular manifestations such as vasculitis (Seymour, Worsley, Smith, & Thomas,
2001).

Epidemiology
Rheumatoid arthritis affects around one percent of the adult population
worldwide (Gabriel, 2001) and approximately 2 to 2.5 million people in the United
States (ACR Guidelines, 2002; Griffiths, Bar-Din, MacLean, Sullivan, Herbert, &
Yelin, 2001). The annual incidence of RA diagnosis is about two to four people per
100,000 (Cimino & O’Malley, 1998). Like most rheumatic disorders, the prevalence of
RA is higher in women than men, with a reported female to male ratio of 2.5 to 1. The
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incidence of RA is found to increase with age, with peak occurrence ranging from the
fourth to sixth decade (Terebelo, 2003).

Burden of Illness
Rheumatoid arthritis is associated with pain, deformity, decreased quality of life
and disability; the disease affects patients’ ability to work, and hence, their
socioeconomic status. In addition to causing significant morbidity and mortality, RA
results in substantial medical resource use and costs. The combined direct and indirect
costs resulting from RA in the United States are estimated to be approximately $26 to
$32 billion per year (1998 values; Pugner, Scott, Holmes, & Hieke, 2000). A recent
study by Michaud and colleagues (2003) examined costs of patients with RA after the
introduction of tumor necrosis factor (TNF) inhibitors. A sample of 7,527 patients with
RA responded to semi-annual questionnaires from January 1999 to December 2001.
Direct medical costs were calculated based on physician and other health professional
visits, laboratory tests, radiological examinations, outpatient surgeries, hospitalizations,
and medications. Patients on TNF inhibitors or other RA drugs reported a mean direct
cost of $9,519 (2001 values), where 66% was due to drug costs, 16% due to hospital
costs, and 17% due to outpatient costs. A sub analysis of the mean direct costs revealed
that the direct cost of patients on TNF inhibitors was almost three times higher
($19,016) than those not receiving these agents ($6,164).

Patients with RA have a significantly shorter life expectancy compared with the
general population, with mean life expectancy shortened by seven years in males and
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three years in females (Pinals, 1987). Rheumatoid arthritis frequently leads to work
disability, and the social impact of the disease is profound. Rates of work disability in
the United States and Europe range from 22 to 85% and 31 to 80%, respectively
(Barrett, Scott, Wiles, & Symmons, 2000). Income loss is reported to be 50% for men
and 63% for women and the divorce rate in patients with RA is 70%, higher than that of
the general population (Allaire, Prashker, & Meenan, 1994; Doyle, 2001).

Etiology and Pathophysiology
Despite extensive epidemiologic research, the etiology of RA is poorly
understood. Rheumatoid arthritis appears to be a multi-factorial disease and a number
of risk factors have been postulated in the development or progression of RA. The
familial nature of this disease indicates that genetic factors are important risk factors in
the etiology of this disease (Gabriel, 2001). Other suspected risk factors include
infectious factors such as helicobacter pylori (Zentilin et al., 2002), Epstein Barr virus
(Silman & Pearson, 2002), and environmental factors such as cigarette smoking
(Gabriel, 2001). Sex hormones are also implicated in the etiology of RA as there is an
increased incidence in women (Jobanputra, Barton, Bryan, & Burls, 2002).

Rheumatoid arthritis begins as a synovial microvasculature injury. This is
accompanied by proliferation of inflammatory exudate into the joint cavity. The
synovial fluid in RA is highly cellular and contains lymphocytes, macrophages, T- and
B- cells. The normal joint layer consists of one to two layers of thick fibroblastic-like
cells. In disease, the layer increases to a ten-cell thick layer and forms a pannus that
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actively destroys the periarticular bone and cartilage. Erosions can be seen in x-rays,
which are very useful for diagnosis.

Role of Tumor Necrosis Factor (TNF)
Almost all biological processes involve cytokines. Cytokines are low molecular
weight soluble proteins synthesized by different types of cells that play a key role in the
function and regulation of the immune system. The most prominent cytokines include
interleukins (IL-1α, IL-1β) and TNF- α and β (Toussirot & Wendling, 2004).
Interleukins and TNF play a prominent role in the mechanisms of inflammation and
joint degradation as they can activate different cells in the synovium and can regulate
the cartilage and bone turnover. It has been demonstrated that blocking TNF results in
down regulation of pro-inflammatory cytokines such as IL-1 as well as other cytokines
and angiogenic factors. Thus, TNF plays a pivotal role in the pathogenic mechanisms
of RA and is a major therapeutic target in the disease treatment.

Goals of RA Management
According to the guidelines for the management of RA issued by the American
College of Rheumatology (ACR), the goals of RA treatment is to prevent or control
joint damage, prevent loss of function, and decrease pain (ACR Guidelines, 2002).
Figure 1 depicts the RA treatment algorithm. The long-term treatment plan for RA
requires a comprehensive coordinated care and the expertise of a number of health care
providers. In addition, the care provided has to be reevaluated in light of clinical
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parameters and patient preferences. Clinicians incorporate various factors when
choosing treatment protocols with/for their patients:
a) Therapeutic options including drug and non-drug treatments as well as their risk and
benefits.
b) Modes of drug administration and monitoring for safe use of these drugs.
c) Educational needs of patients and care-givers.
d) Patient co-morbidities that may influence drug use and prognosis. For example, a
number of RA patients have coexisting cardiovascular disease at diagnosis.
e) Drug costs.
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Figure 1. Rheumatoid arthritis treatment algorithm (ACR Guidelines)
Diagnosis and evaluation of patient
with RA

Classification of RA

Mild disease with no disease
progression

Active disease with disease
progression

STEP ONE
1. NSAIDs
2. Low dose corticosteroids
3. Non pharmacologic treatment (rest,
occupational therapy, physical
therapy, use of assisted device)
4. Patient education

No disease
progression,
remission or
satisfactory
response

STEP TWO
Disease Modifying Anti-Rheumatic
Drugs (Monotherapy)
Methotrexate
Leflunomide
Sulfasalazine
Hydrochloroquine
Etanercept
Adalimumab
Anakinra

Disease
progression or
unsatisfactory
response

Continue therapy, monitor
for change in disease
activity

If disease
progression
occurs

Combine Therapy in STEP
ONE & STEP TWO

No disease
progression,
remission or
satisfactory response

DMARD naïve, move to
STEP TWO in algorithm
On current DMARD
therapy, return to STEP
THREE in algorithm

Disease progression
or unsatisfactory
response

STEP THREE
DMARD Therapy – Switch to
combination of methotrexate with
any option in Step two or
infliximab
If inadequate response try another
DMARD or combination with
methotrexate
6

Assessment of Response to Treatments
The ultimate goals of treatment are to prevent or control joint damage, prevent
loss of function, and decrease pain. In short, the goal is complete remission; this may
be somewhat unrealistic in RA. The ACR has developed criteria to define
improvement and clinical remission in RA. The ACR criteria of a 20% clinical
response is defined as a decrease of at least 20% in the number of swollen joints, a
decrease of at least 20% in the number of tender joints, and a 20% improvement in
three of the following five criteria: patients’ global assessment of disease status,
patients’ assessment of pain, health assessment questionnaire estimate of disability,
physicians’ global assessment of disease status, and erythrocyte sedimentation rate
(ESR) or C-reactive protein (CRP) concentration. These criteria have been expanded to
include criteria for a 50% (ACR50) and a 70% (ACR 70) improvement measures (ACR
Guidelines, 2002).

Pharmacotherapy
Pharmacotherapy for active RA may include one or a combination of the
following four classes of drugs: nonsteroidal anti-inflammatory drugs (NSAIDs),
analgesics, corticosteroids (prednisolone and methylprednisolone), and disease
modifying anti-rheumatic drugs (DMARDs) including sulfasalazine, methotrexate, gold
preparations, penicillamine, azathioprine, hydroxychloroquine, leflunomide, and
cyclosporin A, anakinra (interleukin inhibitor), etanercept, infliximab, and adalimumab
(TNF inhibitors).
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The treatment of RA has evolved over the past few years. Four pathways of
drugs for RA have been identified in the literature (Wolfe, Rehman, Lane, & Kremer,
2001):
1) Time-based pyramid: In this approach, NSAIDs are the first line of therapy and
disease modifying anti-rheumatic drugs (DMARDs) are used in the end with caution.
2) Severity-based pyramid: In this approach, the most effective treatment is given to
those with more active disease.
3) Cost-based approach: The primary goal of this approach is to contain cost. Criteria
are established which allow less expensive drugs to be used before more expensive
ones. Additionally, use of some DMARDs and TNF inhibitors are restricted for use in
patients based on severity of the disease. Thus, the severity-based approach is tied with
cost considerations.
4) Patient preference: The treatment is based on the patient’s needs and wishes
regardless of the severity.

Studies in the literature indicate that time-based and severity-based pathways
are no longer used and patients with varying severity and disease duration are treated
aggressively with DMARDs and TNF inhibitors (Wolfe et al., 2001). Modern RA
management stresses the importance of early diagnosis and treatment with DMARDs,
particularly methotrexate (MTX) which is considered to be the “gold standard.”
However, several problems exist with the use of traditional DMARDs. The duration of
treatment is often limited to intervals of less than two years. Patients usually
discontinue the usage of these drugs either due to toxicity or lack of effectiveness. The
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next step in the management is to administer combinations of DMARDs to patients
who do not respond to higher doses of single agents. Combinations include
cyclosporine with MTX or hydroxychloroquine with MTX. If favorable outcomes are
not achieved with these combinations, another DMARD is added to the combination,
e.g. sulfasalazine with hydroxychloroquine and MTX (Kremer, 2001).

A significant number of patients (around 10%) fail to respond to traditional
DMARDs, either alone or in combination (Cairns & Taggart, 2002). These patients
appear to be resistant to conventional approaches including MTX, that is, they have
used at least three DMARDs including MTX (> 15 mg/week) and sulfasalazine (dose >
2 g/day) for a minimum of six months (unless there was toxicity) and have persistent
active disease despite therapy. Thus, it is apparent that further therapeutic advances are
required for better treatment of the disease for those patients who do not respond to
conventional approaches.

The treatment of patients with RA has changed dramatically in the last few
years (Kremer, 2001;Yazici, Erkan, & Paget, 2003). Tumor necrosis factor (TNF) has
become an attractive target for treatment in patients with RA. As a result, three new
TNF inhibitors, adalimumab, etanercept, and infliximab, have been approved for use in
patients with RA that inadequately respond to MTX alone (Hochberg, Tracy, HoltHawkins, & Flores, 2003). Infliximab is given in combination with MTX, while
etanercept and adalimumab are administered either alone or in combination with MTX.
Clinical trials of these drugs have shown that they may be more effective than
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traditional agents because of their ability to alter joint remodeling as well as attenuate
symptoms (Louie, Park, & Yoon, 2003). Leflunomide, a dihydroorotate dehydrogenase
inhibitor, is another addition to the list of DMARDs, which in combination with MTX
has been effective in improving signs and symptoms of patients with inadequate
response to MTX (Kremer, 2001).

Economics of Treatments in Patients with RA that Inadequately Respond to MTX
A systematic literature search was conducted among literature published from
January 1996 to October 2004 through MEDLINE, EMBASE, and the Cochrane library
databases to identify studies that addressed the cost-effectiveness of all three TNF
inhibitors and leflunomide in RA patients with inadequate response to MTX. The
search yielded 14 articles of which nine were published in peer-reviewed journals and
five were abstracts presented at various conferences. A study by Kavanaugh and
colleagues (1996) used a six-month decision model to determine and compare the costs
and effectiveness of three single agents (a hypothetical novel biologic agent, MTX, and
parenteral gold. The authors reported that the total cost of MTX and parenteral gold
were substantially lower than those of the hypothetical biological agent. However,
sensitivity analyses indicated that by increasing the clinical efficacy of the hypothetical
biological agent, total cost decreased due to the accrual of fewer indirect costs. In
another study, which also employed a six-month decision model, triple therapy (a
combination of hydroxychloroquine, sulfasalazine, and MTX) was the least expensive
option and had the lowest incremental cost-effectiveness ratio (ICER) per ACR 20 or
ACR 70 weighted response (US $1,500 and US $3,100, respectively). The most
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efficacious option was the combination of etanercept with MTX with ICERs of
$42,600/ACR 20 response and $34,800/ACR 70 weighted response, respectively (Choi,
Seeger, & Kuntz, 2000). A major limitation of these studies was that early withdrawal
of patients from treatments was not built into the six-month model.

Despite promising short-term results for newer TNF inhibitors, very few
economic studies have addressed the long-term effectiveness of these drugs. A costeffectiveness study employing a Markov Model by Wong and colleagues (2002)
demonstrated that infliximab plus MTX, when compared with MTX alone, decreased
the likelihood of having advanced disability from 23% to 11% at the end of 54 weeks;
this projected to a lifetime marginal cost-effectiveness ratio of $30,500 per discounted
quality-adjusted life-year (QALY) gained. A study conducted in the Netherlands,
which also employed a Markov Model, reported that a treatment strategy starting with
leflunomide followed by TNF inhibitors, in case of non-response with MTX, was the
most cost-effective strategy (Welsing, Severens, Hartman, van Riel, & Laan, 2004).

A UK cost-utility analysis indicated that etanercept was more cost-effective
than infliximab in the treatment of patients who had failed DMARD therapy (Brennan,
Bansback, Conway et al., 2001). A study by Bansback and colleagues (2004) looked at
the cost-utility of adalimumab in treating patients with moderate to severe RA who
have failed at least two traditional DMARDs. The cost per QALY for both
adalimumab and etanercept was estimated to be between 35,000-42,000 euros
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suggesting that adalimumab was at least as cost-effective as the other TNF inhibitors.
These studies are discussed in more detail in Chapter 2.

STATEMENT OF PROBLEM
The management of patients with RA that inadequately respond to MTX alone
has changed markedly with the introduction of TNF inhibitors. These agents have been
shown to decrease pain, joint swelling, inflammatory arthritis, and rates of radiologic
damage. Despite the benefits, these treatments are expensive and the annual cost of
therapy with these drugs is approximately $16,000 (Kavanaugh, Cohen, & Cush, 2004).
Given the chronic nature of RA, the economic costs associated with the disease, and the
high costs of the newer treatments, economic evaluations of the costs and benefits of
these new agents could be very useful for optimal resource allocation. Given the
current financial constraints on health care, the ability to demonstrate cost-effectiveness
of new treatments is a critical factor in determining the acceptability of a new therapy
(Tugwell, 2000).

One of the major concerns about economic studies in RA is the duration for
which a study may be conducted. Most existing economic models determine costeffectiveness over a short period of time, since the duration of most clinical trials in RA
are six months. This ignores the possibility that varying duration of efficacy in
treatments can affect cost-effectiveness over a longer time horizon. Since patients with
RA continue to take medications indefinitely, as long as the medication does not have
any side effects, costs and outcomes continue to accumulate over a longer time horizon.
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Tumor necrosis factor inhibitors have been shown to slow down the radiological
progression of the disease and thereby the downstream economic consequences. Thus,
lifetime models are the most accurate way of estimating the cost-effectiveness of RA
therapy. These lifetime models may also assess the impact of the treatment on the
disease course, which might not be apparent in the short-term.

A few studies are reported in the literature that have conducted economic
evaluations of TNF inhibitors using lifetime models (Brennan, Bansback, Reynolds, &
Conway, 2003; Kobelt, Jonsson, Lindgren, Young, & Eberhardt, 2003; Wong et al.,
2002). These studies have mainly compared one TNF inhibitor with the standard
treatment (MTX) or a placebo. A major limitation of these long-term studies, however,
is that none have looked at the effect of etanercept or infliximab on surgery-related
hospitalizations. Disability represents a major cost-driver in RA treatment and clinical
trials of these drugs have shown evidence of slowing disease progression and
eventually disability (Keystone et al., 2004; Maini et al., 1999; Weinblatt et al., 2003;
Weinblatt, Kremer, Bankhurst et al., 1999).

In the absence of any study evaluating the cost-effectiveness of all three TNF
inhibitors in patients with RA that inadequately respond to MTX alone, there is a need
to assess the impact of these agents on long-term outcomes and on disease and drugrelated morbidity and mortality. Also, it is important to determine the costeffectiveness of these new drugs in order to assess the appropriateness of their use in an
increasingly cost-conscious environment. Thus, Phase I of the proposed study will
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examine the incremental cost-effectiveness of TNF inhibitors (adalimumab, etanercept,
and infliximab) and leflunomide used in combination with MTX modeled over a
lifetime in patients with RA that inadequately respond to MTX alone. The analysis will
be conducted from a societal perspective.

Even though infliximab, etanercept, and adalimumab belong to the same class
of drugs, they have distinct clinical, pharmacokinetic, and pharmacodynamic properties
that must be considered when selecting any one of them for therapy. A number of
factors have been found to affect a physician’s decision-making process regarding
choice of therapy. These include patient preference, the disease itself (for example,
disease duration and symptom severity), the drug chosen (for example, potential
adverse events, cost, and route of administration), and published evidence documenting
the overall experience with each drug (Schwartzman, Fleischmann, & Morgan, 2004;
Schwartzman & Morgan, 2004).

Physicians have been prescribing etanercept and infliximab for over four years.
Although adalimumab has recently been introduced, the experience is greatest with the
use of etanercept and infliximab. However, physicians’ preference for these TNF
inhibitors in patients with RA that inadequately respond to MTX have not been well
studied. Another issue with these drugs is identifying the patient population that should
be treated with TNF inhibitors. In their original labeling, all three TNF inhibitors were
approved for patients with moderate to severely active RA. However, their actual uses
have varied according to local availability, standards of practice, and monitoring
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guidelines (Kavanaugh et al., 2004). It is not known whether rheumatologists are using
these agents very early in the disease course to induce remissions or for patients with
active RA as indicated in the labeling of the three agents. Also, very limited data is
available about the issues physicians confront in the use of these drugs or while making
choices among the three TNF inhibitors. Thus, one of the goals of phase II of the
proposed study is to investigate rheumatologists’ current prescribing patterns for the
three TNF inhibitors.

There are very few data available on these agents’ possible side effects and
there are no well-defined laboratory monitoring guidelines. Since the introduction of
these agents, there have been concerns about the potential for adverse events as a result
of inhibiting TNF. Clinical studies report that the frequency of infections and
lymphomas among patients with RA treated with TNF inhibitors may be higher than in
the general population. Thus, there is a need for routine screening of patients using
these agents (Kavanaugh et al., 2004). However, there are currently no guidelines for
blood tests to monitor patients on these agents. Studies indicate that rheumatologists
using these agents seem to monitor patients based on their experience with DMARDs,
particularly MTX. Also, there is no consensus as to how often the monitoring tests
should be performed (Yazici et al., 2003). Hence, another goal of Phase II of the
proposed study is to determine what laboratory monitoring protocols rheumatologists
are using while administering TNF agents.
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The selection of the most appropriate agent in RA treatment is a complex
clinical decision. The TNF inhibitors have been shown to achieve a marked
improvement in clinical outcomes in patients with RA. However, there are a number of
concerns regarding their use by rheumatologists. These include the potential for
adverse events (such as injection and infusion-site reactions, upper respiratory tract
infections), severe infections, high cost of TNF inhibitors, route of administration, and
patient preference (Fleischmann & Yocum, 2004). Thus, one of the goals of Phase II of
the proposed study is to investigate the different factors that rheumatologists perceive
as problematic in prescribing specific TNF inhibitors for patients with RA.

In summary, Phase I of the proposed study will examine the incremental costeffectiveness of the three TNF inhibitors and leflunomide in combination with MTX in
patients with RA that inadequately respond to MTX alone. In Phase II of the study,
rheumatologists’ current prescribing patterns, laboratory monitoring protocols, and
perceived barriers to prescribing the three TNF inhibitors will be assessed.

CONCEPTUAL FRAMEWORK
This study will be conducted in two phases. Phase I will involve the
construction of an economic model to compare the incremental cost-effectiveness of
the three TNF inhibitors and leflunomide in combination with MTX in patients with
RA that inadequately respond to MTX alone. Phase II will assess the current
prescribing patterns of rheumatologists using TNF inhibitors in treating patients with
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RA. Information on laboratory monitoring practices, frequency of tests ordered, and
perceived barriers of rheumatologists to prescribing these drugs will also be assessed.

Phase I
Phase I involves developing a decision analytic model to compare the total costs
and effects of each of the three TNF inhibitors (etanercept, infliximab, and
adalimumab), and leflunomide used in combination with MTX in patients with RA that
inadequately respond to MTX alone. Economic analysis utilizing decision analytic
models is a comparative analysis of different therapeutic options in terms of their costs,
efficacy, and safety parameters. The end result of this analysis is to summarize the
benefits and harms (both clinical and financial) of the different therapeutic options and
identify those options that deliver maximum benefits in the most cost efficient manner
(Homik & Suarez-Alamor, 2004).

The decision analytic model in the proposed study will assume that a base-case
population of 55 year-old women have already failed at least two DMARDs, one of
which is MTX. The selection of the base-case population is because it is the patient
population that has been studied in the majority of the randomized clinical trials
(RCTs), and is therefore most representative of the patients with RA receiving TNF
inhibitors and leflunomide. Since it is assumed that the patients will inadequately
respond to MTX, the five treatment options to be considered in the analysis will include
combination of each of the three TNF inhibitors (adalimumab, etanercept, infliximab)
with MTX, leflunomide plus MTX and standard therapy of MTX.
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The decision model to be employed in the analysis will be a Markov Model
with six-month cycles. Since the current study involves extrapolating results from
short-term RCTs over a patient’s lifetime to quantify the effects of introducing the
treatments, Markov models are particularly suited to handle both costs and outcomes
simultaneously over chronic time intervals (Briggs & Sculpher, 1998; Sonnenberg &
Beck, 1993). Details on the actual working of Markov models are presented in Chapter
2. In each six-month cycle of the model, the patient will either continue with the
treatment or will withdraw due to severe adverse events or lack of efficacy. In the
event of withdrawal, the patients will be switched to palliative care where they will be
treated with a combination of MTX, NSAIDs, and corticosteroids. The effectiveness
measures will consist of American College of Rheumatology 20% response criteria
(ACR 20). Those who will continue with the treatment may respond to treatment by at
least 20% (ACR 20) or may experience adverse events (mild and moderate) minor
enough to continue with the treatment. Thus, at the end of each cycle, patients will be
redistributed in the model based on the transition rates derived from the RCTs of the
respective treatments. The model will run until all the patients are dead.

Rheumatoid arthritis, like other chronic diseases, has a continuous effect on
several functions over a long period of time and therefore several outcome measures
are used. However, RA-specific outcomes like ACR 20 cannot be used to make
absolute statements about whether a given option is cost-effective compared with other
widely accepted cost-effective interventions in medicine (Choi et al., 2000). Thus, a
generic measure of effectiveness such as quality-adjusted life years (QALYs) will also
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be used in the study. Quality-adjusted life years combines QoL with time by adjusting
life-years with a quality weight, measured as utility. Utilities, to calculate QALYs in
the present study, will be derived from a study by Bansback and colleagues (2004).

A societal perspective will be taken in the estimation of costs in the base-case
analysis. The total cost of treatment with each agent is composed of direct costs
associated with treating patients with RA that inadequately respond to MTX, combined
with the indirect costs (for example, loss of productivity and premature mortality)
incurred by the patient as a result of the disease. Incremental cost-effectiveness ratios
will be calculated as additional cost per patient achieving outcomes, compared with the
next more expensive option.

Phase II
As noted earlier, treatments for RA have evolved over time. Randomized
clinical trials are considered as the “gold standard” for assessing the value of a therapy.
However, the short-term data derived from RCTs may not be applicable to long-term
effectiveness of controlling the disease, especially in a chronic and complex disease
like RA. Long-term observational studies are also used to evaluate therapies but these
require investment in terms of time and money. A third approach, in addition to RCTs
and long-term observation studies, is to survey rheumatologists regarding their opinions
on newer therapies (Wolfe, Albert, & Pincus, 1998).
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Since the TNF inhibitors have recently been introduced in the market, there is
not enough data available regarding their safety and effectiveness. Also, there are no
recommended treatment guidelines available for rheumatologists to consult, while
using these drugs. The selection of etanercept, infliximab, or adalimumab depends on a
number of factors. They have different routes of administration, which can affect a
patient’s preference for the drugs. Safety (severe adverse events, moderate events, and
mild events like injection- and infusion-related reactions) is another factor which
physicians may consider to make their choice. In terms of reimbursement issues,
intravenous (IV) dosing (infliximab) may hold an advantage over subcutaneous (SC)
dosing (etanercept and adalimumab), especially in patients with Medicare coverage.
This information can only be clarified with the availability of more data from a clinical
trial or from evaluation of physician practice experiences.

Phase II of the proposed study will assess the current prescribing patterns of
rheumatologists using TNF inhibitors in treating patients with RA through a national
mail survey. The survey will be useful in providing data on the clinical experiences of
rheumatologists. In addition, information on laboratory monitoring practices,
frequency of tests ordered, and perceived barriers of rheumatologists in prescribing
TNF inhibitors will also be collected.

STUDY GOALS AND RESEARCH QUESTIONS
The goals of the study are two fold: 1) to conduct an incremental costeffectiveness analysis of TNF inhibitors (adalimumab, etanercept, and infliximab) and
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leflunomide used in combination with MTX in the treatment of patients with RA that
inadequately respond to MTX alone using a Markov simulation model, and 2) to assess
the current prescribing patterns, laboratory monitoring practices, and perceived barriers
of rheumatologists in prescribing TNF inhibitors in patients with RA

Phase I
Phase I will involve the development of a Markov simulation model to calculate
the incremental cost-effectiveness ratios of TNF inhibitors (adalimumab, etanercept,
and infliximab) and leflunomide used in combination with MTX in the treatment of
patients with RA that inadequately respond to MTX alone

Objectives for Phase I:
Objective 1: To develop a Markov simulation model to assess the long-term costs and
consequences of TNF inhibitors (adalimumab, etanercept, and infliximab) and
leflunomide used in combination with MTX in the treatment of patients with RA that
inadequately respond to MTX alone
Rationale: Decision analysis modeling is a powerful simulation technique and is being
increasingly used to assess the economic outcomes of new drugs. Decision analysis
modeling can be an inexpensive and effective way of synthesizing existing data and
evidence available on costs and outcomes of alternative treatments, and can be used to
extrapolate beyond the follow-up period of a clinical trial, or from an intermediate
outcome to a final health outcome (Brennan & Akehurst, 2000). These analytic models
can assist decision makers until more definitive information is made available about
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outcomes and costs in actual clinical settings. Rheumatoid arthritis is a chronic,
debilitating, and lifelong disease and any decision analytic model developed to evaluate
the cost-effectiveness of the new drugs needs to take into account the lifetime costs of
the therapies. Decision tree models are not appropriate since they report the outcomes
over one to two-year time frame. Also, there is a limit to the manageable size of the
decision tree. Markov models overcome this hurdle and provide a better way of
simulating the progression of RA over time and the possible impact of treatments.

Objective 2: To develop cost-effectiveness models based on the Markov simulation
model that determine the incremental costs and consequences of TNF inhibitors
(adalimumab, etanercept, and infliximab) and leflunomide used in combination with
MTX in the treatment of patients with RA that inadequately respond to MTX alone
Rationale: When considering a drug therapy for RA, several factors appear to be
predictive of positive cost-effectiveness. Disability is a major determinant of expense
in RA and any drug that slows joint destruction and thus delays the onset of disability
has the potential to be cost-effective. Another determinant of RA expense is the cost
associated with treating drug-related adverse events. Thus, a drug with good safety
profile will probably be more cost-effective than a drug with similar efficacy but
causing more side effects. Finally, RA being a chronic disease, the longer the drug
remains effective and tolerable, the more likely it will be cost-effective (Tugwell,
2000).
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The introduction of TNF inhibitors (adalimumab, etanercept, and infliximab)
represents a significant advance in the available treatments for patients with RA. These
agents have demonstrated good efficacy and tolerability in clinical trials (Keystone et.
al., 2004; Kremer et. al., 2002; Maini et. al., 1999; Weinblatt et al., 2003; Weinblatt et.
al., 1999). These agents have also been shown to be more effective than traditional
agents because of their ability to slow disease progression and to improve disability
scores. While all these attributes suggest that these agents will be cost-effective, only
appropriate analyses that examine both efficacy and total costs can provide a true
assessment of cost-effectiveness (Tugwell, 2000).

A few studies have been conducted to evaluate the cost-effectiveness of these
agents. A study by Choi and colleagues (2000) that used a six-month decision model
failed to account for early withdrawals by patients who did not respond to the
treatments. Similarly, two studies that used long-term models, let non-responders stay
on treatment for one full year (Kobelt et al., 2003; Wong et al., 2002). Neglecting to
incorporate early withdrawals potentially biases the results because patients that fail to
respond to treatment will show little gain in health improvement but will continue to
accrue large costs associated with one-year treatment with TNF inhibitors. In addition,
most of the studies failed to include the decrease in future risk of disability, which
could improve the cost-effectiveness of treatments. Conversely, the adverse effects of
TNF inhibitors (including high risk of serious infections), which may increase health
care costs, were not included in most analyses. Simply demonstrating the efficacy of a
treatment does not necessarily establish its economic benefits. Economic evaluation of
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the TNF inhibitors should include their ability to prevent disability and safety profiles,
and should be conducted over a patient’s lifetime thereby determining the true costeffectiveness of these agents.

Phase II
The primary goal of phase II will be to assess rheumatologists’ current
prescribing patterns for the three TNF inhibitors. Secondary goals will include
determining rheumatologists’ laboratory monitoring practices, practice of switching
patient from one TNF inhibitor to another TNF inhibitor, and identifying perceived
barriers to prescribing these drugs.
The specific objectives are as follows:

Objectives for Phase II:
Objective 1: To describe rheumatologists’ prescribing patterns for the three TNF
inhibitors: adalimumab, etanercept, and infliximab.
Rationale: Recent surveys have shown that combinations of DMARDs are preferred in
practice especially to treat patients with moderate or severe RA (Jobanputra, Wilson,
Douglas, & Burls, 2004; Maetzel, Bombardier, Strand, Tugwell, & Wells, 1998; Pope,
Hong, & Koehler, 2002). With the introduction of new TNF inhibitors, it is important
to investigate the current prescribing patterns of rheumatologists. The labeling of these
drugs indicates their use in moderate to severe patients. But whether these drugs are
being prescribed as first-line therapy in RA alone or used in conjunction with other
traditional DMARDs is not known.
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An indirect comparison of the three TNF inhibitors by Hochberg and colleagues
(2003) indicated similar efficacies in RA. Thus, a reasonable question for clinicians is
whether patients who have failed one TNF inhibitor could be given a trial with another
TNF inhibitor. A few studies conducted in rheumatology clinics have reported
switching patients from one TNF inhibitor to another TNF inhibitor, but it is not known
if rheumatologists in different practice settings are doing the same and their reasons for
switching patients from one TNF inhibitor to another TNF inhibitor (Haraoui, 2004;
Yazici & Erkan, 2004).

Objective 2: To determine if the rheumatologists have any preference for a particular
TNF inhibitor.
Null Hypothesis A: Rheumatologists do not have any preference for any of the TNF
inhibitors.

Objective 3: To assess if there are any differences in demographic (age, gender) and
practice-related characteristics (number of years in practice as a rheumatologist,
primary practice site, average number of RA patients seen per week) and perceived
barriers in prescribing TNF inhibitors among rheumatologists who prefer adalimumab,
etanercept, or infliximab as their first choice agent.
Null Hypothesis B: There are no significant differences in demographic (age, gender),
practice-related characteristics (number of years in practice as a rheumatologist,
primary practice site, average number of RA patients seen per week), and perceived
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barriers in prescribing TNF inhibitors among rheumatologists who prefer adalimumab,
etanercept, or infliximab as their first choice agent.

Objective 4: To describe the laboratory monitoring practices and the frequency of tests
ordered by the rheumatologists for patients on TNF inhibitors.
Rationale: There are no known monitoring guidelines established for TNF inhibitors.
There are a number of reports on the safety profile of these agents and at the same time
a dearth of information regarding their long-term outcomes. According to the only
study conducted to find whether or not rheumatologists follow monitoring guidelines,
results indicated that rheumatologists seem to continue their practice of monitoring
based on their experience with earlier traditional DMARDs. However, there seems to
be a significant variation in laboratory tests ordered, and the frequency of ordering
these tests (Yazici et al., 2003). This research question is a follow-up on this study to
determine if the practice is the same or has changed over the years.

Objective 5: To determine if the rheumatologists are following any recommended
monitoring guidelines for patients with RA on adalimumab, etanercept, and infliximab.
Null Hypothesis C: Rheumatologists are not following any recommended monitoring
guidelines for patients with RA on adalimumab, etanercept, and infliximab.

Objective 6: To assess if there are any differences in demographic (age, gender) and
practice-related characteristics (number of years in practice as a rheumatologist,
primary practice site, average number of RA patients seen per week) and perceived
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barriers in prescribing TNF inhibitors between rheumatologists who follow monitoring
guidelines and those who do not follow any guidelines.
Null Hypothesis D: There are no significant differences in demographic (age, gender)
and practice-related characteristics (number of years in practice as a rheumatologist,
primary practice site, average number of RA patients seen per week) and perceived
barriers in prescribing TNF inhibitors between rheumatologist’s who follow guidelines
and those who do not follow any guidelines.

Objective 7: To assess if there are any differences in rheumatologists’ perceptions of
barriers (insurance coverage, route of administration, patient compliance, patient
preference, side effects, costs to the patient, age of the patient, efficacy of the drugs,
and support needed for administration of drugs) to prescribing the three TNF inhibitors.
Null Hypothesis E: There are no significant differences in rheumatologists’ perceptions
of barriers (insurance coverage, route of administration, patient compliance, side
effects, costs to the patient, age of the patient, efficacy of the drugs, and support needed
for administration of drugs) to prescribing the three TNF inhibitors.

SIGNIFICANCE OF THE STUDY
Recent therapeutic advances in the treatment of RA have demonstrated
improvement in inflammatory arthritis and stabilization of radiographic progression,
but these new therapies are expensive due to high acquisition costs, potential toxicity,
and associated monitoring. The costs of not treating RA are also very high due to
increased medical and long-term costs associated with uncontrolled disease. The cost-
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effectiveness of TNF inhibitors is presently unclear. The results of Phase I of the study
can help determine if etanercept, infliximab, adalimumab, or leflunomide used in
combination with MTX in patients with RA that inadequately respond to MTX alone is
cost-effective or not. The TNF inhibitors have been shown to prevent and delay
disability. At the same time, they have also been shown to cause serious adverse
events. The results of the study may also determine if the reductions in nondrug costs
can help offset the high acquisition costs of these agents and the high health care costs
due to higher risk of infections.

However, as discussed earlier, the choice of an optimal agent by a
rheumatologist is based not only on cost but also on accumulated clinical experience,
patient preference, convenience, route of administration, and safety profile of a drug.
The most widely accepted and used guidelines are for MTX and published by the ACR.
For the newer TNF inhibitors, risks exist and infections, neoplasms, and autoimmune
disorders have been reported in patients using these agents. It is important that drug
toxicity is discovered as early as possible by appropriate laboratory monitoring before
serious events become clinically evident. Currently, very little information exists with
regards to the rheumatologists’ prescribing patterns for TNF inhibitors, laboratory
monitoring protocols, and their perceived barriers in prescribing these agents.
Consequently, Phase II of the study was developed to study rheumatologists’ use of the
TNF inhibitors. Results of phase II study will help provide valuable insight into the
prescribing patterns of rheumatologists using these agents for treatment of patients with
RA.
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STUDY LIMITATIONS

The limitations of each phase of the study are discussed below:
The main limitation of Phase I of the study relates to the data available. An
ideal source would have been a very long-term, randomized study with a large sample
size examining the efficacy and resources utilized by all the therapeutic options in RA
patients who have inadequate response to MTX. In the absence of such a study,
evidence has to be assembled from a range of sources and these sources have their
advantages and disadvantages from a health economic perspective. Data from clinical
trials do not have high external validity. In addition, data on actual use of etanercept,
infliximab, and adalimumab are not yet available. Thus, the results of any modeling
study need to be treated with some degree of caution.

Another limitation in Phase I is that the base-case analysis in the decision
analytic model assumes that the baseline characteristics of the study patients across the
source RCTs are comparable based on their close similarities in important baseline
demographic and clinical characteristics. It is a general view that absolute
comparability across different treatments can be established through randomization.
Currently, such data does not exist and it appears doubtful that all the treatment options
considered in the analysis would be evaluated using a single head-to-head randomized
controlled clinical trial in the near future.
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The efficacy data for each treatment option (except for adalimumab plus MTX)
comes from a single respective RCT. Therefore, there will be generalizability issues
with the base-case estimate used in the Phase I of the study. However, sensitivity
analyses will be conducted to address this limitation.

As discussed in the introduction, the significant portion of health services costs
incurred by RA patients is due to surgery-related hospital admissions. It is possible that
effective disease control with more effective therapy could prevent or reduce hospital
admissions. A study by Yelin and Wanke (1999) reported that almost 52% of the direct
costs of RA was due to hospital admissions, of which 95.2% came from surgical
admissions. The authors also reported that functional status measured by Health
Assessment Questionnaire (HAQ) disability score was the only consistent and strong
predictor for the total direct costs. The surgery-related costs for each treatment strategy
was calculated based on an exponential relationship between HAQ score reported from
clinical trials and inpatient surgery costs used by Choi and colleagues (2000).
However, since the data may not be reliable, the study will report results both by
including and excluding surgery-related costs in the model.

The three TNF inhibitors and leflunomide have different modes of
administration. However, the potential impact of compliance was not considered in the
model. No data is available indicating differing rates of compliance among the
different TNF inhibitors and leflunomide in patients with RA.
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In RA, indirect costs can be divided into morbidity costs (lost production) and
mortality costs (present value of lost production due to premature death). In the present
study, indirect cost was estimated as being one to three fold higher than direct costs,
which may limit its accuracy.

Phase II of the study will use a mail survey to elicit current treatment practices
of rheumatologists. The study therefore will have all the limitations associated with
cross-sectional survey design methodology.

This chapter gave a brief description of underlying health problem, the need for
the study, the research questions, the significance and the limitations of the study. The
next chapter will give an extensive review of the existing literature associated with RA
and TNF inhibitors.
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CHAPTER TWO

REVIEW OF LITERATURE
The first section of this chapter will describe the techniques of economic
evaluation and will provide an overview of the use of Markov models in performing
these evaluations. A review of the clinical effectiveness and available
pharmacoeconomic evaluations of tumor necrosis factor inhibitors and leflunomide in
RA patients that inadequately respond to MTX alone will be discussed next. Finally,
studies investigating rheumatologists’ prescribing patterns for specific TNF inhibitors
and their use of monitoring protocols will be reviewed.

Types of Economic Analyses
Rheumatoid arthritis (RA) is a chronic systemic disorder and is associated with
pain, functional limitations, physical disability, and decreased QoL (Blumenauer,
Coyle, & Tugwell, 2002). As a chronic debilitating disease with a progressive course,
RA has an economic impact that is disproportional to its prevalence. Several studies
have been conducted to quantify the economic costs of interventions that delay or
prevent disability and reduce the associated morbidity and mortality in RA. However,
these studies need to include both costs and the consequences to establish the economic
benefit of the therapy.

Studies that consider both costs and consequences are termed as “full’ economic
evaluation and include cost-benefit analyses, cost-effectiveness analyses, and cost-
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utility analyses. These studies consider the total direct, indirect, and intangible costs.
Direct costs include physician services, hospitalizations, medication costs, diagnostic
procedures (laboratory and radiological costs), costs of treating of adverse events,
patient and caregiver time, and rehabilitation and nursing care. Indirect costs include
loss of income due to loss of workdays or loss of employment, house-remodeling costs,
and the intangible costs of impact on social life, pain, deformity, and decreased QoL
(Blumenauer et al., 2002; Drummond, O’Brien, Stoddart, & Torrance, 1998; Emery,
2004; Homik & Suarez-Almazor, 2004).

Cost-benefit analyses express both costs and consequences in monetary terms.
These methods are less commonly used, as they require the consequences of the
treatment to be expressed in dollar terms. The most commonly used economic
evaluations in RA are cost-effectiveness and cost-utility analyses. Cost-effectiveness
analyses measure costs in terms of a defined measure of a clinical outcome; cost-utility
analyses measure costs in relation to an outcome, and take QoL into consideration (e.g.
Quality adjusted life years or QALYs). These types of analyses are more appropriate
since they not only include the total costs of the therapy but also the costs of the disease
process. Patients with active RA may have major disabilities resulting in loss of
workdays, decreased QoL, and other outcomes; cost-effectiveness analyses account for
such non-health expenditures (Drummond et al., 1998; Emery, 2004; Homik & SuarezAlmazor, 2004).
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As opposed to full economic evaluations, “partial” economic evaluations
consider only the cost of intervention (direct and indirect) and not the outcome (clinical
effectiveness or economic benefit) of the intervention (Drummond et al., 1998; Emery,
2004; Homik & Suarez-Almazor, 2004). Cost analyses are considered as partial
economic evaluations and are useful in evaluating the impact of drugs with similar
efficacies. However, cost analyses of the TNF inhibitors against the traditional
DMARDs might not favor the TNF inhibitors due to their high acquisition costs
(Lipsky & Kavanaugh, 1999). A full economic evaluation of TNF inhibitors and
traditional DMARDs, on the other hand, may indicate TNF inhibitors to be costeffective since these evaluations take into account the downstream economic savings
(e.g., surgery-related hospitalizations) that might offset the high acquisition costs of
TNF inhibitors. Thus, cost-effectiveness and cost-utility studies are the most
appropriate studies in evaluating the impact of TNF inhibitors in RA.

Markov Model
One key issue when performing cost-effectiveness analyses of new treatments
in chronic conditions like RA is that the randomized clinical trials to date are for short
time periods compared to the lifetime duration of the disease. Also, clinical trials
exhibit modest external validity due to exclusion of certain age groups or comorbidities
and protocol driven costs (Brennan & Akehurst, 2000). Observation studies may
provide useful data. However, there is limited data available on the use of new
treatments in clinical practice (Moots, Taggart, & Walker, 2003).
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One approach in performing economic analyses is to apply modeling techniques
to available data. Economic modeling can be an inexpensive and effective way of
synthesizing existing data and evidence available on costs and outcomes of alternative
treatments, and can be used to extrapolate beyond the follow-up of a trial or from an
intermediate to a final health outcome (Brennan & Akehurst, 2000). A number of
decision models such as decision trees and Markov models have been reported in the
literature for conducting cost-effectiveness analyses of TNF inhibitors. The following
is a brief description providing a rationale for choosing a Markov model over a decision
tree in the proposed study.

The decision tree is the simplest structure used to represent possible patient
treatment pathways. These pathways can be modeled using probabilities of events and
relevant outcome measures. Decision trees are usually employed when the time frame
of the model is short and there is no difference in mortality across treatment strategies.
This, however, ignores the possibility that varying duration of efficacy in treatments
can affect cost-effectiveness over a longer time horizon. Rheumatoid arthritis is a
chronic, debilitating, and lifelong disease and patients with RA continue to take
medications indefinitely as long as the medication does not have any side effects.
Thus, costs and outcomes continue to accumulate over a long time horizon and any
decision model developed to evaluate the cost-effectiveness of the new drugs need to
take into account the lifetime costs of the therapies (Emery, 2004). If a decision tree
model is used to report the outcomes over a very long period of time, the tree structure
may become unmanageable; with the presence of repetitive outcomes, the structure of
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the decision tree can get complicated. A Markov model overcomes this hurdle by
allowing incorporation of time-dependent events.

Markov models are used in decision analysis to represent stochastic processes,
which evolve over time (Briggs & Sculpher, 1998; Sonnenberg & Beck, 1993). As a
result, they are particularly suited to modeling chronic diseases. The disease in
question is divided into a finite number of health states usually defined by the severity
of the disease. The individual is assumed to be in any one of the health states referred
to as Markov states. All events are then considered as transitions of individuals from
one health state to another. The time horizon in Markov models is divided into equal
increments of time, referred to as Markov cycles, and the length of the cycles are
chosen to represent a clinically meaningful time interval.

During each cycle of the model, transitions are assumed to take place and the
net probability of making a transition from one state to another during one cycle is
called a transition probability. It is assumed that a patient in a given state can make
only a single state transition during a cycle. A patient may remain in one state for a
number of cycles or may transition to a different state. There are states in the Markov
model from which it is impossible for patients to leave; these are called absorbing
states. The most common example of an absorbing state is death.

An important limitation of the Markov model is that the probability of moving
out of the state is not dependent on the state or states a patient may have experienced
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before entering the current state. In other words, a Markov state does not depend on
history. This is often referred to as the ‘Markovian assumption’ and it can be
accounted for by using a combination of distinct states or time-dependent transition
probabilities (Briggs & Sculpher, 1998; Sonnenberg & Beck, 1993).

Markov models are categorized into two different types of models based on
whether the state transition probabilities are constant over time or not. Markov chains
are models in which the transition probabilities are constant over time. Markov models
where transition probabilities vary with time are called time-dependent Markov
processes and are more flexible in modeling a chronic disease.

In order to complete a Markov model, it is important to attach weights to the
model for costs and consequences to be estimated. For example, the calculation of
QALYs or costs over the lifetime of the model will involve weighting the length of
time spent in a particular health state by a value representing either QoL experienced in
that state or the costs incurred in that state. A QALY is an effectiveness measure that
includes both quantity and QoL, by assigning a “utility” weight to life-years.

In economic analyses, utility refers to preferences which individuals or society
place on particular health outcomes and is measured on a scale between zero (dead) and
one (perfect health). Utility can be elicited directly by using techniques such as
standard gamble, time trade-off, and rating scale or can be elicited indirectly by using
questionnaires such as EuroQol (EQ-5D) or the Health Utility Index (HUI-2, HUI-3)
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(Bansback et al., 2005). By running the model over a number of cycles, a QALY score
or total costs can be calculated. However, there are two types of adjustments to costs
and consequences that have to be considered: discounting and a half-cycle correction.

It is a standard practice to adjust costs and consequences for differential timing
by applying a discount rate of three percent based on the recommendation of the “Panel
on Cost-effectiveness in Health and Medicine” which was convened by the United
States Public Health Service (Gold, Russell, Siegel, & Weinstein, 1996). Discounting
allows comparison of costs and consequences in terms of net present value. That is,
discounting costs and effects captures the economic theory that people prefer to
consume more goods in the present than in the future. This notion of time preference
could significantly affect cost-effectiveness ratios, especially given the disability and
time path of disease associated with RA (Bansback et al., 2005). Markov models
assume that transition occurs between cycles and that patient membership is constant
for the duration of the cycle. However, in reality, patients are moving between
different phases of the disease continuously. Thus, instead of assuming that patients
transition between states at the end of the cycle, a half-cycle correction is employed.
The half-cycle correction is based on the assumption that, on average, patients will
transition between states half way through the cycle.

To evaluate a Markov model, matrix algebra is used as a cohort simulation or as
a first order Monte Carlo simulation. Cohort simulation considers a hypothetical cohort
of patients all beginning the process in the initial disease state at time zero, or with
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some distributions between the model states. At each cycle, based on the appropriate
transition probabilities, distribution of patients in each state of the Markov model is
adjusted. By running the model for many cycles, one can predict the number of
patients in each state of the model over time. As discussed earlier, weights based on
QALYs and costs are attached to different states for each cycle. Summing the cycle
QALYs and costs across all cycles of the model gives QALYs and cost estimates for
the overall cohort of patients.

Unlike cohort simulation, in first order Monte Carlo simulation, a large number
of patients are followed through the model individually. The transition probabilities for
cohort simulation and individual patients are the same but since an individual patient
can be in only one state at a given time, s/he may or may not transit between states in
any given cycle. Hence, the path of individual patients will differ based on random
variation. Thus, the sum of results of n simulations of the individual patients through
the model will give estimates for costs and outcomes of the model (Briggs & Sculpher,
1998; Sonnenberg & Beck, 1993). Although mean costs and outcomes obtained in a
first order Monte Carlo simulation will be similar to those obtained by cohort
simulation, an advantage of Monte Carlo simulation is that estimates of variance may
also be determined generating a degree of uncertainty associated with the derived costs
and outcomes.

Markov models for Rheumatoid Arthritis
Two studies have used Markov models to study the progression of RA. Kobelt
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and colleagues (2002) used a Markov simulation model to assess the cost-effectiveness
of treatments that affect progression of RA. Hypothetical treatment interventions were
simulated to illustrate the model. Costs were calculated from data of resource
utilization and patients’ work capacity while utilities were assessed using the EuroQol
instrument. The authors concluded that the model was a valuable tool in assessing the
cost-effectiveness of different interventions in RA. A similar study used decision
modeling and Markov methods to model treatment strategies for patients with RA
(Albert, Aksentijevich, Hurst, Fries, & Wolfe, 2000). Only traditional DMARDs were
compared for their effectiveness. MTX was found to be superior to other DMARDs.
The authors agreed that Markov analysis generated a more realistic appraisal of the
outcome of the drugs as compared to standard decision tree analysis.

Effectiveness of TNF Inhibitors (adalimumab, etanercept, and infliximab) and
leflunomide
Among the traditional DMARDs used to treat RA, MTX has increasingly
become the treatment of choice because of its early onset of action and superior
efficacy and tolerability (Weinblatt et al., 2003; Weinblatt et al., 1999). Even though
MTX has been found to be effective in RA, many patients continue to have persistent
disease and experience less than 50% improvement despite receiving therapeutic doses
of MTX. To increase the clinical response in such patients, rheumatologists frequently
add another DMARD (Kremer, 2001). A number of studies have reported the clinical
efficacy of new agents such as adalimumab, etanercept, infliximab, and leflunomide in
combination with MTX.
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Adalimumab
Two double blind RCTs investigating the clinical efficacy of adalimumab in
patients with RA and an inadequate response to MTX have been published (Keystone
et al. 2004; Weinblatt et al., 2003). A 24-week, randomized, double-blind, placebocontrolled study (ARMADA Trial: Anti-TNF Research Study Program of the
Monoclonal Antibody [D2E7] in Patients with RA) involved 271 patients with active
RA (Weinblatt et al., 2003). The primary efficacy end point was the ACR criteria for
20% improvement (ACR 20) at 24 weeks. Secondary efficacy endpoints were ACR 50
and ACR 70 response rates. The patients were randomized to one of the four treatment
groups, adalimumab 20 mg (n=69), 40 mg (n=67), or 80 mg (n=73) or placebo (n=62)
administered as a SC injection every other week. The patients continued to take their
long-term stable dosage of MTX (12.5-25 mg). An ACR 20 response at week 24 was
achieved by a significantly greater proportion of patients in 20 mg (47.8%), 40 mg
(67.2%), and 80 mg (65.8%) than in placebo plus MTX group (14.5%, p< .001). ACR
50 response rates with all three doses of adalimumab and ACR 70 response rates with
40 and 80 mg of adalimumab were significantly greater than placebo (Weinblatt et al.,
2003).

A second study by Keystone and colleagues (2004) was a multicenter, 52-week,
double-blind, placebo-controlled study involving 619 patients with active RA with an
inadequate response to MTX. Patients were randomized to receive adalimumab 20 mg
SC every week (n=212), 40 mg SC every other week (n=207), or placebo (n=200) plus
concomitant MTX (12.5-25 mg). Adalimumab (20 mg and 40 mg) was more effective

41

than placebo at inhibiting the progression of structural joint damage (p< 0.001). At
week 24 and 52, patients receiving 40 mg of adalimumab achieved ACR 20 response
rates of 65% and 59%, respectively, versus 30% and 24% in the placebo group. Also,
there was an improvement in physical function in patients receiving adalimumab.
Discontinuations were lower in the adalimumab group (22%) compared with placebo
group (30%). However, proportion of patients reporting serious infections was higher
in adalimumab (3.8%) compared to placebo (0.5%).

Etanercept
Three clinical studies support the efficacy of etanercept in patients with RA
with an inadequate response to MTX. In a 24-week, double-blind study, Weinblatt and
colleagues (1999) randomly assigned 89 patients to placebo or etanercept (25 mg SC
twice a week) plus concomitant MTX. At week 24, an ACR 20 response was achieved
by a significantly greater proportion of patients taking etanercept 25 mg (71%) than in
the placebo plus MTX group (14.5%; p< .001). Also, the intervention group achieved
ACR 50 and 70 response rates of 39% and 15%, respectively, compared with 3% and
0%, respectively, for the placebo group. All measures of disease activity were
significantly improved in the etanercept group, and the only adverse events associated
with this therapy were injection-site reaction.

In another double-blind, randomized trial (TEMPO: Trial of Etanercept and
Methotrexate with radiographic Outcomes) 686 patients were randomly allocated to
receive etanercept (25 mg SC twice a week), MTX (up to 20 mg every week) or a
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combination of etanercept and MTX (Klareskog et al., 2004). The combination of
etanercept and MTX was significantly better in reduction of disease activity,
improvement in functional disability, and inhibition of radiographic progression
compared with MTX and etanercept alone. The number of patients reporting infections
or adverse events was similar in all groups.

Lan and colleagues (2004) evaluated etanercept 25 mg given SC twice a week
in patients with active RA who were maintained on MTX therapy (12.5-20 mg per
week). Patients were randomized in the 12-week, double-blind study to receive
etanercept (n=29) or placebo (n=29). Results for the overall improvement in disease
activity assessed by ACR 20 (90% vs. 34%), ACR 50 (66% vs. 10%), and ACR 70
(24% vs. 0%) all favored the etanercept plus MTX group. The number of patients
reporting adverse events was comparable between the two treatments.

Infliximab
The efficacy of infliximab was studied using a large multi-center, doubleblinded, placebo-controlled trial (ATTRACT: Anti-Tumor Necrosis Factor Trial)
involving 428 patients with active RA not responding to MTX therapy (Maini et al.,
1999). Patients were randomized to receive infliximab (3mg/kg or 10 mg/kg) or
placebo every four to eight weeks, in addition to a stable dose of MTX (15 mg per
week). After 30 weeks of therapy, 50% of patients treated with infliximab plus MTX
(3mg/kg every eight weeks) achieved the ACR 20 response criteria compared with 20%
of patients receiving placebo IV injections (p<0.001). Clinical response was rapid and
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over half the responders attained 20% improvement by the second week of follow-up.
Headaches and upper respiratory tract infections were the most frequently reported
adverse events, and infusion reaction was seen in 16-20% of the patients receiving
infliximab plus MTX compared with placebo (10%).

The patients in the ATTRACT trial were followed for 54 weeks to determine
the effect of infliximab and MTX on radiographic progression of the disease (Lipsky et
al., 2000). Results of the study indicated that the combination provided sustained
clinical benefit and halted the progression of joint damage not only in patients with
limited joint damage, but also in those with extensive damage. The combination was
also well tolerated and safe.

Leflunomide
The combination of leflunomide and MTX was studied in a 30-patient openlabel study (Weinblatt, Kremer, Coblyn, et al., 1999). Patients reported an ACR 20
response rate of 56% and ACR 50 response rate of 36%. These responses were
sustained at week 48. The leflunomide plus MTX combination was well tolerated
although an increase in hepatic enzymes was observed.

The results of the open label study were confirmed in a randomized, doubleblind placebo-controlled study (Kremer et al., 2002). Addition of leflunomide to MTX
provided substantial therapeutic benefit compared with adding placebo and it was
generally well tolerated. Following this study, additional information on efficacy and
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safety data on the combination drug was gathered using a 24-week open-label extension
study. Response to therapy was maintained through 48 weeks of treatment in patients
who continued on leflunomide and MTX during the extension. ACR 20 response rates
after 24 weeks of leflunomide therapy were similar between patients switched from
placebo to leflunomide.

In summary, these agents have been proven to be effective and safe in
appropriate and well-conducted clinical trials. In addition, the combination of
adalimumab, etanercept, infliximab, or leflunomide with MTX have been shown to be
better in reducing disease activity, improving functional disability, and inhibiting
radiographic progression. Only one observational study has been reported comparing a
combination of TNF inhibitor plus MTX with TNF inhibitor alone or MTX alone.
Analysis of the Stockholm TNF-α Follow-Up Registry (STURE) data showed that
patients receiving combination of etanercept and MTX had better outcomes compared
with those patients receiving etanercept alone, thereby indicating that for patients
receiving etanercept as monotherapy and having only partially satisfactory responses,
adding MTX might give additional benefits (van Vollenhoven, Ernestam, Harju, and
Klareskog, 2003).

Economics of TNF Inhibitors (adalimumab, etanercept, and infliximab) and
leflunomide
Cost analyses
A study by Nuijten and colleagues (2001) conducted in the Netherlands
estimated the total cost of etanercept therapy to be lower than those of infliximab (US
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$12,648 vs. US $18,046, respectively). The efficacy of the two drugs was assumed to
be equivalent. The difference in the cost was mainly due to the additional costs of
administration of infliximab in outpatient clinics and concomitant use of MTX although
the annual drug costs was similar for both the drugs NLG 31,334 (US $12,534) for
etanercept and NLG 31,526 (US $12,610) for infliximab. As discussed earlier, this
type of analysis is a partial evaluation and ignores the long-term outcomes.

Cost-effectiveness studies: Short-term studies
In the Cost Evaluation of Novel Therapeutics in Rheumatoid Arthritis
(CENTRA) study, a six-month decision tree model was designed to determine and
compare the costs and effectiveness of three single agents (a hypothetical novel
biologic agent, MTX, and parenteral gold) for the treatment of patients with established
RA (Kavanaugh et al., 1996). Both direct costs of treating RA and indirect costs
incurred by patients as a result of the disease were included in the evaluation. The
authors reported that the total costs of MTX and parenteral gold were substantially
lower than those of the hypothetical biological agent. However, sensitivity analyses
indicated that by increasing the clinical efficacy of the hypothetical biological agent,
total costs decreased due to the accrual of fewer indirect costs.

Another study by Choi and colleagues (2000) assessed the relative costeffectiveness of six different treatment options for patients with RA in whom MTX
therapy had failed: etanercept monotherapy, etanercept plus MTX, cyclosporine plus
MTX, triple therapy with hydroxychloroquine, sulfasalazine and MTX, continued MTX
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monotherapy, and no second-line therapy. A decision tree model with a time horizon
of six months was used and an incremental cost-effectiveness ratio (ICER) for
achieving ACR 20 and 70 responses were calculated. Etanercept plus MTX, the most
efficacious therapy, had a higher incremental cost compared with MTX therapy. Triple
therapy had the lowest ICER per ACR 20 or ACR 70 response (US $1,500 and US
$3,100, respectively). The next less costly and more effective treatment option,
etanercept plus MTX, was the most effective. The ICER was estimated to be US
$42,600 and US $34,800, respectively. A limitation of this study was that it did not
account for patients withdrawing from the treatments. As mentioned earlier, neglecting
to incorporate early withdrawals could potentially bias the results.

Two studies evaluated the cost-effectiveness of TNF inhibitors with and without
concomitant MTX using ACR response criteria (ACR 20 and ACR 50) as the endpoint
over one year. The first study evaluated the cost-effectiveness of etanercept and
adalimumab with and without concomitant MTX in RA patients. Etanercept was found
to be more cost-effective than adalimumab. The cost per patient achieving ACR 20 and
ACR 50 response criteria for etanercept monotherapy (25mg twice weekly) was US
$29,369 and US $43,319, respectively, and for adalimumab (40 mg once every other
week) US $40,672 and US $78,643, respectively. The cost per patient achieving ACR
20 and ACR 50 response criteria for etanercept plus MTX was US $26,167 and US
$47,636, respectively; and adalimumab plus MTX was US $29,468 and US $47,605,
respectively (Malone et al., 2003).

47

The second study reported similar results in the cost-efficacy analysis of
etanercept, infliximab, adalimumab, and anakinra with and without concomitant MTX.
Etanercept with and without concomitant MTX was more cost-effective followed by
adalimumab, anakinra, and infliximab (Chiou et al., 2003). As pointed out earlier, the
short study duration of the four studies mentioned above is a major limitation. A longterm model that considers the downstream economic costs is necessary to determine the
most cost-effective treatment in patients who inadequately respond to MTX alone.

Cost-effectiveness studies: Long-term studies
Despite promising short-term results from RCTs for newer TNF inhibitors that
have demonstrated significant effects on functional status and radiographic progression,
very few economic studies have addressed the issue of effectiveness of these drugs in
RA (Brennan et al., 2003; Kobelt et al., 2003; Wong et al., 2002). This could be
attributed to the lack of sufficient longitudinal data to determine whether such an
increased expenditure will eventually be offset by lower total costs of the disease. A
recent cost-effectiveness analysis based on the ATTRACT trial demonstrated that
infliximab plus MTX was more cost-effective in the treatment of patients with RA than
MTX alone (Wong et al., 2002). A Markov simulation model was used to project the
54-week results from the ATTRACT trial into lifetime economic and clinical outcomes
based on the Arthritis, Rheumatism and Aging Medical Information System
(ARAMIS). When compared with MTX alone, infliximab plus MTX decreased the
likelihood of having advanced disability from 23% to 11% at the end of 54 weeks that
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projected to a lifetime marginal cost-effectiveness ratio of $30,500 per discounted
QALY gained.

Another study by Kobelt and colleagues (2003) used the results from the
ATTRACT trial to examine the cost per QALY of infliximab plus MTX compared with
MTX alone in patients with RA. A Markov simulation model assessed the progression
of RA using ten-year data from two epidemiological studies conducted in Sweden and
the United Kingdom (UK). The results indicated that one or two years of infliximab
treatment reduced direct and indirect resource consumption in both countries. The cost
per QALY gained was Swedish Krone (SEK) 32,000 (3,440 Euros) in Sweden and
Great Britain Pounds (GBP) 21,600 (34,800 Euros) in UK for one-year treatment. The
respective QALY gains were 0.248 and 0.298. With two years of treatment, the costs
per QALY gained were SEK 150,000 (16,100 Euros) in Sweden and GBP 29,900
(48,200 Euros) in the UK. However, the problem with both studies was that they
modeled nonresponders to stay on infliximab for one entire year. This potentially
biased the results since the patients were not responding to infliximab treatment yet
were accruing high costs associated with one year of infliximab treatment.

A UK cost-utility analysis indicated that etanercept was more cost-effective
than infliximab in the treatment of patients who had failed DMARD therapy. The
primary clinical outcome used in the study was the HAQ disability score. The study
model defined success as the achievement of ACR 20 responses and this was
extrapolated beyond the time horizon of the clinical trial, to the expected lifetime of the
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cohort, by incorporating withdrawal rates from other clinical investigations. The
discounted cost per QALY for etanercept therapy was £18,938 (US $27,271) when
direct costs were considered and £8,439 (US $12,152) when indirect costs were
considered (Brennan et al., 2001).

Cost-effectiveness studies: Comparing treatment strategies
Although a number of economic analyses demonstrate average trends for
populations and provide some direction for prescribing, they are based on a number of
assumptions such as similarity in baseline characteristics of patient population,
clinically relevant outcome measures, variation in treatment practice, and other
generalizations which may or may not be correct (Emery, 2004). In RA modeling, it is
essential that time-dependent variables such as age, duration, and severity of disease be
matched between data sources (Bansback et al., 2005). Thus, to find the most costeffective option for an individual patient, studies that investigate the relative costeffectiveness of long-term strategies can be useful.

A study conducted in the Netherlands determined the cost-effectiveness of five
different treatment strategies over five years. A Markov simulation model was used
with Markov states based on a Disease Activity Score (DAS). The treatment strategies
compared included: (1) usual treatment (MTX); (2) treatment with leflunomide (in case
of non-response, start usual treatment); (3) TNF inhibitors (in case of non-response,
start usual treatment); (4) treatment with leflunomide (in case of non-response, start
TNF inhibitors, in case of non-response, start usual treatment); (5) TNF inhibitors (in
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case of non-response, start with leflunomide, in case of non-response, start usual
treatment). Expected costs and QALYs were compared between strategies and the
ICER was calculated. The expected effect on QALY and disease activity was better for
strategies three, four, and five than for strategies one and two. A treatment strategy
starting with leflunomide followed by TNF inhibitors in case of non-response was the
most cost-effective (Welsing et al., 2004).

A study by Brennan and colleagues (2003) looked at the cost-effectiveness of
etanercept monotherapy under British Society for Rheumatological guidelines. The
study compared a traditional DMARD sequence with etanercept third line against the
same sequence excluding etanercept. The method involved simulating HAQ disability
scores for 10,000 patients’ lifetimes (Monte Carlo Simulation) using clinical trial data
and other published data. The primary analysis included drug costs, monitoring and
hospitalization. The cost per QALY was estimated to be £16,330 (US $23,515)
suggesting that etanercept was cost-effective when compared with non-biologic agents.
Sensitivity analysis (£7,800 to £42,000, US $11,232 to $60,480) showed that long term
HAQ progression for etanercept, DMARDs, and being a nonresponder were the most
sensitive variables.

Using a method similar to that described by Brennan and colleagues (2003),
Bansback and colleagues (2004) looked at the cost-utility of adalimumab in treating
patients with moderate to severe RA who have failed at least two traditional DMARDs.
The study implemented Swedish unit costs and treatment guidelines from a lifetime
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perspective and compared adalimumab with traditional DMARDs and other TNF
inhibitors. The primary outcome measure, QALYs, was calculated from the
adalimumab trial results. The method involved simulating the experiences of 10,000
hypothetical moderate to severe RA patients for each strategy using clinical trial data
and other published data. The cost per QALY for both adalimumab and etanercept was
estimated to be between 35,000-42,000 euros suggesting that adalimumab was at least
as cost-effective as the other TNF inhibitors.

Two more studies have been conducted by the National Coordinating Center for
Health Technology Assessment (NCCHTA; Barton, Jobanputra, Wilson, Bryan, &
Burls, 2004; Jobanputra et al., 2002) to assess the additional costs and QALY gain
associated with the use of either etanercept or infliximab as the third DMARD in a
sequence of traditional DMARDs. The first study resulted in an ICER of
approximately £83,000 (US $119,520) per QALY for etanercept and approximately
£115,000 (US $165,600) per QALY for infliximab. However, the effects of DMARDs
on joint replacement, hospitalization, mortality, and QoL were not studied. The model
used in the previous study was restructured in a subsequent study and the analysis was
conducted again based on the DMARDs strategies used by rheumatologists in the UK.
An ICER of approximately £59,289 (US $85,376) per QALY for etanercept and
approximately £76,233 (US $109,775) per QALY for infliximab was reported.

In summary, none of the studies have evaluated the incremental costeffectiveness of the TNF inhibitors (adalimumab, etanercept, and infliximab) and
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leflunomide used in combination with MTX in the treatment of patients with RA who
inadequately respond to MTX alone.

Rheumatologists’ Preferences Regarding TNF Inhibitors
In the past, few studies have been conducted to ascertain the prescribing
patterns of rheumatologists. The results of these studies reflect the changing
prescribing patterns of the rheumatologists, indicating a shift from time- and severitybased approaches to patient preference-based approach. Disease modifying antirheumatic drugs have been the standard treatment for RA. Studies to determine the
prescribing patterns of DMARDs show wide variations in dosing and monitoring
schedules (Pope et al., 2002). Because of its favorable efficacy/toxicity trade-off, MTX
has been rated as substantially more effective than any other DMARD by
rheumatologists (Maetzel et al., 1998; Wolfe et al., 1998). A recent study determined
the current DMARD preferences of UK consultant rheumatologists and confirmed
earlier findings that MTX was the drug of choice while newer agents such as TNF
inhibitors and leflunomide had replaced the older traditional DMARDs (Jobanputra et
al., 2004). However, with a growing number of patients not responding to MTX,
coupled with the development of highly effective TNF inhibitors, researchers have yet
to assess how rheumatologists are prescribing these new drugs.

A number of questions remain unanswered regarding the use of TNF inhibitors
in clinical practice. It is not clear in which patients with RA that the TNF inhibitors are
being used. The approved indication for these drugs is in patients with moderate to

53

severe RA. However, with their ability to reduce radiographic damage, it is not clear if
these drugs are being used in patients with early RA (Kavanaugh et al; 2004). Another
question should address how these powerful, new agents are being used. A number of
RCTs (ARMADA, ATTRACT, and TEMPO) have shown that a combination of TNF
inhibitors with MTX is superior to either drug as monotherapy in patients with active
RA, but no long-term follow-up data is available to confirm the findings. Another
important question a clinician faces is whether to prescribe a new TNF inhibitor if the
patient has failed one such agent. A review by van Vollenhoven (2004) on switching
among TNF inhibitors indicated that even though a majority of studies conducted in
rheumatology clinics supported the use of alternative TNF inhibitors, caution has to be
exercised in interpreting the results. The study samples were small and there were
differences in the concurrent use of MTX in patients enrolled in the studies. Thus, until
studies are designed to identify the predictors of response, use of TNF inhibitors will be
governed by clinical judgment and accumulated experience.

Another concern regarding the use of TNF inhibitors is the potential for adverse
events such as infections and lymphomas in patients who are using these drugs.
Appropriately screening and monitoring patients can minimize these complications.
But there are no monitoring protocols established for these drugs One study has
investigated the monitoring practices of rheumatologists for MTX-, etanercept-,
infliximab-, and anakinra-associated adverse events (Yazici et al., 2003). A majority
(76% to 78%) of rheumatologists reported that they ordered ACR recommended
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screening tests for MTX but were not aware of any guidelines for monitoring TNF
inhibitors.

Despite the clinical effectiveness of TNF inhibitors, there are a number of
factors which influence the choice of these drugs. The drug cost is significant and their
reimbursement varies greatly depending on the age of the patient, section of the
country, and third party payer. Drug cost was reported to play a dominant role in
rheumatologists’ choice of treatment regimens (Erkan, Yazici, Harrison, & Paget,
2002). Additionally, the different routes of administration of etanercept, infliximab,
and adalimumab have resulted in different coverage and reimbursement policies
(Gallup, 2001). Medicare covers only infliximab since it reimburses for intravenous
infusion performed in the physicians’ office. However, for patients under 65, insurance
plans insist on documentation for MTX failure before etanercept, infliximab or
adalimumab can be used (Kremer, 2001). Medicaid also restricts payment for these
drugs to those patients who do not demonstrate an adequate clinical response to a full
dose of MTX. Self-injectable drugs such as etanercept and adalimumab are covered by
pharmacy benefits (Gallup, 2001). Due to these requirements, physicians and their
staff are compelled to spend more time on paper work and phone calls.

Despite the increasing use of TNF inhibitors in clinical practice, there are no
studies conducted that report the current rheumatologists’ prescribing patterns and the
potential barriers they face in terms of using these drugs or making a choice among the
currently available three TNF inhibitors.
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CHAPTER THREE

METHODS
The study was conducted in two phases. In phase I, a lifetime model was
constructed using decision analytic techniques to evaluate the total costs and effects of
the TNF inhibitors (adalimumab, etanercept, and infliximab) and leflunomide, used in
combination with MTX, in patients with RA that inadequately respond to MTX alone.
In phase II, the study assessed the current prescribing patterns of rheumatologists using
TNF inhibitors to treat patients with RA through a national mail survey. The survey
also assessed laboratory monitoring practices, frequency of tests ordered, and perceived
barriers of rheumatologists prescribing these drugs.

Phase I
The following sections describe the design of the economic model,
operationalizing the model, data used in the model, analytical methods, model
assumptions and rationale that were utilized in this phase of the study.

Design of the Model
The study involved the development of a Markov model using DATA 4.0
TreeAgeTM software (Data TreeAge Software, Inc., 2002). This model was used to
evaluate the incremental cost-effectiveness of different treatment strategies in patients
with RA that inadequately respond to MTX alone.
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The five treatment strategies compared using a decision analytic method
included 1) adalimumab plus MTX, 2) etanercept plus MTX, 3) infliximab plus MTX,
4) leflunomide plus MTX, and 5) a standard therapy of MTX alone. The main
analytical plan was to calculate incremental cost-effectiveness ratios. This approach
involved combining cumulative measures of costs over time with a cumulative measure
of effectiveness, resulting in incremental costs per clinical benefit gained. A societal
perspective was taken in the estimation of costs in the base-case analysis. The total
costs of therapy with each agent was composed of direct costs associated with treating
MTX-resistant RA combined with indirect costs incurred by patients as a result of the
disease.

The effectiveness measure consisted of American College of Rheumatology
20% response criteria (ACR 20) and quality adjusted life years (QALYs). An
advantage of using ACR outcomes in cost-effectiveness analysis is their availability
from publications of RCTs, and that these outcomes can be used to compare
interventions within RA. However, it is difficult to make an absolute statement about
whether any given option is cost-effective compared with other widely accepted costeffective interventions in medicine. To overcome this limitation, a generic measure of
effectiveness such as QALY was used. The QALY combines QoL with time by
adjusting life-years with a quality weight, measured as a utility.
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Operationalizing the Model
Outcomes Measure in Rheumatoid Arthritis Clinical Trials (OMERACT)
acknowledges that the underlying characteristics of a clinical trial population define
which population the economic analysis is applicable to (Bansback et al., 2005). Most
reported efficacy data pertain to subjects in the 50- to 60-year-old age group since this
patient population is most representative of the patients with RA receiving TNF
inhibitors and leflunomide. Therefore, a cohort of 55-year-old women was selected as
the base-case population. The hypothetical cohort included 10,000 women who had
already failed two DMARDs, one of which was MTX.

The efficacy data were based on five double blinded, randomized controlled
trials conducted in patients with inadequate responses to MTX (Keystone et al., 2004;
Kremer et al., 2002; Maini et al., 1999; Weinblatt et al., 2003; Weinblatt et al., 1999).
The baseline patient characteristics across the RCTs were similar, especially the
duration of RA, HAQ disability score, and the number of previous traditional
DMARDs used (Table 1).

American College of Rheumatology 20% response data (ACR 20) for all
treatment options were available in each clinical trial. The efficacy represents the
probability of achieving ACR response on each drug subtracting the effect of placebo
from among those who have not improved on placebo (Choi, Seeger, & Kuntz, 2002;
Choi et al., 2000). Thus, efficacy estimates were calculated for all treatment options.
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Table 1. A review of published RCT results for TNF inhibitors and leflunomide
N

Baseline HAQ at
HAQ
24 weeks
(0-3)
(0-3)

Previous no.
DMARDs

Disease Avg.
duration age
(yrs)
(yrs)

67
207

1.6
1.5

0.9
0.9

2.9
2.4

12.2
11.0

55.5
56.1

76.8
76.3

67
62

Weinblatt et al., 2003
Keystone et al., 2004

Etanercept
25mg 2 x wkly+MTX 59
25mg 2 x wkly+MTX 231

1.5
NA

0.8
NA

2.7
2.3

13.0
6.8

48.0
52.5

90.0
74.0

71
85

Weinblatt et al., 1999
Klareskog et al., 2004

Infliximab
3mg/8 week+MTX

86

1.8

1.5

2.8

8.4

56.0

81.0

50

Maini et al., 1999

Leflunomide
20mg a day+MTX

130

1.5

1.1

NA

10.5

55.6

76.2

46

Kremer et al., 2002

Adalimumab
40mg eow+MTX
40mg eow+MTX

Females
(%)

% Patients
Responding
ACR20

Reference

N= number of patients enrolled in the trial
NA=Data not available
eow=every other week
Avg.= average
Wkly=weekly
RCT= randomized clinical trial
HAQ = Health Assessment Questionnaire (0 = No disability, 3=severely disabled)
DMARDs = Disease modifying anti-rheumatic drugs
ACR 20: American College of Rheumatology Response Rate
MTX = Methotrexate
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Since more than one trial provided the efficacy estimates of adalimumab plus MTX and
standard therapy of MTX, average of the estimates were used in the analysis.

Treatment withdrawal rates were calculated from all RCTs by determining the
proportion of patients withdrawing from the studies due to severe adverse events, lack
of efficacy, or withdrawing due to other reasons. Severe adverse events included
sepsis, pneumonia, or any diseases requiring hospitalization. In addition, studies were
also screened for information on mild and moderate adverse events, in particular the
number of patients suffering one or more mild and moderate adverse events. Mild
adverse events included injection or infusion site reactions, headache, rhinitis,
dizziness, abdominal pain, rash, and dyspepsia. Moderate adverse events included
upper respiratory infection, pharyngitis, respiratory disorder, and sinusitis. Rate of
mild and moderate adverse events was then calculated as the number of patients
experiencing a mild and moderate event per patient year of follow-up for each drug.

Utilities for Markov states, such as being on medication, palliative care, and
post-joint replacement were calculated from a study by Bansback and colleagues
(2004). The clinical trials for all the treatments in RA report baseline and six-month
HAQ disability scores. In addition, adalimumab clinical trials use Health Utility Index3 (HUI-3) as an indirect measure of health utility. Thus, an analysis of adalimumab
trial data of almost 2,000 patients permitted transformation from HAQ disability scores
to HUI-3 using the equation:
HUI-3 utility = 0.76 – 0.28*HAQ-DI + 0.05* Female
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This transformation was necessary since etanercept, infliximab, and leflunomide trials
do not report any health utility measures (Bansback et al., 2004).

Operationalizing the Model for adalimumab, etanercept, infliximab, leflunomide,
and MTX
Adalimumab
The clinical efficacy of adalimumab in combination with MTX was assessed in
two randomized, double-blinded studies in RA patients greater than or equal to 18 years
of age with an inadequate response to MTX alone. Adalimumab (40 mg) was
administered every other week subcutaneously. The results of both studies were
similar; patients achieved ACR 20 rates of 63.3 to 67.2% (Keystone et al., 2004;
Weinblatt et al., 2003). As described earlier, the efficacy represents the probability of
achieving ACR response on each drug subtracting the effect of placebo from among
those who have not improved on placebo. Thus, efficacy estimate for ACR 20 response
of adalimumab in one trial was calculated to be 0.616 (0.672-0.145/1-0.145) and in
another was 0.479 (0.633-0.295/1-0.295). An average of these two efficacy estimates
(0.548) was used as the baseline probability of achieving ACR 20 improvements for
adalimumab.

The proportion of patients withdrawing from the study (23.2%) and the subset
of withdrawals due to severe adverse events, lack of efficacy, and due to other reasons
were estimated from the study by Keystone and colleagues (2004). The rate of mild
and moderate adverse events for adalimumab was calculated to be 1.85 patients per
patient-year (331 patients experiencing an event/ 179.2 patient-years of follow-up).
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Event rates cannot be directly used in the model and have to be converted to
probabilities (risks) which represent the actual transitions by the cohort of individuals
over a period of time (Miller et al., 1994). Probabilities (risks) are estimated in one of
three ways: (1) simple cumulative method (2) actuarial method and (3) density method.

Density method was used to convert rates into probabilities (risks). This
method uses group-specific rates (incidence densities (ID)) to estimate probabilities
(risks) for a specified time interval (Kleinbaum, Kupper, & Morgenstern, 1982). Thus,
the ∆-year probability (risk) [P (to, t)] can be estimated as a function of the estimated
average rate (ID) by using the following expression:
P (to, t) = 1 – (N t / No) = 1 – exp [-ID (∆)]
where N t = number of subjects remaining at time t during the follow-up
No = number of disease free subjects at time to
ID = estimated average rate
∆ = elapsed time (t - to)

Etanercept
The clinical efficacy of etanercept in combination with MTX was assessed in a
randomized, double-blinded study involving patients with RA that responded
inadequately to MTX alone. Etanercept (25 mg) was administered twice every week
subcutaneously. Almost 71% of patients reported achieving ACR 20 response rates
(Weinblatt et al., 1999). Subtracting the placebo effect, the efficacy estimate for ACR
20 response was calculated to be 0.603. The proportion of patients withdrawing from
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the studies (9.7%) and the subset of withdrawals due to severe adverse events, lack of
efficacy, or due to other reasons were estimated from two studies (Klareskog et al.,
2004; Weinblatt et al., 1999). The rate of mild and moderate adverse events for
etanercept was calculated to be 3.92 patients per patient-year.

Infliximab
The randomized, double-blinded trial assessing the clinical efficacy of
infliximab (3mg/kg every 8 weeks, IV) in combination with MTX in patients with RA
that inadequately respond to MTX alone reported an ACR 20 response rate of 50%
(Maini et al., 1999). After accounting for the placebo effect, the efficacy estimate for
ACR 20 response was calculated to be 0.375. The proportion of patients withdrawing
from the study (26.7%) and the subset of withdrawals due to severe adverse events,
lack of efficacy, and due to other reasons were estimated from the same study. The rate
of mild and moderate adverse events for infliximab was calculated to be 2.79 patients
per patient-year.

Leflunomide
The 24-week randomized, double-blinded trial assessing the clinical efficacy of
leflunomide (20 mg once a day, orally) in combination with MTX reported an ACR 20
response rate of 52% (Kremer et al., 2002). Subtracting the placebo effect, the efficacy
estimate for ACR 20 response was calculated to be 0.332. The proportion of patients
withdrawing from the study was 23.1% and the rate of mild and moderate adverse
events for leflunomide was calculated to be 3.71 patients per patient-year.
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Methotrexate
All the RCTs included a control group receiving MTX plus placebo. The ACR
20 response rates were pooled for the five trials and, after accounting for the placebo,
an average efficacy estimate of 0.19 was calculated for MTX. There was 31.2%
withdrawal (pooled estimate) and the rate of mild and moderate adverse events for
MTX was calculated to be 2.3 patients per patient-year. To calculate the efficacy due
to MTX, the probability of achieving an ACR response due to placebo had to be
calculated. The estimate for efficacy of placebo (0.11) was taken from the study by
Choi and colleagues (2000) who had calculated the value from an etanercept
monotherapy trial.

Operationalizing the Model for Joint Replacement Therapy
The need for a joint replacement therapy is generally perceived to reflect a
failure of medical treatments. Data from short-term clinical trials of TNF inhibitors and
leflunomide indicate a decrease in radiological progression of the disease; however,
nothing is known about the potential long-term impact of these drugs in preventing
joint replacement surgeries. A study by Wolfe and Zwillich (1998), using a database of
1,600 patients with RA, reported that 25% of the patients had joint replacement within
22 years of disease onset. The age of the study cohort was 54 years; like the baseline
population in RCTs used in this study, the cohort had a baseline HAQ disability score
of 1.5, disease duration of over 10 years, and had failed two to three DMARDs. Since
very little published evidence is available, an assumption was made that one-fourth of
the patients on palliative care will undergo joint replacement after 12 years (22 years
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from the disease onset) in the model. A one-time cost of $19,490 (adjusted to 2004
dollars) was applied each time joint replacement occurred and this cost was varied by +
20% in the sensitivity analysis (Kremer, 2001).

Operationalizing the Model for Mortality
The OMERACT statement recommends that risk of mortality be included in
decision-analytical modeling studies (Bansback et al., 2005). However, there are
conflicting reports regarding the effect of RA on the risk of mortality. Some
epidemiologic studies have shown an increased mortality in patients with severe RA
with mean standardized mortality ratio (SMR) of 1.87 to 2.26 (Guedes, 1999; Wolfe et
al., 1994). However, more recent studies have not found any effect of RA on mortality
(Kobelt et al., 2003). For the baseline model, an SMR of two was considered for RA.
Since some studies report that with aggressive therapy, RA mortality may be similar to
that of the general population, an alternative possibility was also tested where SMR was
designated as one (Wong, Ramey, & Singh, 2001; Wong et al., 2002).

Model Structure and Simulation
The transition state model for rheumatoid arthritis is illustrated in Figure 2. The
model used transition probabilities to move 10,000 different patients randomly through
different Markov states over time. The time horizon of the analysis was divided into
equal increments, referred to as Markov cycles, during which a patient was allowed to
transition from one Markov state to another. A cycle length of six months was chosen.
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Figure 2. Transition state model

ACR
Response

RA patient

On Medication

Post-Joint
Replacement

Withdrawals

Joint
Replacement

Palliative Care

Dead
ACR=American college of rheumatology
RA=Rheumatoid arthritis
= Markov states
= Events

66

By following patients until death, the model estimated the costs and QALYs for each
treatment. The analysis assumed a societal perspective (direct and indirect costs) and
followed the reference case recommendations of the panel on Cost-effectiveness
Analysis in Healthcare and Medicine (Gold et al., 1996). Future costs and benefits
were discounted at a three percent annual rate (Gold et al., 1996).

Figure 3 shows the model structure for each strategy. The model structure for
each of the five treatment arms was identical. The first branch point on the decision
tree was a decision node indicating a choice of treatment being made: adalimumab plus
MTX, etanercept plus MTX, infliximab plus MTX, leflunomide plus MTX, or standard
therapy of MTX. Subsequent to the decision node, a Markov cycle is shown and is
identical for all five treatments options.

The model had four Markov states: on medication, palliative care, post-joint
replacement, and death state. In the model, individual patients started in the Markov
state ‘on medication’. After applying the age- and sex-adjusted mortality rate (U.S.
Census Bureau, 2004), the patients experienced two events: they either continued
taking the treatment or stopped the treatment. These transitions were based on prespecified transition probabilities. If the patients continued the medication, they may or
may not respond to medication by at least ACR 20% response criteria. In both cases,
the patients could experience mild and/or moderate adverse events that were minor
enough to continue treatment.
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Figure 3. Markov structure
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Patients who stopped the treatment did so because of the following reasons:
severe adverse events, lack of efficacy, or withdrawal due to other reasons. These
patients then entered the ‘palliative care’ state where they were treated with a
combination of MTX, NSAIDs, and corticosteroids. Patients in this state were assumed
to be at an increased risk of RA episodes and experienced one event: joint replacement
surgery. Joint replacement surgery in patients with RA is widely perceived to result
from inadequate disease control (Jobanputra et al., 2002). Once a patient had
undergone joint replacement surgery, she then entered the ‘post-joint replacement’ state
and stayed in this state for the remainder of their lifetime, eventually moving to the
death state.

In the model, all the patients ultimately transitioned into the “death” state. Once
the patient entered the “death” state, she could not leave that state. This, “death” state
was called the absorbing state. Ideally, the model should be terminated when the entire
cohort of patients are dead. However, since the Markov process is evaluated
probabilitistically, the proportion of people in “non-dead” state approaches zero but is
never equal to zero. Thus, an approximation was introduced to artificially terminate the
cohort such that the approximation error would be minimal. Thus, in the current study,
the cohort was followed until 99.999% was in the “dead” state; the remainder was
treated as an error of approximation (DATA TreeAge Software manual).
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Model Assumptions and Rationale
1. The patients enrolled in the clinical trials of adalimumab, etanercept, infliximab,
and leflunomide reported a previous use of two to three DMARDs. It was assumed
that effectiveness and toxicity of these DMARDs were captured as a consequence
on costs through increased use in health care resources and thus would be consistent
across the five treatment strategies.

2. The use of NSAIDs in patients with RA was not included in the current analysis,
because previous studies have shown that such use did not differ significantly
between different levels of disease severity, and costs were minimal (Kobelt et al.,
2003). The simulation model was focused on estimating the effects of treatments
that influence the progression of the disease, rather than on calculating the precise
costs of illness. Markov models are driven by the differences in costs and utilities
between states and by the transition probabilities between the states. Thus,
increasing or decreasing costs by the same amounts in all health states of the model
will not affect the cost-effectiveness calculation. Since small costs such as NSAID
use is identical in all states, these will not change the total cost of the disease
significantly.

3. It was assumed that patients who did not respond to the treatments were switched to
palliative care. Patients who responded, continued to stay on the medication until
they experienced any severe adverse event, lack of efficacy, or withdrawal due to
other reasons. Currently, there is no data to show the actual distribution of time a
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patient spends on each of these drugs. Clinical trials have reported the efficacy of
these drugs over a six-month or one year period. Also, in actual clinical settings, if
the patient fails to respond to one agent, rheumatologists may switch the patient to a
different DMARD or to a TNF inhibitor. Patients switched to palliative care will be
at an increased risk of RA episodes.

4. Clinical trials of the TNF inhibitors have shown that these drugs may cause
radiological stabilization of structural joint damage. This indicates a likely decrease
in future risk of joint replacement and disability. However, for those patients who
stopped taking TNF inhibitors or leflunomide, there is an increased future risk of
joint replacement and disability. A study by Wolfe and Zwillich (1998), using a
database of 1,600 patients with RA, had reported that 25% of the patients had joint
replacement within 22 years of disease onset. Since the base-case population of the
model was 55 years old and had disease duration of 10 years, it was assumed that
one-fourth of the population who withdrew from the TNF inhibitors and
leflunomide underwent joint surgery after 12 years. A one-time joint replacement
cost was applied for patients reaching this stage.

5. The evidence regarding the effect of RA on life expectancy is conflicting. Some
epidemiologic studies have shown increased mortality in patients with severe RA
while more recent studies have not demonstrated any effect of RA on mortality
(Guedes, 1999; Kobelt et al., 2003; Wolfe et al., 1994). The study model assumed
that the risk of mortality, compared with a normal age-, sex-, and race-matched
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general population, was the same. An alternative possibility was also tested where
the risk of mortality was considered twice as compared with a normal age-, sex-,
and race-matched general population (Wong et al., 2001; Wong et al., 2002).

Data for the Model
Three different types of data were used to populate the model:

Probabilities
The six-month transition probabilities were obtained from a formal review of
the literature. The transition probabilities used in the model were calculated directly
from patient-level data from active and placebo groups of the RCTs. The model
assumed that after one cycle, the patients experienced the same disease progression and
clinical outcomes as seen in the RCTs. Probabilities for other outcomes such as
mortality and joint replacement therapy were also derived from the literature.

The base-case estimates for each variable and ranges used for sensitivity
analysis are shown in Table 2. The base-case estimate for the probability of achieving
ACR improvements for adalimumab was calculated from the efficacy estimate of each
component using the formula:
PPlacebo + (1-PPlacebo) * Efficacy of drug 1 + (PPlacebo + (1-PPlacebo) * Efficacy of drug 1) * Efficacy of drug 2

Where PPlacebo is the proportion of patients achieving ACR response with any drug,
Drug 1 = MTX (MTX is used in combination with other drugs used in all trials)
Drug 2 = either adalimumab, etanercept, infliximab, or leflunomide
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Table 2. Base-case estimates (efficacy and percent probability of achieving ACR 20 response) and their ranges for sensitivity
analyses: 6-month data
Variable

Baseline estimate (range)

Efficacy of individual drug+ (ACR 20)
MTX

19.0 (16.5-21.0)

Adalimumab

54.8 (47.9-61.6)

Etanercept
Infliximab
Leflunomide

60.3 (+ 20%)
37.5 (+ 20%)
33.2 (+ 20%)

Percent probability of achieving ACR 20 response++
Placebo
MTX

11.0 (9.0-13.0)
27.9 (25.7-29.7)

Adalimumab

67.4 (62.4-72.3)

Etanercept
Infliximab
Leflunomide

71.4 (+ 20%)
54.9 (+ 20%)
51.8 (+ 20%)

References
Choi et al., 2000, Moreland et
al., 2001; Strand et al., 1999
Keystone et al., 2004;
Weinblatt et al., 2003
Weinblatt et al., 1999
Maini et al., 1999
Kremer et al., 2002
Choi et al., 2000
Choi et al., 2000, Moreland et
al., 2001; Strand et al., 1999
Keystone et al., 2004;
Weinblatt et al., 2003
Weinblatt et al., 1999
Maini et al., 1999
Kremer et al., 2002

MTX = Methotrexate
ACR 20: American College of Rheumatology Response Rate
+
The efficacy data is the net drug effect after adjusting for the placebo effect in each trial
Efficacy represents the probability of achieving ACR response on each drug subtracting the effect of placebo from among those who have not improved on
placebo (Choi et al., 2000)
(Drug –Placebo)/ (1-Placebo)
++
Probability of achieving ACR response: PPlacebo + (1-PPlacebo) * Efficacy of drug 1 + (PPlacebo + (1-PPlacebo) * Efficacy of drug 1) * Efficacy of drug 2 (Choi et al.,
2000)
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For example, when treated with adalimumab and MTX, the proportion of patients
achieving ACR 20 response was 0.674 [0.11 + (1-0.11) * 0.19 + (0.11 + (1-0.11) *
0.19) * 0.548]. This method of calculating the ACR response implicitly assumed the
additive pharmacologic effect of each component in a therapeutic option (Choi et al.,
2000). The same formula was applied to calculate the proportion of patients achieving
ACR 20 responses for etanercept, infliximab, leflunomide, and MTX.

Probabilities of withdrawal from treatment and the subset of withdrawals due to
severe adverse events, lack of efficacy, and due to other reasons were estimated from
the respective clinical trials (Table 3). In RCTs, both the mild and moderate adverse
events (reported as number of patients with events), and the total number of patientyears of follow-up, are reported. Rate of mild and moderate adverse events were
calculated from the information (number of patients with events / patient-years) and
this was converted to probabilities using the density method described earlier (Table 4).

Utilities
Utilities are numerical values assigned to health states, which reflect the
desirability of living in a given state. Health state utilities range from perfect health
(weighted 1.0) to death (weighted 0). The weights are multiplied by the amount of time
spent in each health state, and these products are summed over the patient’s lifetime in
the different states to obtain an estimate of QALYs. Utilities for different states in the
Markov model were derived from a study by Bansback and colleagues (2004) and are
reported in Table 5.
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Table 3. Base-case estimates (total withdrawals and subset of withdrawals) and their ranges for sensitivity analyses: 6-month
data
Variable

Baseline estimate (+ 20%)

References

Total withdrawals, %
Adalimumab
Adverse events (%)
Lack of efficacy (%)
Other reasons (%)

23.2
54.2
12.5
33.3

Keystone et al., 2004
Weinblatt et al., 2003

Etanercept
Adverse events (%)
Lack of efficacy (%)
Other reasons (%)

9.7
31.6
7.9
60.5

Klareskog et al., 2004
Weinblatt et al., 1999

Infliximab
Adverse events (%)
Lack of efficacy (%)
Other reasons (%)

26.7
21.7
73.9
4.3

Maini et al., 1999

Leflunomide
Adverse events (%)
Lack of efficacy (%)
Other reasons (%)

23.1
53.3
30.0
16.7

Kremer et al., 2002

MTX

31.2
55.8
20.4
23.9

Choi et al., 2000, Moreland et
al., 2001; Strand et al., 1999

Adverse events (%)
Lack of efficacy (%)
Other reasons (%)
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Table 4. Base-case estimates (mild/moderate adverse event) and their ranges for sensitivity analyses: 6-month data
Variable

Baseline estimate (+ 20%)

Rate#

References

Probability

Mild/moderate adverse event
Adalimumab

1.85

0.6035

Keystone et al., 2004

Etanercept

3.92

0.8591

Weinblatt et al., 1999

Infliximab

2.79

0.7522

Maini et al., 1999

Leflunomide

3.71

0.8435

Kremer et al., 2002

MTX

2.30

0.6830

Choi et al., 2000, Moreland et
al., 2001; Strand et al., 1999

#

Rate expressed as number of patients with events per patient year
MTX=Methotrexate
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Table 5. Utilities for Markov states used in the decision analysis model #
Markov States

Utilities (+20%)

On Medication
Adalimumab+MTX
Etanercept+MTX
Infliximab+MTX
Leflunomide+MTX
Standard MTX Therapy

0.558 (0.446-0.669)
0.586 (0.469-0.703)
0.460 (0.368-0.552)
0.502 (0.402-0.602)
0.446 (0.357-0.535)

Palliative Care

0.283 (0.227-0.340)

Post-Joint Replacement

0.152 (0.122-0.182)

# Utilities were estimated using an equation derived by Bansback and Colleagues (2004): HUI-3 = 0.76 – 0.28*HAQ DI + 0.05* Female
MTX=Methotrexate
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Utilities for the five different treatments were calculated based on the HAQ
disability score at six-months derived from their respective RCTs using the equation:
HUI-3 utility = 0.76 – 0.28*HAQ-DI + 0.05* Female
HUI-3 = Health Utility Index-3
HAQ-DI= Health Assessment Questionnaire Disability Score

Since the patients who withdrew from the treatments and moved to the
palliative care or post-joint replacement states were assumed to experience an increase
in RA episodes, it was decided that after six months there will be a 25% increase in
their baseline HAQ disability score. For the palliative care state, the baseline HAQ
disability score was assumed to be 1.50; for the post-joint replacement state, the
baseline HAQ disability score was assumed to be 1.88. The increase in the HAQ
disability score at six months was then substituted in the above equation to generate
utilities for each of these two states.

Costs
Direct costs: The costs of each of the TNF inhibitors, leflunomide, and MTX included
the drug costs, costs of monitoring, costs of treating mild and/or moderate and severe
adverse events arising from the treatment, and the cost of joint replacement therapy
(Table 6). Drug costs were calculated from Drug Topics Red Book (2004). The Red
Book lists the average wholesale price (AWP) for prescribed medications. Drug costs
were based on the standard dose derived from the package insert of the drug. In
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Table 6. Costs: 6-month data used in the decision analysis model for each drug
Variables

Methotrexate

Adalimumab

Etanercept

Infliximab

Leflunomide

Dose

15 mg/week

40 mg every
other week

25 mg twice
every week

3 mg/kg
every 8 weeks

Medication costs§

$714.8 (+20%)

$7,894.8 (+20%)

$7,894.8 (+20%)

$8,520.6*(+20%)

Administration cost +

-

-

-

$848.6 ($663.6-$1,033.6)

Monitoring costs§§
(First 6-month)

$707.7
($488.4-$927)

$996.5
($730.5-$1,262.5)

$996.5
($730.5-$1,262.5)

$996.5
($730.5-$1,262.5)

Monitoring costs§§
(After 6-month)

$404.4
($299.6-$501.2)

$354.5
($240.2-$468.8)

$354.5
($240.2-$468.8)

$354.5
($240.2-$468.8)

$473.2
($347.9-$598.4)

Costs of treating severe
Adverse Event

$8,500 (+20%)

$8,500 (+20%)

$8,500 (+20%)

$8,500 (+20%)

$8,500 (+20%)

Costs of treating mild/
moderate adverse event

$165.3
($126.2-$204.3)

$165.3
($126.2-$204.3)

$165.3
($126.2-$204.3)

$165.3
($126.2-$204.3)

20 mg/
day

Direct Costs ($) #
$2,233.9 (+20%)
-

$670
($487.4-$852.5)

$165.3
($126.2-$204.3)

#

All costs adjusted to 2004 dollars
Based on Drug Topics Red Book (AWP 2004)
§§
Based on Medicare and Managed Care reimbursement rates
*
Mean dose per infusion = 2.8 vials, number of infusion per 6-month = 4.4
+
Medicare rate (2004) $150.8 per infusion (First hour infusion rate=$117.79, Every additional hour = $33.02); Administration cost = 150.8*4.4=$663.6
Cost of treating mild/moderate adverse event= 1office visit + CBC + LFT + Urine analysis + Chest X-ray+10 day antibiotic treatment
Medicare:http://www.cms.hhs.gov/providers/pufdownload/default.asp?
Managed care: http://www.purdue.edu/hr/Benefits/mac.htm
§
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addition, infliximab is administered as an infusion and the administration cost was
added to the treatment costs. All five drugs required intensive monitoring in the first
six months, after which routine monitoring was required. Thus, the model incorporated
higher monitoring costs in the first six months and lower constant monitoring costs
after the first six months. Monitoring costs were identified by applying Medicare and
managed care current laboratory fees to the recommended laboratory schedule. An
average of the two costs was included in the model (Tables 6 and 7).

The cost of drug-related severe adverse events was based on the cost of treating
pneumonia, which is the most commonly reported severe adverse event due to
treatment with TNF inhibitors. The cost of treating pneumonia ($8,500) was derived
from the reimbursement rates paid by Medicare. Treatment of mild and/or moderate
events was assumed to result in an office visit, a complete blood count test (CBC), one
liver function test (LFT), one urine analysis, a chest X-ray, and a ten day antibiotic
treatment. The costs of physician visit and laboratory tests were identified by applying
Medicare and managed care current lab fees. The antibiotic cost was calculated from
the Drug Topics Red Book (2004).

Joint replacement therapy was treated as an event and a one-time cost was
applied at the time of joint replacement. The estimate ($19,490) came from the
published literature (Kremer, 2001). For patients in palliative care, there was no startup cost, but a constant cost of $1,141 per six-months was applied. This cost included
the six-month average cost of NSAIDs, corticosteroids, and MTX. The costs of
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Table 7. Monitoring costs: 6-month data used in the decision analysis model for each drug
Variables

CPT

Chest X-ray

71020

Complete blood count

Methotrexate
(Frequency)
1st 6-mth/
After 6-mth

Adalimumab
(Frequency)
1st 6-mth/
After 6-mth

Etanercept
(Frequency)
1st 6-mth/
After 6-mth

Infliximab
(Frequency)
1st 6-mth/
After 6-mth

$65.6/$36.3

1

1

1

1

1

85007

$9.6/$4.8

7/6

13/6

13/6

13/6

7/6

Urine analysis

81005

$6.1/$3.0

2

13

13

13

-

Creatinine

82575

$26.4/$13.2

7

13

13

13

7

LFTs
ALT
AST
Albumin

84460
84450
82040

$7.3/$7.4
$7.1/$7.2
$11.5/$6.9

7/6
7/6
7/6

1/1
1/1
1/1

1/1
1/1
1/1

1/1
1/1
1/1

7/6
7/6
7/6

Protein purified test

86580

2$2.07/-

-

1

1

1

-

Antinuclear antibody

86039

$31.2/$15.6

2

13/1

13/1

13/1

-/1

$72.1/$35.5

3.3/3.3

3.3/3.3

3.3/3.3

3.3/3.3

3.3/3.3

1.6/1.6
$730.5-$1,262.5
$996.5
$240.2-$468.8
$354.5

1.6/1.6
$730.5-$1,262.5
$996.5
$240.2-$468.8
$354.5

1.6/1.6
$730.5-$1,262.5
$670
$347.9-$598.4
$473.2

Rheumatologist (visits)

Unit Rate ($)
Managed care/ Medicare
Reimbursement Rates

Nonrheumatologist (visits)
$72.1/$35.5
1.6/1.6
1.6/1.6
Total monitoring costs (First 6-month, Range)
$488.4-$927
$730.5-$1,262.5
Average monitoring costs (First 6-month)
$707.7
$996.5
Total monitoring costs (After 6-month, Range)
$299.6-$501.2 $240.2-$468.8
Average monitoring costs (First 6-month)
$404.4
$354.5
LFT=Liver function test, ALT=Alanine transferase test, AST= Aspartame transferase test
Medicare:http://www.cms.hhs.gov/providers/pufdownload/default.asp?
Managed care: http://www.purdue.edu/hr/Benefits/mac.htm

Leflunomide
(Frequency)
1st 6 mth/
After 6-mt
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NSAIDs and corticosteroids were calculated from the Drug Topics Red Book (2004).
Patients in the post-joint replacement state were assumed to have the same cost of
treatment as those in the palliative care state. The costs of hospitalizations due to RArelated surgeries were calculated by using an exponential equation which is a function
of the HAQ disability score (Choi et al., 2000; Table 8).
Cost of surgery = 635.5 e1.0935 (HAQ score)
where HAQ score is the score at 24 week

Indirect costs: Indirect costs were included to capture potential savings associated with
improvement in RA with each treatment. Studies have shown that indirect costs in RA
patients are one to three times the direct costs (Meenan, Yelin, Henke, Curtis, &
Epstein, 1978; Stone, 1984). In the present study, indirect costs was calculated as one
to three times that of direct costs.

Adjusting Costs
When costs are taken from the literature or from electronic datasets, they often
require adjustments before they can be included in the cost-effectiveness analysis.
When older costs are used, they underestimate the cost of medical care in present-day
terms, unless they are adjusted for inflation (Muennig, 2002). Thus, all the costs that
were taken from the literature in this study were adjusted to 2004 dollars. The annual
changes in medical inflation between 1990 and 2004 are reported by the Bureau of
Labor Statistics. The proportional increase in the prices was then calculated using the
formula: (high year index value – low year index value)/low year index value
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Table 8. Base-case estimates and their ranges for sensitivity analyses: 6-month data
Variables
Hospitalization costs

Baseline estimate (range )

$1302.7 (+20%)

Adalimumab

$859.8 (+20%)

Etanercept

$762.0 (+20%)

Infliximab

$1639.1 (+20%)

Leflunomide

Joint replacement cost
Palliative care cost
+++

Choi et al., 2000

+++

MTX

References

$928.2 (+20%)
$19,490.0 (+20%)

Kremer, 2001

$1141.0 (+20%)

Hospitalization costs calculated using the formula:
Cost of surgery = 635.5 e1.0935 (HAQ score) where HAQ score is the score at 24 week
MTX = methotrexate
All costs adjusted to 2004 dollars
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Discounting Future Costs
Medical interventions often result in decreased future medical costs that must be
accounted for in present-day terms. Based on the recommendation of the “Panel on
Cost-effectiveness in Health and Medicine” which was convened by the United States
Public Health Service, all future costs and outcomes were discounted into their net
present value by three percent before they were included in the cost-effectiveness
analysis (Gold et al., 1996). The general formula for discounting future costs used was:
Cost of future event/ (1+ discount rate) years

Analysis
The base-case analysis represented the expected average effectiveness and costs
per patient population, discounted at three percent for a hypothetical cohort of 10,000
patients. A Markov Model can be evaluated by using a Markov cohort simulation
where the patients in the cohort are followed as they move among the predetermined
Markov states. Also, the Markov Model can be evaluated by using a first order Monte
Carlo simulation. In the first order Monte Carlo simulation, a large number of patients
are followed through the model individually. A single simulation trial will randomly
select a path at each uncertainty, based on the probability of each outcome’s
occurrence. Thus, the path followed by different patients will differ by chance (Shaw
& Zachary, 2002).

The baseline model in this study was analyzed using a first order Monte Carlo
simulation. Even though costs and outcomes estimated by the two methods are similar,
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an advantage of using a first order Monte Carlo simulation is that estimates of variance
associated with costs and outcomes in each arm of the model are also determined,
giving a measure of uncertainty of the derived costs and outcomes. Estimated average
costs and QALYs were then used to calculate an incremental cost-effectiveness ratio
(ICER). An ICER was calculated as the additional cost per patient achieving a
particular outcome, compared with the next more expensive option.

The use of tracker variables in the Markov Model also dictated the use of a first
order Monte Carlo simulation. A tracker variable is a special type of variable that can
only be used in Monte Carlo simulation trials and not during Markov cohort simulation.
The primary function of a tracker variable is to serve as a memory within a Markov
process. For example, if a patient encounters a node containing the tracker variable
definition numEvents=numEvents+1, DATA will take the current global value of
numEvents for that patient’s trial, add one to it, and store the new global value (DATA
TreeAge Software manual). Two tracker variables were created in the model. The
tracker variable ‘Number_JR’ was created to count the number of joint replacements a
patient underwent in the model. Another tracker variable ‘Number_JRage’ was created
to estimate the age at which the patient underwent joint replacement.

Sensitivity analysis is used to deal with uncertainty in the model parameters.
Sensitivity analysis was performed by varying baseline variables over a plausible range
to test the robustness of the model over a range of assumptions and probability
estimates. One-way sensitivity analysis was used to vary one parameter at a time from
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its baseline value and the analyses used a first order Monte Carlo simulation to observe
the effect on the choice of strategy. Because the overall variability of a model is poorly
characterized by one-way sensitivity analysis, a second order Monte Carlo simulation
(probabilistic sensitivity analysis) was also used to characterize this variability.

In second order Monte Carlo simulation, each parameter in the model, instead
of taking on a single value, was assumed to be a variable quantity with a known range
of possible values and an associated range of distribution functions. For a cohort of
patients, all the model parameters were allowed to vary within assigned ranges
according to an assigned distribution and the average cost and effect of each treatment
strategy was calculated. This process was repeated a large number of times to generate
empirical distributions for mean costs and effects of each treatment strategy (Shaw &
Zachary, 2002).

Phase II
Primary data for phase II was collected using a survey instrument. The survey
was developed to determine rheumatologists’ current prescribing patterns, laboratory
monitoring practices, and perceived barriers in prescribing the three TNF inhibitors.
The following section describes selection of the study population, development and
administration of the survey instrument, data collection, and data analytical techniques
that were used for this phase of the study.

Study Population and Sample Selection
The research design used for this phase of the study was a cross-sectional
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survey design. The population of interest was a national sample of rheumatologists. A
mailing list of all the rheumatologists in the United States was obtained from SK&A
Information Services Inc., a private mailing list firm. The total number of
rheumatologists obtained from SK&A was 3,008.

Sample Size Calculation
The sample size for the study was determined on the basis of getting an estimate
of the true proportion of a variable of interest in the population within + 5% points with
95% confidence (Kalton, 1987). The sample size necessary was determined using the
following formula:
n = Z2 * Π (1 - Π)
E2
n: estimate of appropriate sample size
Z: the number of standard errors away from the mean, or the Z score for the confidence
interval chosen, and equals 1.96
Π: True population proportion and is equal to 33% (considering that all three TNF
inhibitors are being equally prescribed by the rheumatologists)
E: acceptable level of error in estimation of population proportion, and is equal to 5%.
Substituting the values in the equation gave a sample size of 340
rheumatologists that need to be surveyed from the study population. Assuming a 20%
response rate for physician mail surveys, a total of 1,700 rheumatologists were needed
to achieve the required sample size. After excluding trainees, non-clinical, and pediatric
rheumatologists (n = 45), a total of 1,970 rheumatologists were randomly selected from
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3,008 rheumatologists and mailed a survey questionnaire. To assess the nonresponse
bias, a one-page non-response questionnaire was mailed to 200 randomly selected nonresponding rheumatologists.

Instrument Development and Content
A self-administered survey was used for this phase of the study. Surveys allow
information to be collected from a sample group and to be generalized to the population
at large. Mail surveys are used more frequently than telephone and face-to-face
interviews because they are easy to implement, incur relatively low cost, and have been
found to be more reliable than telephone and face-to-face interviews (Dillman, 1999;
DeLeeuw, 1992).

The survey questionnaire was designed to investigate rheumatologists’ current
prescribing patterns for the three TNF inhibitors in patients with RA. Specifically, the
survey was designed to gather information on rheumatologists’ preference for any
particular TNF agent, to identify the patient population in which these agents were
being used, to determine what laboratory monitoring protocols were being followed,
and to identify rheumatologists’ perceived barriers in prescribing these agents.

The first section of the survey questionnaire was focused on exploring
rheumatologists’ prescribing patterns of the three TNF inhibitors. Rheumatologists
were asked to identify the patient population (newly diagnosed, mild RA, moderate
RA, or severe RA) in which they prescribed each of the TNF inhibitors.
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Rheumatologists were also asked to rank, in order of preference, the TNF inhibitor they
were more likely to prescribe in patients with RA. The next question in this section
asked the rheumatologists to indicate how they used TNF inhibitors in patients who
responded inadequately to MTX alone. The last question in this section asked the
rheumatologists if they had switched any patient to a different TNF inhibitor if the first
TNF inhibitor had not worked. A follow-up question required the respondents to
indicate the reasons for switching.

The second section of the survey questionnaire was designed to investigate the
use of adalimumab, etanercept, and infliximab by rheumatologists in their clinical
practice. For each drug, respondents were asked to provide the dose and frequency of
dosing they prescribed in patients with newly diagnosed, mild, moderate, and severe
RA. The respondents were also asked about the laboratory tests ordered for each drug
and the frequency of ordering these tests. Respondents could select from a list of five
laboratory tests. These tests included anti-nuclear antibody test, complete blood count
test, creatinine test, chest x-ray, and purified protein derivative test.

The third section of the questionnaire was designed to measure rheumatologists’
perceived barriers in prescribing each of the TNF inhibitors. Respondents were asked
to rate factors such as insurance coverage, cost, safety and efficacy of these drugs, and
route of administration, on a one to seven Likert-type scale where one was ‘no
problem’ and seven was ‘major problem’.
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Demographic and practice-related information were obtained in the last section
of the questionnaire. Data collected included age in years, gender, number of years in
practice as a rheumatologist, primary practice site, average number of patients with RA
seen per week, average number of prescriptions written per week for each of the drugs,
and the monitoring guidelines (ACR, EULAR, both, or none) used by the respondents
in treating patients with TNF inhibitors.

Instrument Validation
Faculty members from a School of Pharmacy and a School of Medicine were
approached to assess the clarity, readability levels, and appropriateness of the
instrument. All the comments provided were incorporated in order to enhance the face
and content validity of the survey questionnaire. Feedback on the content of the
questionnaire was also obtained from rheumatologists practicing at West Virginia
University Hospital. This process helped determine the relevance of questions and
clarity of instructions included in the survey. It also helped determine if any important
variables were omitted or if any information was redundant.

Instrument Administration
Approvals for all survey related documents (survey questionnaire, cover letters,
and non-response survey) were sought from the West Virginia University’s Institutional
Review Board (WVU-IRB). Once approved, the survey process was initiated by
mailing a cover letter, the survey instrument, and a business reply envelope to a
randomly selected national sample of rheumatologists. The cover letter (Appendices A
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& B) explained the study, noting the importance of determining the prescribing patterns
of rheumatologists and their perceived barriers in prescribing the TNF inhibitors. In
addition to the purpose of the study, the letter also emphasized voluntary participation
and assured confidentiality of responses. Respondents were asked to return the
completed survey (Appendix C) in a self-addressed business reply envelope. The
surveys were coded for follow-up purposes only.

A second mailing followed after a period of four weeks. This consisted of a
cover letter, the survey instrument, and a business reply envelope; and this second
packet was mailed only to those rheumatologists who did not respond to the first
mailing. Finally, about ten weeks after the first mailing, a one page non-response
questionnaire was mailed to a randomly selected sample of non-responding
rheumatologists to assess non-response bias. The non-response survey (Appendix D)
was conducted to determine if there is a difference between respondents and nonrespondents. The non-response survey assessed the reasons for not participating in the
study and also collected critical demographic and prescribing-related information on
the use of TNF inhibitors.

Data Handling and Analysis
All the returned surveys were checked for completeness. Incomplete responses
were not included in the analyses. Data entry and statistical analyses were performed
using the Statistical Package for Social Sciences® (SPSS) for Windows, Version 12.0.
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Descriptive statistics such as means and standard deviations (SDs) were used to
report data. Independent t-tests, analysis of variance (ANOVA), and repeated measures
ANOVA were used to assess differences among groups. Frequency distributions were
generated for demographic and practice characteristics of the respondents.

This chapter discussed in detail the methodology employed to meet the study
goals and to address the research questions of both phases I and II. The next chapter
will present the results of both of the study phases.
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CHAPTER FOUR

RESULTS AND DISCUSSION

Phase I
In phase I, a Markov model was constructed to evaluate the total costs and
effects of five treatments: adalimumab plus MTX, etanercept plus MTX, infliximab
plus MTX, leflunomide plus MTX, and a standard therapy of MTX in patients with RA
that inadequately respond to MTX alone. The model was evaluated using a first order
Monte Carlo simulation. The patients entered the model at age 55 and moved through
the three Markov states of ‘on medication, ‘palliative care’, and ‘post-joint
replacement’. Each state was associated with some events such as response to
treatment, withdrawal from drug therapy, or experiencing joint replacement surgery.
Finally the patients entered the absorbing state (death state). Estimates of population
mean costs and mean effects (e.g. QALYs) were obtained using first order Monte Carlo
simulation, which were then used to calculate the ICERs.

The transition from Markov states to ‘death’ state can be considered as a
function of two independent forces: disease-specific mortality and all-cause mortality
excluding the disease under consideration. As described earlier, there are conflicting
reports regarding the effect of RA on the risk of mortality. For the baseline model, a
standardized mortality ratio (SMR) of one was considered for RA and therefore, age-,
sex-, race-adjusted all-cause mortality rates were used. Since some studies report that
the mortality due to RA may be twice that of the general population, age-, sex-, race-
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adjusted all-cause mortality rates was adjusted by a factor of two to reflect the increase
in risk of mortality due to RA. The probability of dying based on age, sex, and race
were obtained from the Statistical Abstract of the United States (U.S Census Bureau,
Vital Statistics, 2004). These probabilities and the adjusted probabilities to reflect the
increased risk in mortality due to RA are reported in Tables 9 and 10.
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Table 9. Probability of dying based on age-, sex-, and race-adjusted all-cause mortality rates
Age

Probability

Age

Probability

Age

Probability

Age

Probability

55

0.0041

67

0.0125

79

0.0392

91

0.1357

56

0.0047

68

0.0141

80

0.0438

92

0.1485

57

0.0046

69

0.0151

81

0.0491

93

0.1620

58

0.0055

70

0.0169

82

0.0533

94

0.1764

59

0.0060

71

0.0186

83

0.0621

95

0.1915

60

0.0069

72

0.0199

84

0.0645

96

0.2075

61

0.0072

73

0.0220

85

0.0753

97

0.2242

62

0.0080

74

0.0242

86

0.0836

98

0.2417

63

0.0088

75

0.0266

87

0.0925

99

0.2599

64

0.0097

76

0.0295

88

0.1022

100

0.2788

65

0.0107

77

0.0321

89

0.1126

>101 1.0000

66

0.0117

78

0.0356

90

0.1238

Source: Statistical Abstract of the United States (U.S Census Bureau, Vital Statistics, 2004)
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Table 10. Probability of dying based on RA-adjusted mortality rates
Age

Probability

Age

Probability

Age

Probability

Age

Probability

55

0.0082

67

0.0248

79

0.0769

91

0.2530

56

0.0094

68

0.0280

80

0.0857

92

0.2749

57

0.0092

69

0.0300

81

0.0958

93

0.2978

58

0.0110

70

0.0335

82

0.1038

94

0.3217

59

0.0120

71

0.0369

83

0.1203

95

0.3463

60

0.0138

72

0.0394

84

0.1248

96

0.3719

61

0.0143

73

0.0435

85

0.1449

97

0.3981

62

0.0159

74

0.0478

86

0.1602

98

0.4250

63

0.0175

75

0.0525

87

0.1764

99

0.4523

64

0.0193

76

0.0581

88

0.1939

100

0.4799

65

0.0213

77

0.0632

89

0.2125

>101 1.0000

66

0.0233

78

0.0699

90

0.2323

Source: Statistical Abstract of the United States (U.S Census Bureau, Vital Statistics, 2004)
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Base-case Analysis Results
Ten thousand hypothetical patients were sampled for all the five treatments
using a first order Monte Carlo simulation. Natural mortality (adjusted for age, gender,
and race) was incorporated into the model via standard life tables for a United States
(US) population (U.S Census Bureau, Vital Statistics, 2004). A discount rate of three
percent, applied to costs and benefits in the base-case analysis, was based on the
recommendation of the “Panel on Cost-effectiveness in Health and Medicine” which
was convened by the United States Public Health Service (Gold et al., 1996). As
discussed earlier, the indirect costs due to RA are estimated to be one to three times that
of the direct costs. In the base-case analysis, we assumed that the indirect costs were
the same as the direct costs. Analyses were also performed assuming indirect costs at
two and three times the direct costs and these results are reported later in this chapter.

Estimated lifetime mean total costs and QALYs for each treatment are reported
in Table 11. The standard MTX treatment was the least expensive ($82,956 for a
lifetime treatment) and etanercept plus MTX was the most expensive treatment
($314,895). The two other TNF inhibitors, infliximab plus MTX ($189,145) and
adalimumab plus MTX ($187,748) were less expensive than etanercept plus MTX but
were more expensive than leflunomide plus MTX ($116,991). Etanercept plus MTX
had the highest gain of 15.84 QALYs followed by adalimumab plus MTX (13.28
QALYs), leflunomide plus MTX (12.94 QALYs), infliximab plus MTX (12.51
QALYs), and standard MTX treatment (12.29 QALYs).
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Table 11. Base-case results for total costs and effectiveness using Monte Carlo simulations of 10,000 hypothetical patients with
RA that inadequately respond to MTX (using age-, sex- race-adjusted all-cause mortality rates)

Total Costs* ($)
Treatment Strategy

Min $

Median $

Max $

82,956 (+25,567) 1,362

86,420

168,706

Leflunomide+MTX

116,991 (+52,012) 2,276

107,578

Infliximab+MTX

189,145 (+123,914) 6,360

Adalimumab+MTX
Etanercept+MTX

Standard MTX

Mean $ (+SD)

Effectiveness (QALYs)
Mean (+SD)

Min

Median

Max

12.29 (+2.93) 0.22

13.12

19.00

338,463

12.94 (+3.18) 0.25

13.55

23.24

157,079

853,187

12.51 (+3.00) 0.23

13.26

20.96

187,748 (+113,828) 5,232

157,689

701,482

13.28 (+3.35) 0.28

13.74

25.32

314,895 (+193,655) 5,184

272,060

888,545

15.84 (+4.88) 0.29

15.49

36.05

*

Total costs = Direct costs + Indirect costs (Indirect costs calculated the same as direct costs)
QALYs = Quality adjusted life years
MTX = Methotrexate
SD = Standard deviation
Min = Minimum
Max = Maximum
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An incremental cost-effectiveness analysis was performed to determine whether
costs incurred due to the addition of a TNF inhibitor or leflunomide to standard MTX
treatment achieved any additional benefits. This involved determining the ICERs. The
ICERs were calculated for both total costs and direct costs only of the treatments and
are reported in Table 12.

Under base-case assumptions using total costs, etanercept plus MTX provided
more health benefits and was more costly than standard MTX treatment, with a
resulting cost-effectiveness ratio of $49,724/QALY. The second most cost-effective
treatment was leflunomide plus MTX with an ICER of $52,833/QALY. Infliximab
plus MTX was less effective and more costly than adalimumab plus MTX (i.e.,
dominated), and adalimumab plus MTX had a higher ICER and costs compared with
leflunomide plus MTX (i.e., ruled out through extended dominance). The results for
total costs are also represented graphically in Figure 4 where the X-axis represents the
effectiveness in QALYs and the Y-axis gives the total costs in dollars.

In the analysis including only direct costs, the dominance status of each
considered treatments remained the same as in the base-case analysis using total costs
consideration. In the analysis including only direct costs, the ICER of etanercept plus
MTX compared with standard MTX treatment was $24,333/QALY, while the ICER of
leflunomide plus MTX compared with standard MTX treatment was $27,717/QALY.
Infliximab plus MTX was dominated by leflunomide plus MTX and adalimumab plus
MTX was ruled out through extended dominance.
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Table 12. Base-case direct costs, total costs, effectiveness, and incremental cost-effectiveness ratios of different treatments for
patients with RA that inadequately respond to MTX (using age-, sex-, and race-adjusted all-cause mortality rates)
Treatment Strategy

Direct costs
($)

Effectiveness Incremental
(QALYs)
cost-effectiveness
Ratios ($/QALYs)

Standard MTX

73,016

12.21

-

Leflunomide+MTX

90,866

12.86

Infliximab+MTX

128,553

Adalimumab+MTX
Etanercept+MTX

Total costs*
($)

Effectiveness Incremental
(QALYs)
cost-effectiveness
ratios ($/QALYs)

82,956

12.29

-

27,717

116,991

12.94

52,833

12.43

Dominated+

189,145

12.51

Dominated#

129,066

13.19

Extended Domination++

187,748

13.28

Extended Domination##

192,080

15.78

24,333

314,895

15.84

49,724

All treatments compared to the reference case: Standard MTX treatment
MTX= Methotrexate
*
Total costs = Direct costs + Indirect costs (Indirect costs calculated as same as direct costs)
+
Infliximab+MTX dominated by Leflunomide+MTX
++
Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.623 and 0.884.
# Infliximab+MTX dominated by Adalimumab+MTX
## Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.642 and 0.881.
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Figure 4. Total costs and effectiveness of different treatments for patients with RA
that inadequately respond to MTX (using age-, sex-, race-adjusted all-cause
mortality rates)
320000
290000
260000
230000
200000

Costs 170000
140000

Extended Dominance:

110000
80000
11.50

0.647 <= k <= 0.884
12.50

13.50

14.50

15.50

16.50

Effectiveness

Adalimumab+MTX
Infliximab+MTX

Etanercept+MTX
Leflunomide+MTX

Continue with MTX
MTX = methotrexate
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Sensitivity Analysis Results
Sensitivity analysis is used to deal with uncertainty in the model parameters.
These analyses are performed to determine the robustness of the base-case results with
regards to variation in the base-case estimates, both costs and effectiveness. A
comparison between the original cost-effectiveness ratios and the sensitivity analysis
cost-effectiveness ratios of an input parameter provides an indication of how sensitive
the overall model results are to changes in that particular parameter. Thus, if the results
are found to be stable over a wide range of input parameter, the model’s conclusions
are considered to be robust (Gold et al., 1996).

Since the baseline estimates were obtained by analyzing the model using a first
order Monte Carlo simulation, one-way sensitivity analysis also employed first order
Monte Carlo simulation. One-way sensitivity analysis was conducted by vary one
input parameter at a time from their baseline values to observe the effect on the choice
of treatment strategy. Probabilities and costs were varied between ranges or +20%.
Results of one-way sensitivity analyses on different input parameters and their effect on
total costs, effectiveness, and ICERs are reported in Tables 13-23. The first row in the
tables gives the base-case results which serve as a benchmark against which all the
subsequent derived values from the sensitivity analysis can be compared.

102

Table 13. One-way sensitivity analyses - Probability of withdrawals
Parameter/range

MTX

Lef+MTX

Inf+MTX Ada+MTX Eta+MTX

Ada+MTX

Eta+MTX

Total Cost

Total Cost

Total Cost

Total Cost

QALYs

QALYs

QALYs

82,956

116,991

189,145

187,748

314,895

12.29

12.94

12.51

13.28

15.84

Adalimumab (-20%) 82,499

116,093

187,601

216,493

314,416

12.16

12.84

12.38

13.61

15.75

(+20%) 82,182

116,204

188,814

165,245

316,414

12.18

12.84

12.41

12.86

15.78

Etanercept (-20%) 82,135

115,559

187,091

185,609

355,238

12.17

12.80

12.39

13.15

16.60

(+20%) 82,589

116,712

188,123

187,416

284,419

12.24

12.89

12.45

13.24

15.18

(-20%) 81,625

115,323

220,212

185,035

313,359

12.12

12.78

12.62

13.12

15.68

(+20%) 82,558

116,043

164,589

186,139

315,450

12.25

12.88

12.29

13.23

15.78

Leflunomide (-20%) 82,332

127,693

185,981

183,786

316,044

12.23

13.24

12.45

13.20

15.82

(+20%) 82,463

107,378

188,157

185,473

315,450

12.22

12.62

12.44

13.20

15.77

(-20%) 85,645

116,062

187,318

186,467

312,632

12.41

12.86

12.42

13.21

15.72

(+20%) 80,064

116,341

188,468

187,076

315,830

12.07

12.87

12.44

13.22

15.80

Base Case

Infliximab

MTX

MTX

Total Cost QALYs

Lef+MTX
QALYs

Inf+MTX

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 14. One-way sensitivity analyses - Probability of withdrawals due to severe adverse events
Parameter/range

MTX

Lef+MTX

Lef+MTX

Inf+MTX

Base Case

Total Cost
82,956

Total Cost
116,991

Total Cost
189,145

Total Cost
187,748

Total Cost
314,895

QALYs
12.29

QALYs
12.94

QALYs
12.51

QALYs
13.28

QALYs
15.84

Adalimumab (-20%) 82,333

116,246

188,343

185,137

317,377

12.22

12.86

12.42

13.20

15.81

(+20%) 81,806

115,694

187,136

187,456

312,667

12.14

12.81

12.35

13.15

15.71

Etanercept (-20%) 82,380

115,541

186,667

185,096

312,606

12.19

12.82

12.40

13.14

15.73

(+20%) 82,361

116,108

187,831

186,072

317,839

12.29

12.86

12.42

12.21

15.84

(-20%) 82,245

116,005

188,077

186,325

314,690

12.19

12.82

12.40

13.17

15.74

(+20%) 82,381

115,791

189,164

185,566

315,083

12.23

12.86

12.43

13.20

15.80

Leflunomide (-20%) 82,498

115,521

189,128

186,815

316,097

12.22

12.88

12.45

13.22

15.78

(+20%) 82,320

116,663

188,163

185,758

314,707

12.19

12.83

12.41

13.18

15.74

(-20%) 81,528

116,556

189,915

187,414

318,828

12.22

12.86

12.44

13.21

15.84

(+20%) 82,678

115,206

186,861

184,440

312,838

12.13

12.79

12.36

13.13

15.70

Infliximab

MTX

Inf+MTX Ada+MTX Eta+MTX

MTX

Ada+MTX

Eta+MTX

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 15. One-way sensitivity analyses - Probability of mild/moderate adverse event
Parameter/range

Ada+MTX Eta+MTX

MTX

Lef+MTX

Inf+MTX

Total Cost

Total Cost

Total Cost

QALYs

QALYs

QALYs

QALYs

QALYs

116,991

189,145

187,748

314,895

12.29

12.94

12.51

13.28

15.84

Adalimumab (-20%) 82,125

115,716

186,652

185,383

313,820

12.20

12.85

12.42

13.19

15.77

(+20%) 82,115

115,637

186,411

185,091

311,861

12.18

12.85

12.40

13.18

15.69

Etanercept (-20%) 82,120

115,228

185,102

183,887

312,504

12.19

12.84

12.41

13.18

15.78

(+20%) 82,683

116,092

188,138

185,677

315,641

12.25

12.89

12.47

12.23

15.80

(-20%) 81,796

115,506

186,065

185,258

314,397

12.14

12.80

12.36

13.15

15.70

(+20%) 81,911

115,602

185,984

185,479

316,197

12.17

12.82

12.38

13.16

15.77

Leflunomide (-20%) 82,175

116,170

188,102

187,249

314,811

12.16

12.83

12.37

13.17

15.75

(+20%) 82,249

116,413

188,178

187,017

314,545

12.21

12.85

12.42

13.20

15.77

(-20%) 81,725

115,359

186,556

184,491

312,368

12.16

12.82

12.38

13.16

15.71

(+20%) 82,333

116,608

189,036

187,461

315,370

12.19

12.85

12.41

13.20

15.77

Base Case

Infliximab

MTX

MTX

Lef+MTX

Total Cost

Total Cost

82,956

Inf+MTX

Ada+MTX

Eta+MTX

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 16. One-way sensitivity analyses – Probability of joint replacement and discount rate
Parameter/range

Base Case

MTX

Lef+MTX

Inf+MTX Ada+MTX Eta+MTX

MTX

Total Cost

Total Cost

Total Cost

Total Cost

Total Cost

QALYs

82,956

116,991

189,145

187,748

314,895

12.29

Lef+MTX

Inf+MTX

Ada+MTX

Eta+MTX

QALYs

QALYs

QALYs

QALYs

12.94

12.51

13.28

15.84

Probability of joint replacement
(0.1)

79,246

112,750

183,244

182,448

311,608

12.56

13.22

12.80

13.57

16.14

(0.5)

83,420

116,666

189,199

186,113

313,172

12.01

12.65

12.23

12.98

15.53

(0%)

14,962

187,978

266,748

266,251

444,484

20.91

21.66

21.18

22.04

25.79

(5%)

61,465

92,971

159,864

158,538

264,591

19.37

9.98

9.58

10.31

12.41

Discount rate

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 17. One-way sensitivity analyses – Utilities: on medication, palliative care, and post-joint replacement
Parameter/range

MTX

Lef+MTX

Ada+MTX

Eta+MTX

Total Cost

Total Cost

Total Cost

Total Cost

Total Cost

QALYs

QALYs

QALYs

QALYs

82,956

116,991

189,145

187,748

314,895

12.29

12.94

12.51

13.28

15.84

Adalimumab (-20%)

82,968

116,414

188,832

186,252

317,218

12.29

12.91

12.50

12.56

15.85

(+20%)

82,497

116,409

188,808

186,937

314,330

12.23

12.87

12.44

13.91

15.76

(-20%)

82,044

115,569

186,640

185,492

315,142

12.16

12.81

12.38

13.16

14.09

(+20%)

82,673

115,934

186,438

185,119

313,793

12.24

12.88

12.46

13.22

17.38

(-20%)

81,471

115,652

186,241

186,061

313,641

12.14

12.80

11.86

13.15

15.72

(+20%)

82,159

115,767

187,125

185,503

313,890

12.21

12.85

12.90

13.19

15.72

Leflunomide (-20%)

82,397

116,099

188,336

186,637

315,912

12.20

12.22

12.43

13.20

15.78

(+20%)

82,103

115,862

188,141

186,145

313,873

12.19

13.46

12.40

13.18

15.72

(-20%)

82,222

115,709

188,063

185,661

314,782

11.80

12.84

12.42

13.18

15.73

(+20%)

81,917

115,516

187,661

185,018

315,897

12.57

12.83

12.39

13.17

15.78

UPall. Care (-20%)

82,305

116,314

188,827

187,033

315,317

10.51

11.27

10.79

11.16

14.60

(+20%)

81,822

115,485

187,255

185,455

314,426

13.84

14.40

14.01

14.74

16.91

(-20%)

82,036

115,638

187,336

185,503

316,368

11.82

12.46

12.04

12.81

15.46

(+20%)

82,389

116,234

188,648

186,658

316,882

12.58

13.22

12.80

13.56

16.13

Base Case

Inf+MTX Ada+MTX Eta+MTX

MTX

Lef+MTX
QALYs

Inf+MTX

On medication Utilities

Etanercept

Infliximab

MTX

UPost-JR

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
UPall.care = Palliative care utilities, UPost-JR = post-joint replacement utilities

107

Table 18. One-way sensitivity analyses - medication costs and infliximab administration costs
Parameter/range

MTX

Lef+MTX

Inf+MTX

Ada+MTX Eta+MTX

MTX

Total Cost

Total Cost

Total Cost

Total Cost

Total Cost

QALYs

82,956

116,991

189,145

187,748

314,895

12.29

Adalimumab (-20%) 82,206

116,013

187,189

167,384

316,082

(+20%) 82,656

116,745

188,589

206,667

Etanercept (-20%) 81,961

114,731

188,132

(+20%) 82,392

116,026

(-20%) 82,285

Lef+MTX

Ada+MTX

Eta+MTX

QALYs

QALYs

QALYs

12.94

12.51

13.28

15.84

12.21

12.85

12.41

13.19

15.80

317,777

12.24

12.88

12.44

13.23

15.86

183,286

272,391

12.19

12.81

12.39

13.15

15.76

187,046

186,003

358,282

12.21

12.85

12.43

13.19

15.78

115,950

169,784

185,710

314,081

12.20

12.84

12.42

13.18

15.76

(+20%) 82,369

116,215

205,646

186,682

316,016

12.21

12.86

12.42

13.20

15.82

Leflunomide (-20%) 81,897

110,672

188,814

186,646

318,205

12.18

12.84

12.39

13.18

15.83

(+20%) 82,059

120,755

186,701

184,826

313,864

12.18

12.84

12.41

13.18

15.76

(-20%) 81,617

114,708

186,923

185,126

310,428

12.24

12.88

12.45

13.23

15.78

(+20%) 83,344

118,521

190,856

189,643

319,301

12.20

12.87

12.43

13.22

15.79

Base Case

QALYs

Inf+MTX

Medication costs

Infliximab

MTX

Infliximab infusion administration costs
($663.6) 82,222

115,866

185,702

186,068

315,605

12.18

12.82

12.40

13.16

15.75

($1,033.6) 82,281

115,901

190,038

186,002

314,196

12.20

12.85

12.43

13.19

15.78

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 19. One-way sensitivity analyses - Costs of monitoring in first six months
Parameter/range

MTX

Lef+MTX

Inf+MTX

Ada+MTX Eta+MTX MTX

Total Cost

Total Cost

Total Cost

Total Cost

Total Cost

QALYs

Lef+MTX
QALYs

Inf+MTX

Ada+MTX

Eta+MTX

QALYs

QALYs

QALYs

Base Case

82,956

116,991

189,145

187,748

314,895

12.29

12.94

12.51

13.28

15.84

Adalimumab ($730)

81,782

115,293

185,304

184,320

313,735

12.17

12.82

12.38

13.15

15.72

($1,262) 81,767

115,349

186,791

185,420

314,904

12.13

12.78

12.34

13.12

15.71

81,782

115,293

185,304

184,320

313,735

12.17

12.82

12.38

13.15

15.72

($1,262) 81,767

115,349

186,791

185,420

314,904

12.13

12.78

12.34

13.12

15.71

($730)

81,782

115,293

185,304

184,320

313,735

12.17

12.82

12.38

13.15

15.72

($1,262) 81,767

115,349

186,791

185,420

314,904

12.13

12.78

12.34

13.12

15.71

Etanercept ($730)

Infliximab

Leflunomide ($487)

82,533

115,877

187,278

185,844

314,059

12.25

12.88

12.45

13.22

15.79

($852)

82,050

116,057

188,246

186,393

316,781

12.18

12.82

12.40

13.17

15.79

($488)

81,846

116,127

187,559

186,872

316,117

12.15

12.81

12.36

13.16

15.76

($927)

82,251

115,767

187,139

185,321

312,891

12.20

12.86

12.43

13.21

15.73

MTX

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 20. One-way sensitivity analyses - Costs of monitoring after six months
Parameter/range

Base Case

MTX

Lef+MTX

Inf+MTX

Ada+MTX Eta+MTX MTX

Lef+MTX

Inf+MTX

Ada+MTX

Eta+MTX

QALYs

QALYs

QALYs

QALYs

Total Cost

Total Cost

Total Cost

Total Cost

Total Cost

QALYs

82,956

116,991

189,145

187,748

314,895

12.29

12.94

12.51

13.28

15.84

Adalimumab ($240)

82,054

115,798

186,126

184,532

310,690

12.17

12.83

12.40

13.17

15.74

($468)

82,378

116,040

188,697

187,627

318,616

12.20

12.84

12.40

13.18

15.80

Etanercept ($240)

82,054

115,798

186,126

184,532

310,690

12.17

12.83

12.40

13.17

15.74

($468)

82,378

116,040

188,697

187,627

318,616

12.20

12.84

12.40

13.18

15.80

($240)

82,054

115,798

186,126

184,532

310,690

12.17

12.83

12.40

13.17

15.74

($468)

82,378

116,040

188,697

187,627

318,616

12.20

12.84

12.40

13.18

15.80

Leflunomide ($347)

81,691

113,664

186,649

184,830

311,460

12.12

12.77

12.34

13.12

15.63

($598)

82,190

117,091

187,375

185,751

315,068

12.19

12.83

12.41

13.17

15.70

($299)

81,947

115,987

187,949

185,612

315,163

12.23

12.86

12.45

13.21

15.77

($501)

82,608

116,121

188,349

186,587

313,890

12.17

12.83

12.40

13.18

15.71

Infliximab

MTX

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX

110

Table 21. One-way sensitivity analyses - Hospitalization costs
Parameter/range

MTX

Lef+MTX

Inf+MTX

Ada+MTX Eta+MTX MTX

Total Cost

Total Cost

Total Cost

Total Cost

82,956

116,991

189,145

187,748

314,895

12.29

Adalimumab (-20%) 82,013

115,381

186,793

183,197

312,126

(+20%) 82,545

116,774

188,736

189,783

Etanercept (-20%) 81,995

115,718

186,503

(+20%) 81,765

114,929

(-20%) 82,327

Eta+MTX
QALYs

12.94

12.51

13.28

15.84

12.18

12.80

12.38

13.14

15.65

317,130

12.23

12.88

12.45

13.23

15.83

185,713

309,141

12.18

12.81

12.39

13.15

15.66

185,185

183,947

315,162

12.17

12.80

12.39

13.14

15.68

115,883

185,401

186,471

314,022

12.18

12.82

12.41

13.17

15.73

(+20%) 82,098

115,377

190,159

184,921

313,339

12.19

12.82

12.41

13.16

15.73

Leflunomide (-20%) 82,316

113,864

188,251

186,741

314,372

12.18

12.83

12.39

13.17

15.77

(+20%) 82,323

118,169

188,645

186,157

314,211

12.20

12.84

12.42

13.19

15.75

(-20%) 80,778

115,605

187,490

184,951

313,237

12.24

12.87

12.46

13.21

15.73

(+20%) 83,701

115,460

187,065

185,153

313,164

12.17

12.81

12.38

13.14

15.72

MTX

QALYs

Ada+MTX
QALYs

Infliximab

QALYs

Inf+MTX
QALYs

Base Case

Total Cost

Lef+MTX

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 22. One-way sensitivity analyses - Costs of treating mild/moderate adverse event, severe adverse event, joint
replacement, and palliative care treatment
Parameter/range

Base Case

MTX

Lef+MTX

Inf+MTX

Ada+MTX Eta+MTX MTX

Total Cost

Total Cost

Total Cost

Total Cost

Total Cost

QALYs

82,956

116,991

189,145

187,748

314,895

12.29

Lef+MTX
QALYs

Inf+MTX

Ada+MTX

Eta+MTX

QALYs

QALYs

QALYs

12.94

12.51

13.28

15.84

Costs of treating mild/moderate adverse event
($126) 82,014

115,240

186,511

185,077

316,321

12.17

12.82

12.39

13.16

15.80

($204) 82,640

116,400

187,147

186,751

316,475

12.24

12.88

12.43

13.22

15.83

Costs of treating severe adverse event
(-20%) 81,127

114,405

185,071

182,421

312,683

12.20

12.81

12.40

13.15

15.73

(+20%) 83,550

117,147

189,318

188,943

315,027

12.23

12.86

12.44

13.21

15.76

($15,592) 79,518

113,048

184,607

182,407

310,011

12.21

12.86

12.42

13.20

15.72

($23,388) 85,075

118,490

190,108

188,345

320,584

12.18

12.81

12.39

13.16

15.78

73,013

106,675

177,380

176,135

307,692

12.24

12.85

12.43

13.19

15.79

($1,369) 91,585

125,270

198,056

195,972

324,216

12.20

12.86

12.42

13.21

15.82

Costs of joint replacement

Costs of palliative care treatment
($912)

MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 23. Summary of main results in one-way sensitivity analyses
Parameter/range

Leflunomide+MTX

Infliximab+MTX

Adalimumab+MTX

Etanercept+MTX

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

52,833

Dominated

Extended Domination

49,724

(-20%)

52,058

Dominated

Extended Domination

38,033

(+20%)

52,058

Dominated

Extended Domination

38,033

(-20%)

52,058

Dominated

Extended Domination

46,773

(+20%)

52,058

Dominated

Extended Domination

38,033

(-20%)

52,058

Dominated

Extended Domination

40,078

(+20%)

52,058

Dominated

Extended Domination

34,986

(-20%)

52,059

Dominated

Extended Domination

30,371

(+20%)

52,059

Dominated

Extended Domination

50,047

(-20%)

45,638

Dominated

Extended Domination

38,033

(+20%)

63,126

Dominated

Extended Domination

38,033

(-20%)

Extended Domination

Dominated

Extended Domination

38,033

(+20%)

45,256

Dominated

Extended Domination

38,033

Base Case
Probability of Achieving ACR 20 Response
All Five Treatments

Probability of Total Withdrawals
Adalimumab

Etanercept

Infliximab

Leflunomide

MTX

All treatments compared to Standard MTX treatment
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Table 23. Summary of main results in one-way sensitivity analyses
Parameter/range

Leflunomide+MTX

Infliximab+MTX

Adalimumab+MTX

Etanercept+MTX

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

52,833

Dominated

Extended Domination

49,724

(-20%)

52,058

Dominated

Extended Domination

38,033

(+20%)

52,058

Dominated

Extended Domination

38,033

(-20%)

52,058

Dominated

Extended Domination

38,033

(+20%)

52,058

Dominated

Extended Domination

38,033

(-20%)

52,058

Dominated

Extended Domination

37,917

(+20%)

52,058

Dominated

Extended Domination

38,130

(-20%)

52,058

Dominated

Extended Domination

38,070

(+20%)

52,058

Dominated

Extended Domination

37,996

(-20%)

51,802

Dominated

Extended Domination

38,033

(+20%)

52,296

Dominated

Extended Domination

38,033

(-20%)

52,201

Dominated

Extended Domination

38,033

(+20%)

51,916

Dominated

Extended Domination

38,033

Base Case
Probability of Withdrawal Due to Loss of Efficacy
All Five Treatments

Probability of Mild/Moderate Adverse Events
Adalimumab

Etanercept

Infliximab

Leflunomide

MTX

All treatments compared to Standard MTX treatment
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Table 23. Summary of main results in one-way sensitivity analyses
Parameter/range

Leflunomide+MTX

Infliximab+MTX

Adalimumab+MTX

Etanercept+MTX

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

52,833

Dominated

Extended Domination

49,724

(0.1)

52,069

Dominated

Extended Domination

38,193

(0.5)

52,058

Dominated

Extended Domination

37,966

(0%)

51,253

Dominated

Extended Domination

38,923

(5%)

52,493

Dominated

Extended Domination

37,017

Base Case
Probability of Joint Replacement

Discount Rate

All treatments compared to the reference case: Standard MTX treatment
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Table 23. Summary of main results in one-way sensitivity analyses
Parameter/range

Leflunomide+MTX

Infliximab+MTX

Adalimumab+MTX

Etanercept+MTX

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

52,833

Dominated

Extended Domination

49,724

(-20%)

52,058

Dominated

Dominated

38,033

(+20%)

52,058

Dominated

67,246

38,033

(-20%)

52,058

Dominated

Extended Domination

74,628

(+20%)

Extended Domination

Dominated

Extended Domination

25,519

(-20%)

52,058

Dominated

Extended Domination

33,159

(+20%)

52,058

Dominated

Extended Domination

44,587

(-20%)

Extended Domination

Dominated

Extended Domination

38,033

(+20%)

26,362

Dominated

(-20%)

32,218

Dominated

Extended Domination

38,033

(+20%)

Extended Domination

Dominated

Extended Domination

50,048

(-20%)

44,932

Dominated

Extended Domination

33,377

(+20%)

61,872

Dominated

Extended Domination

44,199

(-20%)

52,047

Dominated

Extended Domination

37,888

(+20%)

Extended Domination

Dominated

Extended Domination

38,033

Base Case
Utilities – On Medication
Adalimumab

Etanercept

Infliximab

Leflunomide

MTX

Palliative Care

Post-JR

Dominated

38,033

All treatments compared to the reference case: Standard MTX treatment
Post-JR = Post-Joint Replacement
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Table 23. Summary of main results in one-way sensitivity analyses
Parameter/range

Leflunomide+MTX

Infliximab+MTX

Adalimumab+MTX

Etanercept+MTX

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

52,833

Dominated

Extended Domination

49,724

(-20%)

52,058

Dominated

Extended Domination

38,033

(+20%)

52,058

Dominated

Extended Domination

42,714

(-20%)

52,058

Dominated

Extended Domination

25,489

(+20%)

52,058

Dominated

Extended Domination

50,577

(-20%)

52,058

Dominated

Extended Domination

50,047

(+20%)

52,058

Dominated

Extended Domination

32,045

(-20%)

43,720

Dominated

Extended Domination

38,033

(+20%)

60,397

Dominated

Extended Domination

38,033

(-20%)

50,822

Dominated

Extended Domination

37,333

(+20%)

53,295

Dominated

Extended Domination

38,734

($663)

52,058

Dominated

Extended Domination

50,047

($1,033)

52,058

Dominated

Extended Domination

37,470

Base Case
Medication Costs
Adalimumab

Etanercept

Infliximab

Leflunomide

MTX

Infliximab Infusion Administration Costs

All treatments compared to the reference case: Standard MTX treatment
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Table 23. Summary of main results in one-way sensitivity analyses
Parameter/range

Leflunomide+MTX

Infliximab+MTX

Adalimumab+MTX

Etanercept+MTX

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

52,833

Dominated

Extended Domination

49,724

($730)

52,058

Dominated

Extended Domination

38,033

($1,262)

52,058

Dominated

Extended Domination

38,033

($487)

51,917

Dominated

Extended Domination

38,033

($852)

52,199

Dominated

Extended Domination

38,033

($488)

52,228

Dominated

Extended Domination

38,033

($927)

51,889

Dominated

Extended Domination

38,033

($240)

52,058

Dominated

Extended Domination

37,473

($468)

52,058

Dominated

Extended Domination

38,593

($347)

49,823

Dominated

Extended Domination

38,033

($598)

52,199

Dominated

Extended Domination

38,033

($299)

53,022

Dominated

Extended Domination

38,033

($501)

51,168

Dominated

Extended Domination

38,033

Base Case
Monitoring Costs in First Six Months
TNF inhibitors

Leflunomide

MTX

Monitoring Costs after Six Months
TNF inhibitors

Leflunomide

MTX

All treatments compared to the reference case: Standard MTX treatment
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Table 23. Summary of main results in one-way sensitivity analyses
Parameter/range

Leflunomide+MTX

Infliximab+MTX

Adalimumab+MTX

Etanercept+MTX

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

52,833

Dominated

Extended Domination

49,724

(-20%)

52,058

Dominated

Extended Domination

38,033

(+20%)

52,058

Dominated

Extended Domination

49,248

(-20%)

52,058

Dominated

Extended Domination

36,822

(+20%)

52,058

Dominated

Extended Domination

39,244

(-20%)

52,058

Dominated

Extended Domination

50,047

(+20%)

52,058

Dominated

Extended Domination

37,035

(-20%)

48,603

Dominated

Extended Domination

38,033

(+20%)

55,514

Dominated

Extended Domination

38,033

(-20%)

54,655

Dominated

Extended Domination

38,033

(+20%)

49,461

Dominated

Extended Domination

38,033

($126)

51,924

Dominated

Extended Domination

37,938

($204)

52,193

Dominated

Extended Domination

38,129

Base Case
Costs of Hospitalization
Adalimumab

Etanercept

Infliximab

Leflunomide

MTX

Cost of Treating Mild/ Moderate Adverse Events

All treatments compared to the reference case: Standard MTX treatment
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Table 23. Summary of main results in one-way sensitivity analyses
Parameter/range

Leflunomide+MTX

Infliximab+MTX

Adalimumab+MTX

Etanercept+MTX

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

ICER (Total Cost/QALY)

52,833

Dominated

Extended Domination

49,724

(-20%)

52,492

Dominated

Extended Domination

37,993

(+20%)

51,625

Dominated

Extended Domination

38,073

($15,592)

52,060

Dominated

Extended Domination

38,058

($23,388)

52,057

Dominated

Extended Domination

38,008

($912)

52,698

Dominated

Extended Domination

38,623

($1,369)

51,418

Dominated

Extended Domination

37,443

Base Case
Cost of Treating Severe Adverse Events

Cost of Joint Replacement

Costs of Palliative Care Treatment

All treatments compared to the reference case: Standard MTX treatment
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The total costs were sensitive to changes in the medication costs. However, the
dominance status of each considered treatments remained the same as in the base-case
analysis. As seen in the results, changes in the cost parameters influenced only the total
costs and not the effectiveness and resulted in marked changes in the ICERs for the
treatments. For example, reducing the medication costs of etanercept and leflunomide
(the two nondominated treatments) by 20% resulted in an ICER of $25,489/QALY and
$43,720/QALY, respectively. Conversely, increasing the medication costs of
etanercept and leflunomide by 20% resulted in an ICER of $50,577/QALY and
$60,397/QALY, respectively.

Changes in the utility parameter also resulted in changes in the ICERs.
Increasing the utilities of etanercept and leflunomide by 20% resulted in an ICER of
$25,519/QALY and $26,362/QALY, respectively. Decreasing the utilities of these
treatments by 20% resulted in an ICER of $74,628/QALY for etanercept and
leflunomide was ruled out by extended dominance. Results varied little with changes
in the utilities associated with palliative care and post-joint replacement care.

The results were most sensitive to changes in medication costs, cost of palliative
care, and probability of total withdrawals (Figure 5 and 6). The results were not
sensitive to the changes in the probability of ACR 20 responses and probability of lack
of efficacy of treatments. Also, results varied little with the changes in probability of
joint replacement, discount rate, monitoring costs, costs of hospitalizations, and costs of
severe and mild/moderate adverse events. The ICER for leflunomide plus MTX
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Figure 5. One-way sensitivity analysis: Etanercept
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Figure 6. One-way sensitivity analysis: Leflunomide

Cost of severe ADR
Cost of hospitalization

-20%

Cost of palliative care

20%

Input Parameters

Cost of JR
Monitoring cost
Cost of medication
Utilities
Discount rate
Probability of JR
Probability of mild/moderate ADR
Probability of lack of efficacy
Probability of withdrawal
Probability of ACR 20

15

35

55
Incremental CE Ratio

75
Thousands

ADR= Adverse Drug Reaction
ACR=American College of Rheumatology
JR=Joint Replacement
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remained fairly stable across the ranges of all variables, except when medication costs
and utilities of leflunomide were reduced or increased by 20%.

The ICER for etanercept plus MTX was found to be even more favorable in the
sensitivity results than in the base-case analysis. The ICER for etanercept plus MTX
in the sensitivity analysis for a number of variables was around $38,000/QALY
compared to an ICER of $49,724/QALY reported in the base-case analysis. This is
because the total costs of adalimumab plus MTX and infliximab plus MTX are very
similar to each other. Varying any of the variables in the sensitivity analysis between
+20% resulted in a change in position of adalimumab plus MTX and infliximab plus
MTX in the calculation of incremental costs and this made the ICER for etanercept plus
MTX even more favorable. For example, when the treatment cost of adalimumab plus
MTX is reduced by 20%, the lifetime cost of adalimumab plus MTX is $167,384 while
that of infliximab plus MTX is $187,189 and etanercept plus MTX is $316,082. The
incremental cost of etanercept plus MTX is calculated by subtracting infliximab plus
MTX cost from etanercept plus MTX cost. However, when treatment cost of
adalimumab plus MTX is increased by 20%, the lifetime cost of adalimumab plus MTX
increases to $206,667 while that of infliximab plus MTX and etanercept plus MTX
remain approximately the same. The incremental cost of etanercept plus MTX is now
calculated from adalimumab plus MTX since the cost of adalimumab plus MTX is
higher than that of infliximab plus MTX. This results in a lower ICER for etanercept
plus MTX treatment.
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Probabilistic Sensitivity Analysis
Because the overall variability of a model is poorly characterized by a
univariate sensitivity analysis, probabilistic sensitivity analysis (second order Monte
Carlo simulation) was also used to characterize this variability. As discussed earlier,
each parameter in the model, instead of taking a single value, was assumed to be a
variable quantity with a known range of possible values and an associated distribution
function. Since all costs, probabilities, and utilities were given ranges, a triangular
distribution was specified for each of the variable. Triangular distribution takes into
consideration the lowest, highest, and the likeliest value of any variable.

The process of resampling from each of the distributions and recalculating the
cost-effectiveness from the model was repeated 10,000 times to generate the total costs,
effectiveness, and ICERs of each treatment. The results are presented in Table 24 and
are similar to those obtained in the base-case analysis. Etanercept plus MTX and
leflunomide plus MTX had an ICER of $49,689/QALY and $51,288/QALY,
respectively. Infliximab plus MTX was dominated by leflunomide plus MTX and
adalimumab plus MTX was ruled out by extended domination. The advantage of using
a probabilistic sensitivity analysis is that it instills more confidence in the validity of the
model by taking into consideration the relevant uncertainty in the parameter; and by
specifying a prior distribution for a particular parameter that increases the clarity of the
model.
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Table 24. Probabilistic sensitivity analysis results for total costs, effectiveness, and incremental cost-effectiveness ratios of
different treatments for patients with RA that inadequately respond to MTX (using age-, sex-, race-adjusted all-cause
mortality rate
Treatments

Total costs*
($)

Effectiveness
(QALYs)

Incremental
cost-effectiveness ratios
($/QALY)

Standard MTX

83,003

12.25

-

Leflunomide+MTX

116,506

12.91

51,288

Infliximab+MTX

186,868

12.47

Dominated#

Adalimumab+MTX

187,352

13.25

Extended Domination##

Etanercept+MTX

316,468

15.85

49,689

All treatments compared to the reference case: Standard MTX treatment
MTX=methotrexate
*
Total costs = Direct costs + Indirect costs (Indirect costs calculated as same as direct costs)
# Infliximab+MTX dominated by Leflunomide+MTX
## Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.645 and 0.884.
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Effect of RA-adjusted Mortality Rate on ICERs
There are uncertainties relating to the available data on the effects of RA on the
risk of mortality. To examine the effect of increased risk of mortality due to RA, it was
assumed that mortality was two-fold greater compared with an age-, sex-, and racematched general population. Results of the analyses comparing the direct costs, total
costs, effectiveness, and ICERs of the five treatments are shown in Tables 25 and 26.

The dominance status of each treatment remained the same as in the base-case
analysis using total costs and direct costs. The standard MTX treatment was the least
expensive (direct costs = $62,504, total costs = $71,867) and lowest QALY gain (10.9
QALY). Etanercept plus MTX was the most expensive treatment (direct costs =
$177,197, total costs = $297,171) and highest QALY gain (14.3 QALY). This
treatment provided more health benefits and was more costly than standard MTX
treatment, with resulting cost-effectiveness ratios of $24,421/QALY (direct costs) and
$50,782/QALY (total costs). The second most cost-effective option was leflunomide
plus MTX with an ICER of $28,127/QALY (direct costs) and $51,905/QALY (total
costs). Infliximab plus MTX was dominated by adalimumab plus MTX and
adalimumab plus MTX was ruled out through extended dominance.
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Table 25. Results for total costs and effectiveness using Monte Carlo simulations of 10,000 hypothetical patients with RA that
inadequately respond to MTX (using RA-adjusted mortality rates)
Total Costs* ($)
Treatment Strategy

Effectiveness (QALYs)

Min $

Median $

Max $

Mean (+SD)

71,867 (+28,069) 1,362

77,196

153,563

Leflunomide+MTX

104,865 (+53,091) 2,276

97,161

Infliximab+MTX

173,920 (+122,090) 6,360

Adalimumab+MTX
Etanercept+MTX

Standard MTX

Mean (+SD) $

Min

Median

Max

10.91 (+3.40) 0.22

12.00

18.61

343,265

11.55 (+3.65) 0.25

12.46

23.46

135,807

858,419

11.13 (+3.47) 0.23

12.16

21.08

173,314 (+112,921) 5,233

142,950

731,753

11.88 (+3.81) 0.28

12.68

25.85

297,171 (+190,522) 5,184

256,584

851,614

14.32 (+5.22) 0.29

14.29

33.88

All treatments compared to the reference case: Standard MTX treatment
MTX=methotrexate
*
Total costs = Direct costs + Indirect costs (Indirect costs calculated the same as direct costs)
QALYs = Quality adjusted life years
MTX = Methotrexate
SD = Standard deviation
Min = Minimum
Max=Maximum
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Table 26. Direct costs, effectiveness, total costs, and cost-effectiveness of different treatments for patients with RA that
inadequately respond to MTX (using RA-adjusted mortality rates)
Treatment Strategy

Direct costs Effectiveness
($)
(QALYs)

Incremental
cost-effectiveness
ratios
($/QALY)

Standard MTX

62,504

10.90

-

Leflunomide+MTX

80,254

11.53

Infliximab+MTX

118,205

Adalimumab+MTX
Etanercept+MTX

Total costs*
($)

Effectiveness Incremental
(QALYs)
cost-effectiveness
ratios
($/QALY)

71,867

10.91

-

28,127

104,865

11.55

51,905

11.14

Dominated+

173,920

11.13

Dominated#

118,383

11.87

Extended Domination++

173,314

11.88

Extended Domination##

177,197

14.28

24,421

297,171

14.32

50,782

All treatments compared to the reference case: Standard MTX treatment
MTX=methotrexate
*
Total costs = Direct costs + Indirect costs (Indirect costs calculated as same as direct costs)
+
Infliximab+MTX dominated by Adalimumab+MTX
++
Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.609 and 0.878.
# Infliximab+MTX dominated by Adalimumab+MTX
## Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.644 and 0.880.
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Effect of Indirect Costs on ICERs
Additional analyses were conducted to determine if there was any change in the
dominance of treatments with regards to changes in the indirect costs. Indirect costs
were calculated as two and three times that of direct costs. Tables 27 and 28 give the
total costs, effectiveness, and ICERs for each treatment using both age-, sex-, and raceadjusted mortality rate and RA-adjusted mortality rates.

When indirect costs were considered as twice that of direct costs, etanercept
plus MTX had the lowest ICER of $75,502 to $75,577/QALY followed closely by
leflunomide plus MTX with an ICER of $75,688 to $77,398/QALY. However, when
indirect costs were considered as three times that of direct costs, leflunomide plus MTX
had the lowest ICER of $101,704 to $101,919/QALY followed by etanercept plus
MTX by with an ICER of $101,875 to $102,548/QALY. In both scenarios, infliximab
plus MTX and adalimumab plus MTX were ruled out by dominance and extended
dominance, respectively.
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Table 27. Total costs, effectiveness, and incremental cost-effectiveness ratios of different treatments for patients with RA that
inadequately respond to MTX

Treatment Strategy

ASR-adjusted All-cause Mortality Rates

RA Adjusted All-cause Mortality Rates

Total costs*
($)

Total costs*
($)

Effectiveness
(QALYs)

Incremental
cost-effectiveness
ratios
($/QALY)

92,428

12.25

-

Leflunomide+MTX

141,666

12.90

Infliximab+MTX

246,826

Adalimumab+MTX
Etanercept+MTX

Standard MTX

Effectiveness
(QALYs)

Incremental
cost-effectiveness
ratios
($/QALY)

81,565

10.93

-

75,688

130,099

11.55

77,398

12.47

Dominated#

230,437

11.15

Dominated§

243,493

13.25

Extended Domination##

234,753

11.89

Extended Domination§§

440,085

15.86

75,502

418,168

14.38

75,577

All treatments compared to the reference case: Standard MTX treatment
MTX=methotrexate
ASR = Age, Sex, Race
*
Total costs = Direct costs + Indirect costs (Indirect costs calculated as two times that of direct costs)
#
Infliximab+MTX dominated by Adalimumab +MTX
##
Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.659 and 0.882.
§
Infliximab+MTX dominated by Adalimumab +MTX
§§
Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.652 and 0.879.
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Table 28. Total costs, effectiveness, and incremental cost-effectiveness ratios of different strategies for patients with RA that
inadequately respond to MTX
Normal ASR-adjusted All-cause Mortality Rates

RA Adjusted All-cause Mortality Rates

Treatment Strategy

Total costs*
($)

Effectiveness
(QALYs)

Incremental
cost-effectiveness
ratios
($/QALY)

Total costs*
($)

Effectiveness
(QALYs)

Incremental
cost-effectiveness
ratios
($/QALY)

Standard MTX

102,224

12.30

-

90,509

10.87

-

Leflunomide+MTX

165,852

12.93

101,704

152,332

11.48

101,919

Infliximab+MTX

305,123

12.52

Dominated#

290,420

11.09

Dominated§

Adalimumab+MTX

297,229

13.27

Extended Domination##

280,414

11.81

Extended Domination§§

Etanercept+MTX

557,684

15.82

101,875

530,070

14.25

102,548

All treatments compared to the reference case: Standard MTX treatment
MTX=methotrexate
ASR = Age, Sex, Race
*
Total costs = Direct costs + Indirect costs (Indirect costs calculated as three times that of direct costs)
#
Infliximab+MTX dominated by Adalimumab +MTX
##
Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.665 and 0.883.
§
Infliximab+MTX dominated by Adalimumab +MTX
§§
Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.661 and 0.880.
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Hospitalization Costs
There are uncertainties relating to the available data on the effects of TNF
inhibitors, leflunomide, or methotrexate on hospitalization costs. Unlike the base-case
analysis that included hospitalization costs, this analysis was carried out by excluding
the hospitalization costs and studying its effect on the ICERs. The results of the
analysis using age-, sex-, race-adjusted all-cause mortality rates and RA-adjusted
mortality are shown in Table 29. Etanercept plus MTX had the lowest ICER followed
by leflunomide plus MTX. Infliximab plus MTX and adalimumab plus MTX were
ruled out by dominance and extended dominance, respectively. The ICERs reported in
Table 29 are similar to those obtained in the base-case analysis.
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Table 29. Total costs, effectiveness, and cost-effectiveness of different strategies for patients with RA that inadequately
respond to MTX (without hospitalization costs)

Treatment Strategy

ASR-adjusted All-cause Mortality Rates

RA Adjusted All-cause Mortality Rates

Total costs*
($)

Total costs*
($)

Effectiveness
(QALYs)

Incremental
cost-effectiveness
ratios
($/QALY)

74,487

12.29

-

Leflunomide+MTX

105,296

12.91

50,246

Infliximab+MTX

171,508

12.49

Adalimumab+MTX

176,335

Etanercept+MTX

295,922

Standard MTX

Effectiveness
(QALYs)

Incremental
cost-effectiveness
ratios
($/QALY)

63,207

10.86

-

93,788

11.49

48,013

Dominated#

159,098

11.07

Dominated§

13.25

Extended Domination##

163,854

11.83

Extended Domination§§

15.82

46,529

274,493

14.20

46,714

All treatments compared to the reference case: Standard MTX treatment
MTX=methotrexate
ASR = Age, Sex, Race
*
Total costs = Direct costs + Indirect costs (Indirect costs calculated as same as direct costs)
#
Infliximab+MTX dominated by Leflunomide+MTX
##
Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.627 and 0.882.
§
Infliximab+MTX dominated by Leflunomide+MTX
§§
Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.612 and 0.874.
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Effect of Joint Replacement Therapy
The Markov model included two tracker variables that provided information
regarding the proportion of people undergoing joint replacement therapy and the mean
age at which people underwent joint replacement therapy. As seen from the results
presented in Table 30, the proportion of patients undergoing joint replacement therapy
is the lowest for the combination of MTX and TNF inhibitors followed by standard
MTX treatment and leflunomide plus MTX. Among the TNF inhibitors, the lowest
proportion of patients undergoing joint replacement therapy was seen with etanercept
plus MTX. Also, the mean age (68.58 years) and maximum age of undergoing joint
replacement (83.5 years) is the highest for etanercept plus MTX indicating that more
patients stay on the treatment before moving on to palliative care where they may
undergo joint replacement. Thus, patients continue to stay on etanercept plus MTX for
a longer time period compared with the other treatments thereby accumulating higher
costs and outcomes.
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Table 30. Proportion of patients undergoing joint replacement and age at which
joint replacement occurs for each treatment
Treatment Strategy

Proportion of
Patients with JR

Mean Age
in yrs (+SD)

Min. Age
in yrs

Max. Age
in yrs

Standard MTX

78.9

68.42 (+1.7)

67.0

79.5

Leflunomide+MTX

79.5

68.33 (+1.5)

67.0

77.5

Infliximab+MTX

77.9

68.26 (+1.5)

67.0

78.0

Adalimumab+MTX

77.9

68.40 (+1.6)

67.0

75.5

Etanercept+MTX

76.4

68.58 (+2.0)

67.0

83.5

Min. Age - Minimum age when patients underwent Joint replacement, Max. Age - Maximum age when
patients underwent Joint replacement, SD - Standard deviation, JR - Joint Replacement
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Discussion for Phase I Results
Background
Cost-effectiveness analysis has become the standard metric for the assessment
of the clinical and economic value of new treatments (Ruff, 1999). These analyses
translate the clinical benefits of any treatment into both lifetime costs and effectiveness
measures such as quality-adjusted life years (QALYs). Thus, by applying a long time
horizon, these analyses account for future benefits and savings or expense. Also, these
analyses help decision makers, clinicians, and patients compare relative costeffectiveness of alternative treatments (Wong, 2004).

It has become a practice to compare new treatments to standard care so that new
treatments that are more effective and less costly over a lifetime can be cost saving and
also dominate the current standard treatments (Gabriel, Tugwell, O’Brien et al., 1999).
More often, new treatments introduced in the market are more effective but also cost
more. To establish their effectiveness against standard treatments, incremental costeffectiveness analysis are conducted which takes into account the increased cost of the
new treatment divided by the increased benefits the new treatment offers. Typically, the
outcome measures used in these analyses are expressed as the net additional costs to
increase life expectancy by one discounted QALY.

Tumor Necrosis Factor Inhibitors
Tumor necrosis factor inhibitors offer important treatment options to patients
who fail multiple traditional DMARDs. Results from RCTs conducted in patients that
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inadequately respond to MTX alone have shown that these new treatments have the
potential to reduce future disability (Keystone et al., 2004; Maini et al., 1999; Weinblatt
et al., 2003; Weinblatt et al., 1999). However, these agents are expensive compared to
the traditional DMARDs. Based on the average US wholesale price, adalimumab and
etanercept cost around $16,000 and infliximab costs $17,000 per year (Drug Topics
Red Book, 2004). These costs do not include pre-therapy testing for opportunistic
infections or monitoring for treatment complications. Also, a number of patients (2634%) discontinue treatment in the first year due to toxicities or ineffectiveness
(Flendrie, Creemers, Welsing, Den Broeder, & Van Riel, 2003). A cost-effectiveness
analysis of these new treatments is thus warranted. The resulting cost-effectiveness
ratio will express the relationship between the extra costs and additional benefits of
these new treatments in comparison with the traditional DMARDs they replace.

Economic Model for RA
In RA, the health benefits and economic costs of treatments are more evident in
the longer term. However, data on the efficacy of TNF inhibitors are limited and only
available from short-term RCTs. Therefore, decision analytical modeling is used to
synthesize short-term clinical trial results with long-term disease epidemiological
aspects, quality of life, mortality, and resource use (Bansback et al., 2005). In the last
few years, a few economic studies assessing the incremental cost-effectiveness of TNF
inhibitors versus standard therapies have been published. As discussed in Chapter 2,
these studies have been limited by their study duration, failing to include withdrawal of
patients in the first year of treatment due to lack of efficacy or toxicities, or failing to
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include additional costs due to monitoring or treating for complications in patients
using TNF inhibitors. Additionally, no study has evaluated the cost-effectiveness of all
three TNF inhibitors in RA patients that inadequately respond to MTX.

The current study utilized results from RCTs that were conducted in patients
that inadequately responded to MTX alone. Outcome Measures in Rheumatology
(OMERACT) acknowledge that the underlying characteristics of the clinical trial
should define the population to which the economic analysis is applicable (Bansback et
al., 2005). A hypothetical cohort of 55-year old women was selected as the base-case
population who had failed two DMARDs, one of which was MTX. The study model
used cost per QALY as the outcome measure.

Review of Study Results
A Markov Model was constructed to evaluate the total costs and effects of five
treatments: adalimumab plus MTX, etanercept plus MTX, infliximab plus MTX,
leflunomide plus MTX, and a standard therapy of MTX in patients with RA that
inadequately respond to MTX alone. The model was evaluated using a first order
Monte Carlo simulation. The base-case simulation model yielded an ICER of
$49,724/QALY for etanercept plus MTX followed by the next nondominated option of
leflunomide plus MTX with an ICER of $52,833/QALY. Infliximab plus MTX was
dominated by adalimumab plus MTX and adalimumab plus MTX was ruled out
through extended dominance. Thus, the net societal economic cost of etanercept plus
MTX in treatment of patients that inadequately respond to MTX alone is at most
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$49,724 to increase life expectancy by one quality-adjusted life year, i.e., one year of
perfect health.

Taking only total costs into account, the standard MTX treatment was the least
expensive ($82,956 for a lifetime treatment) and etanercept plus MTX was the most
expensive treatment ($314,895). The two other TNF inhibitors, infliximab plus MTX
($189,145) and adalimumab plus MTX ($187,748) were less expensive than etanercept
plus MTX but were more expensive than leflunomide plus MTX ($116,991). The total
QALY gain was the highest in etanercept plus MTX (15.84 QALYs) followed by
adalimumab plus MTX (13.28 QALYs), leflunomide plus MTX (12.94 QALYs),
infliximab plus MTX (12.51 QALYs), and standard MTX treatment (12.29 QALYs).

As this study was the first to evaluate the cost-effectiveness of all three TNF
inhibitors and leflunomide in patients with RA that inadequately respond to MTX
alone, results were not directly comparable to other studies. As reported earlier, there
are few economic studies that have compared each of the TNF inhibitor to a standard
therapy. Also, the decision analytic models used in these studies have used disparate
time horizons, comparators, quantities of drugs, discount rates, and treatment sequences
making it very difficult to compare the cost-effectiveness ratios between the analyses.

Reports of the cost-effectiveness of TNF inhibitors and leflunomide are
available from other countries (Bansback et al., 2004; Barton et al., 2004; Brennan et
al., 2003; Jobanputra et al., 2002; Kobelt et al., 2003; Kobelt et al., 2002). Different
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methodologies were employed in each of these studies to extrapolate long-term HAQ
scores for patient cohorts. Kobelt and colleagues (2003) and Wong and colleagues
(2002) used patient level data from infliximab clinical trial (ATTRACT) and
epidemiological database to calculate Markov transition rates. Brennan and colleagues
(2003) utilized clinical data and published annual progression rates to measure mean
HAQ improvements for both responders and nonresponders of treatment. Jobanputra
and others (2002) did not include differential disability progression in the model.

The study by Bansback and others (2004) modeled patients with moderate to
severe RA who had failed at least two traditional DMARDs and estimated incremental
QALY versus traditional DMARDs at 1.20 and 1.25 for adalimumab plus MTX and
etanercept plus MTX, respectively. The cost-effectiveness was estimated at 40,875
euros per QALY (US $53,137/QALY) for adalimumab plus MTX and 51,976 euros
(US $67,568/QALY) for etanercept plus MTX.

Brennan and colleagues (2003) conducted a cost-effectiveness analysis of
etanercept monotherapy under British Society for Rheumatological guidelines. The
study compared a DMARD sequence with etanercept as a third-line agent against the
same sequence excluding etanercept. The study reported a cost-effectiveness ratio of
£16,330/QALY (US $26,000/QALY; costs adjusted to 2004 values) suggesting that
etanercept was cost-effective when compared with non-biologic agents. The costeffectiveness ratio in the sensitivity analysis ranged from £7,800 to £42,000 (US
$11,232 to $60,480).
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The study by Kobelt and colleagues (2002) investigated the cost-effectiveness
of leflunomide compared to MTX in the UK. The analyses covered a timeframe of 10
years. Leflunomide was reported to have costs of £44,017 (US $63,384) and effects of
4.307 QALY compared to £44,988 (US $64,782) and effects of 4.158 QALY for MTX.
Another study by Kobelt and colleagues (2003) evaluated the cost per QALY of
infliximab plus MTX with MTX alone in patients with advanced disease. Including
both direct and indirect costs, the cost per QALY over 10 years was 3, 440 euros (US
4,953) in Sweden and 34,800 euros (US $50,112) in UK. The respective QALY gains
were 0.248 and 0.298. However, these analyses included markedly different
assumptions regarding treatment effectiveness, disease progression, and quality
adjustments.

Studies by Jobanputra and colleagues (2002) and Barton and colleagues (2004)
assessed the additional costs and QALYs gain associated with the use of either
etanercept or infliximab as the third DMARD in a sequence of DMARDs. The first
study resulted in an ICER of approximately £83,000 (US $130,000; costs adjusted to
2004 values) per QALY for etanercept and approximately £115,000 (US $180,000;
costs adjusted to 2004 values) per QALY for infliximab. The second study
incorporated the effects of DMARDs on joint replacement, mortality, and QoL in the
model developed by Jobanputra and colleagues (2002) and reported an ICER of
approximately £59,289 (US $85,376) per QALY for etanercept and approximately
£76,233 (US $109,775) per QALY for infliximab was reported. Wong and colleagues
(2002) examined costs and QALYs of infliximab plus MTX over a patient’s lifetime
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using Markov model. The study reported an ICER of $31,000/QALY (costs adjusted to
2004 values).

Despite lack of homogeneity in the methodological approaches and different
model assumptions, these studies do provide a benchmark against which to compare the
present study results. The discounted incremental costs per QALY estimates from
these analyses for different treatments range from $26,000 to $109,755. Measurement
of costs in the present study was comprehensive and included costs due to monitoring,
costs of treating mild/moderate events, costs of treating severe adverse events,
hospitalization costs and laboratory tests costs. This may explain the higher ICER of
etanercept plus MTX compared with results of some of economic studies discussed
earlier in the section. In terms of improvement in HRQoL, the incremental QALY
reported for etanercept was 1.660 (Brennan et al., 2003), 0.214 (Jobanputra et al.,
2002), and 0.248 (Kobelt et al., 2003); 0.116 for infliximab (Jobanputra et al., 2002)
and 0.290 (Wong et al., 2002). The incremental QALY gain against standard MTX
treatment in the present study was 3.55 for etanercept plus MTX, 0.99 for adalimumab
plus MTX, 0.65 for leflunomide plus MTX, and 0.22 for infliximab plus MTX.

During the last two decades, cost-effectiveness ratios of less than or equal to
$50,000 per discounted QALY have been considered as acceptable, ratios greater than
$50,000 and less than or equal to $100,000 per discounted QALY have been considered
as reasonable, and ratios greater than $100,000 per discounted QALY have been
considered as unreasonable or high (Maetzel, 2004). Recent studies in different disease
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areas have found cost-effectiveness ratios of $60,000 per discounted QALY for chronic
hemodialysis and $ 1,000,000 for interferon beta for multiple sclerosis (Wong et al.,
2002). In the present study, the ICER of etanercept plus MTX, and the next
nondominated treatment, leflunomide plus MTX, fall within the acceptable range of
$50,000 and $100,000. In the sensitivity analysis, the base-case results were sensitive
to variations in utilities and medication costs of etanercept and leflunomide. The lowest
cost/QALY for etanercept plus MTX and leflunomide plus MTX were $30,371 and
$43,720, respectively and the highest cost/QALY values were $74,628 and $63,126.
These ICERs for both treatments remain below the acceptable range of $50,000 and
$100,000.

There are conflicting reports regarding the effect of RA on the risk of mortality.
The OMERACT statement recommends that the risk of mortality be included in the
decision analytical modeling studies. Wong and colleagues (2002) assumed that an
increase in disability level was equivalent to a 1.77-fold increase in mortality risk.
Removing this assumption, the base-case results increased the base-case cost per
QALY from $30,690 to $35,800 (1998 values). The study by Brennan and others
(2003) estimated the impact of the change in HAQ score on mortality via a COX
proportional hazard regression. Kobelt and colleagues (2003) did not account for
increased risk of mortality in their model and used age- and gender-adjusted all cause
mortality rates. To test the effect of mortality assumption, Jobanputra and colleagues
(2002) assumed standardized mortality ratios (SMR) of 1.1 and 2.1. These made no
difference to the ICERs. The ICER for etanercept against standard treatment changed
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from £71,659/QALY to £71,471 with SMR 1.1 and to £71,838 with SMR 2.1. In the
present study, the incremental cost per QALY was calculated by adjusting the age-,
gender-, race-adjusted all cause mortality rates by a factor of two (SMR = 2) to reflect
the increased risk of mortality due to RA. The dominance status remained the same
though the incremental cost per QALY for etanercept plus MTX increased from
$49,724/QALY to $50,782/QALY and leflunomide plus MTX decreased slightly from
$52,833/QALY to $51,905/QALY.

The indirect costs associated from disability associated with rheumatoid
arthritis are substantial (Callahan, 1998), including unemployment with increasing
disease duration, decreased productivity, and increased work absenteeism (Wong et al.,
2002). The inclusion of productivity costs in economic analyses remains contentious
and even OMERACT states that all direct costs and societal costs should be reported
separately. Therefore, the present study reported base-case results separately for directs
costs and for societal (total costs). Considering only direct costs, the dominance status
remained the same for both, all cause mortality rate and RA-adjusted mortality rate.
The incremental cost per QALY for etanercept plus MTX was $24,333/QALY and
$24,421/QALY for all cause mortality rate and RA-adjusted mortality rate,
respectively. Similarly, the incremental cost per QALY for leflunomide plus MTX was
$27,717/QALY and $28,127/QALY for all cause mortality rate and RA-adjusted
mortality rate, respectively.
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The study population included in this analysis was patients with severe RA that
were refractory to standard therapy. Due to their disease severity, the indirect costs of
these patients are expected to be higher for the patients with mild RA or newly
diagnosed RA (Kavanaugh et al., 1996). Since the estimation of indirect costs is
severely limited by data availability, indirect costs in the present study were considered
to be one to three times that of direct costs. In the base-case analysis, indirect costs
were considered equal to direct costs (Wong et al., 2002). When indirect costs were
considered as twice that of direct costs, etanercept plus MTX had the lowest ICER
followed closely by leflunomide plus MTX. However, when indirect costs were
considered as three times that of direct costs, leflunomide plus MTX has a lowest ICER
than etanercept plus MTX. In both scenarios, infliximab plus MTX and adalimumab
plus MTX were ruled out by dominance and extended dominance, respectively. The
ICER became favorable for leflunomide plus MTX at higher total costs since
leflunomide plus MTX had lower direct costs compared to etanercept plus MTX.
However, even after considering high indirect costs, the ICERs of etanercept plus MTX
and leflunomide plus MTX seemed to be in a reasonable range of $75,000 - $100,000.

One of the main contributors to the high cost-effectiveness ratios may be the
high acquisition cost of the TNF inhibitors, which if lowered, would make the costeffectiveness ratios even more acceptable. However, no rheumatologist, knowing the
important role and value of TNF inhibitors would want cost-effectiveness ratios to
influence the way patients receive these treatments. A study by Erkan and colleagues
(2002) demonstrated that economic factors did influence DMARD preferences.
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However, in addition to the cost of treatment, a number of other factors have been
found to influence a rheumatologist’s decision-making process regarding choice of
therapy. These include patient preference, the disease itself (for example, disease
duration and symptom severity), the drug chosen (for example, potential adverse
events, cost, and route of administration), and published evidence documenting the
overall experience with each drug (Schwartzman et al., 2004; Schwartzman & Morgan,
2004). No study has assessed rheumatologist’s prescribing patterns and the factors that
influence rheumatologist’s choice of a particular TNF inhibitor over less costly
standard RA treatments. The lack of information on the actual use of TNF inhibitors by
rheumatologists led to the development of phase II of this study.
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Phase II
Phase II of the study involved a cross-sectional mail survey of randomly
selected national sample of rheumatologists. The study assessed the current
rheumatologists’ prescribing patterns, their laboratory monitoring guidelines, and the
potential barriers they face in terms of using TNF inhibitors or making a choice among
the three agents. The mailing list had a total of 1,970 rheumatologists. Trainees, nonclinical, and those in pediatric practices, were excluded from the survey. A survey
instrument developed for this study was mailed to each rheumatologist. Table 31 gives
the response rate analysis. Of the 1,970 surveys mailed, 48 were undeliverable due to
incomplete or incorrect addresses, death or retirement of the rheumatologist. Thus,
1,922 rheumatologists were presumably reached by the mailings. A total of 432 usable
responses were returned after two mailings for a response rate of 22.5%. Four surveys
were excluded from the analysis because they had less than 50% complete item
responses, thereby reducing the response rate to 22.3%.
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Table 31. Response rate
N
Original sample size
Undeliverable surveys
Effective Sample Size
Number of questionnaires returned
Incomplete questionnaire
Usable Response
Usable Response Rate

1,970
48
1,922
432
4
428

Percent (%)

100.0
22.5

22.3
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Non-response Analysis
The nonresponse survey was mailed to a randomly selected sample of
rheumatologists who did not respond to the two mailings of the survey. Of the 200
nonrespondent surveys mailed, 40 were returned, thus giving a response rate of 20%.
The reasons cited by the rheumatologists for their nonparticipation in the study are
listed in Table 32. The most common reasons cited were: do not respond to mail
surveys (35%), did not have enough time to complete the survey (30%), the survey was
too long (15.4%), forgot the survey (10%), no incentive to participate (7.5%), did not
receive the survey (5%), not interested in such studies (5%), the survey was misplaced
(7.5%), and other reasons (22.5%).

Demographics and practice-related characteristics of nonrespondents are
presented in Table 33. Of the 40 rheumatologists who responded to the non-response
survey, 61% were males and 39% were females. The mean age was 46.8 (SD =+8.5)
years. The mean number of years in practice as a rheumatologist was 14.6 (SD =+8.7)
years and the mean number of patients with RA seen per week was 26.3 (SD =+13.1).
A total of 66.7% described their primary practice site as group-based, 19.4% as solobased, 8.3% as university-affiliated hospital, 2.8% as hospital-based, and 2.8% as other.
Rheumatologists reported using all three agents in patients with varying disease
severity. Rheumatologists prescribed all three agents in patients with moderate RA
(88-100%) and severe RA (88-97%). Also, some rheumatologists (11-26%) reported
using these agents in newly diagnosed and mild RA patients (Table 34).
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Table 32. Reasons for not participating in the study survey
Reasons for Non Participation

N (40)*

Percent (%)

Do not respond to mail surveys

14

35.0

Did not have enough time to complete the survey

12

30.0

The survey was too long

6

15.4

Forgot the survey

4

10.0

No incentive to participate

3

7.5

The survey was misplaced

3

7.5

Did not receive the survey

2

5.0

Not interested in such studies

2

5.0

Other

9

22.5

*

Multiple responses were checked by responders of nonresponse survey, hence total greater than 100%
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Table 33. Demographic and practice-related characteristics of respondents of the
non-response survey
Characteristics

N

Age, years (Mean+S.D)

46.8+8.5

Percent (%)

Gender
Males

22

61.1

Females

14

38.9

Hospital-based

1

2.8

University affiliated hospital

3

8.3

Solo-based

7

19.4

24

66.7

1

2.8

Primary practice site

Group-based
Other
Number of years in practice as a
rheumatologist (Mean+S.D)

14.6+8.7

Number of patients with RA seen
per week (Mean+S.D)

26.3+13.1

S.D = Standard deviation, RA = Rheumatoid arthritis
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Table 34. Patient population in which TNF inhibitors used by respondents of the
non-response survey*
TNF
inhibitors

Newly Diagnosed
N (%)

Mild RA
N (%)

Moderate RA
N (%)

Severe RA
N (%)

Adalimumab

6 (17.6)

7 (20.6)

33 (97.1)

32 (94.1)

Etanercept

9 (26.5)

8 (23.5)

34 (100)

33 (97.1)

Infliximab

4 (11.8)

6 (17.6)

30 (88.2)

30 (88.2)

*

Multiple responses were checked by responders of nonresponse survey, hence total greater than 100%
TNF = Tumor necrosis factor, RA = Rheumatoid arthritis
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Respondents and nonrespondents were compared on the basis of their
demographic and practice-related characteristics. The variables compared were age,
gender, primary practice site, number of years in practice as a rheumatologist, and
mean number of patients with RA seen per week. Independent t-tests and Chi-square
tests were conducted for comparisons of these variables. The result of the analysis is
presented in Table 35. The respondents and nonrespondents were significantly
different on age and years of practice. The nonrespondents were younger and had less
number of years in practice as a rheumatologist compared to the respondents.
However, no significant differences were noted between respondents and
nonrespondents for gender, primary practice site, and average number of patients with
RA seen each week.
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Table 35. Analysis of non-response bias for demographic and practice-related
characteristics
Characteristics

Respondents Nonrespondents

Test
Statistic

Significance
P

Age, years (Mean+S.D)

50.9+9.4

t=2.492

0.013*

χ2=3.293

0.07

χ 2=5.389

0.25

46.8+8.5

Gender , n (%)
Males

323 (93.6)

22 (6.4)

Females

108 (88.5)

14 (11.5)

Primary practice site, n (%)
Hospital-based

18 (94.7)

1 (5.3)

University-affiliated 75 (96.2)
hospital

3 (3.8)

Solo-based

111 (94.1)

7 (5.9)

Group-based

223 (90.3)

24 (1.8)

Other

3 (75)

1 (25)

Number of years in practice as a
rheumatologist (Mean+S.D) 18.2+9.6

14.6+8.7

t=2.211

0.028*

Number of patients with RA
seen per week (Mean+S.D) 29.9+20.1

26.3+13.1

t=1.009

0.314

* Significant at p< 0.05, S.D = Standard deviation, RA = Rheumatoid arthritis
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Demographics and Practice-related Characteristics of Responding
Rheumatologists
Demographics and practice-related characteristics of respondents are presented
in Table 36. Of the 432 respondents, 25.1% were women and 74.9% were men. Mean
age in years (S.D) was 50.9 (SD =+9.4), mean number of years in practice as a
rheumatologist was 18.2 (SD =+9.6), and mean number of patients with RA seen per
week was 29.9 (SD =+20.1). Eighteen (4.2%) rheumatologists reported their practice
site as hospital based, 75 (17.4%) as university-affiliated hospital, 111 (25.8%) as solo
office-based, 223 (51.9%) as group office-based, and three (0.7%) as other practice
sites.
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Table 36. Demographic and practice-related characteristics of respondents
Characteristics

N

Percent (%)

Age, years (Mean+S.D)

50.9+9.4

Gender
Males

323

74.9

Females

108

25.1

Hospital-based

18

4.2

University affiliated hospital

75

17.4

Solo-based

111

25.8

Group-based

223

51.9

3

0.7

Primary practice site

Other
Number of years in practice as a
rheumatologist (Mean+S.D)

18.2+9.6

Number of patients with RA
seen per week (Mean+S.D)

29.9+20.1

S.D = Standard deviation, RA = Rheumatoid arthritis
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Results for Objective 1
The questionnaire asked the respondents to indicate their use of specific TNF
inhibitors in different groups of patients with RA. For study purposes, four groups of
patients were identified based on the severity of the disease: newly diagnosed, mild
RA, moderate RA, and severe RA. Rheumatologists reported using all three TNF
inhibitors in patients with moderate RA (82-90%) and severe RA (94-96%). Also,
some rheumatologists (10-18%) reported using these agents in newly diagnosed and
patients with mild RA (Table 37).

The questionnaire also asked rheumatologists regarding their use of TNF
inhibitors in patients with severe RA that responded inadequately to methotrexate
alone. The response was based on the use of TNF inhibitors reported in clinical
practice: TNF inhibitor alone, used in combination with one disease modifying antirheumatic drug (DMARD), used in combination with two other DMARDs, TNF
inhibitors not used, and other treatments or approaches used. Rheumatologists were
asked to check either one or more responses based on their use of TNF inhibitors in this
patient population. A majority of rheumatologists (n = 392; 91.2%) reported using a
TNF inhibitor with one other (DMARD), 120 (28%) used a TNF inhibitor with two
other DMARDs, 73 (17.0%) rheumatologists reported using a TNF inhibitor as
monotherapy, 11 (2.6%) reported not using any TNF inhibitors in such patients, and 35
(8.2%) used other treatments or approaches.
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Table 37. Respondents prescribing TNF inhibitors in patients based on the
severity of the disease*
TNF
inhibitors

Newly Diagnosed
N (%)

Mild RA
N (%)

Moderate RA
N (%)

Severe RA
N (%)

Adalimumab

64 (14.8)

54 (12.5)

375 (87.2)

411 (95.4)

Etanercept

77 (17.9)

68 (15.8)

390 (90.5)

416 (96.7)

Infliximab

46 (10.7)

43 (10.0)

357 (82.8)

408 (94.7)

*

Multiple responses were checked by responders of nonresponse survey, hence total greater than 100%
TNF = Tumor necrosis factor, RA = Rheumatoid arthritis
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Rheumatologists were asked if they had ever switched any patient from one
TNF inhibitor to a different TNF inhibitor. Also, if they had switched patients to a
different TNF inhibitor, their reasons for switching were elicited using an open-ended
question. Over 94% rheumatologists stated switching patients from one TNF inhibitor
to a different TNF inhibitor in case of a nonresponse. The following reasons were
given by the respondents for switching patients from one TNF inhibitors to another:
lack of efficacy (44.9%), adverse events (20.1%), insurance and reimbursement issues
(3.7%), differences in the mechanism of action of the three TNF inhibitors (3.5%),
success of switching based on study reports and case studies (3.5%), allergic reaction
and infusion-site reaction to infliximab (2.1%), cost (1.9%), and patient preferences
(1.6%).

Rheumatologists were also asked to indicate the average number of
prescriptions written per week for each drug. The average number of prescriptions per
week reported for adalimumab, etanercept, and infliximab were 3.68 (SD = +5.11),
6.05 (SD = +8.99), and 4.22 (SD = +8.24), respectively.
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Discussion for Objective 1
Modern RA management stresses the need for an aggressive treatment
preferably at an early stage of the disease. The original labeling of the TNF inhibitors
indicates their use in patients with moderate to severely active RA despite treatment
with MTX. However, there are some emerging clinical reports that indicate their
success in patients who have been recently diagnosed or those who have a mild form of
the disease (Genovese, Bathon, & Martin, 2002; Smolen, ven der Heijde, Emery et al.,
2004). While there is a tremendous excitement regarding the potential for disease
modification in those patients with an early forms of the disease, there are issues such
as costs and access that restrict the use of these agents in patients with early form of
disease. Results of this study show that a majority of rheumatologists are prescribing
TNF inhibitors for moderate to severe patients as indicated. However, there appears to
be some rheumatologists who seem to broaden the official indication of TNF inhibitors
to patients with early-onset RA.

For the most severe group of patients with RA that inadequately respond to
MTX alone, it is not known if the TNF inhibitors are being prescribed alone or used in
combination with other DMARDs, or are being used as a second- or a third-line
therapy. Recent results from clinical trials have demonstrated a synergistic effect of
MTX and TNF inhibitors in reducing signs and symptoms of RA, inhibiting structural
damage, and improving physical functions in patients with RA (Klareskog et al., 2004;
Smolen et al., 2004). Thus, a combination of TNF inhibitors with MTX has become
somewhat of a standard for patients with aggressive disease (Choy, 2004; Schnabel,

161

2004). The result of this study is consistent with the reports that TNF inhibitor with
one DMARD is the most commonly used combination followed by a combination of
TNF with two DMARDs. Some rheumatologists reported using TNF inhibitors alone
while others reported using other treatments or approaches in treating patients with
severe disease.

Not all patients respond to TNF inhibitors and some who do respond develop
treatment limiting side-effects. Since the three TNF inhibitors seem to have similar
efficacies in RA, an important practical question for clinicians is whether there is a
rationale for prescribing another TNF inhibitor in case of a failure with the first TNF
inhibitor or whether this practice only increases treatment costs (van Vollenhoven,
2004). The results indicate that an overwhelming majority of rheumatologists switched
patients from one TNF inhibitor to another. Major reasons for switching included lack
of efficacy or adverse events associated with the TNF inhibitor. Kavanaugh and
colleagues (2004) have reported that reasons for switching patients from one TNF
inhibitor to another are varied and include toxicity, loss of efficacy, cost, and
reimbursement issues.

Other reasons for switching could include the differences in mechanism of
action of the TNF inhibitors. Tumor necrosis factor (TNF-α), the proinflammatory
cytokine, is believed to be an important factor in determining clinical response.
Etanercept is made of two P75 soluble receptors and is capable of binding to both TNFα and TNF- β while infliximab and adalimumab are monoclonal antibodies and specific
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to TNF-α. Infliximab is administered intermittently in large doses and after achieving
peak levels, decrease to undetectable levels after 6 to 8 weeks. This warrants
shortening of intervals of infusions in patients who do not respond to the 8-week
interval. On the other hand, shorter half life of etanercept and its administration twice a
week leads to more sustained levels that may be inadequate in patients who require
more rapid and drastic suppression. This subset of patient population may benefit most
from a switch to infliximab (Haraoui, 2004). However, much remains to be learned
about the exact mechanisms of these agents and until predictors of response have been
identified, the use of these agents and switching between them will be governed by
clinical judgment and accumulated experience.
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Results for Objective 2
Rheumatologists ranked, in order of preference, the TNF inhibitors they would
give to patients in whom one is determined as necessary. Etanercept was ranked first
by 292 (68.2%) respondents, adalimumab by 120 (28.2%), and infliximab by 86
(20.4%) respondents (Table 38). Of those who ranked etanercept as first choice
(n=292), 38 (13%) and 33 (11.5%) also ranked adalimumab and infliximab as first
choice, 159 (54.5%) and 97 (33.2%) ranked adalimumab and infliximab as second
choice, and 90 (31.0%) and 154 (53.5%) ranked adalimumab and infliximab as third
choice.

Of those who ranked adalimumab as first choice (n=120), 38 (31.7%) and 32
(26.7%) also ranked etanercept and infliximab as first choice, 71 (59.2%) and 15
(12.5%) ranked etanercept and infliximab as second choice, and 11 (9.2%) and 69
(58.5%) ranked etanercept and infliximab as third choice. Of those who ranked
infliximab as first choice (n=86), 32 (37.2%) and 33 (38.4%) also ranked adalimumab
and etanercept and as first choice, 22 (25.6%) and 32 (37.2%) ranked adalimumab and
etanercept as second choice, and 32 (37.2%) and 21 (24.4%) ranked adalimumab and
etanercept as third choice.
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Table 38. Ranking of TNF inhibitors based on rheumatologist’s preference
TNF inhibitors

Rank 1
N (%)

Rank 2
N (%)

Rank 3
N (%)

Adalimumab

120 (28.2)

181 (42.5)

122 (28.6)

Etanercept

292 (68.2)

104 (24.3)

32 (7.5)

Infliximab

86 (20.4)

107 (25.4)

223 (53.0)

Rank 1: First choice agent, TNF = Tumor necrosis factor

165

Discussion for Objective 2
Etanercept was ranked first by 292 (68.2%) respondents, adalimumab by 120
(28.2%) and infliximab by 86 (20.4%). Around 42.5% and 53% of the respondents
ranked adalimumab and infliximab as their second and third choice TNF inhibitor,
respectively. Thus, this indicates a clear preference for etanercept as the first choice
TNF inhibitor compared to the other two TNF inhibitors among the responding
rheumatologists. Thus, the null hypothesis A that rheumatologists do not have any
preference for any of the TNF inhibitors is rejected.

The analysis revealed that there is a preference for etanercept and that
infliximab is the third choice agent among the three TNF inhibitors for a majority of the
rheumatologists. The preference for etanercept could be due to the fact that it was the
first TNF inhibitor to be launched in the market in the year 1999 and therefore, has the
most clinical use experience among the three agents. Also, data from clinical trials,
practice experiences, and post-marketing surveillance reports have shown that
etanercept is effective and quite safe (Fleischmann & Yocum, 2004).
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Results for Objective 3
Rheumatologists who preferred adalimumab, etanercept, or infliximab as their
first choice agent were compared on the basis of their demographic (age, gender),
practice-related characteristics (primary practice site, number of years in practice as a
rheumatologist, and average number of patients with RA seen per week), and perceived
barriers to prescribing the TNF inhibitors. Analysis of variance (ANOVA) and Chisquare tests were conducted to compare these variables. Significant ANOVAs were
further investigated by post-hoc Tukey comparisons. Since the analysis compared
rheumatologists who preferred adalimumab, etanercept, or infliximab as their first
choice agent, rheumatologists who ranked all the three TNF inhibitors as their first
choice agent were excluded from the analysis (n = 32).

Table 39 gives the results of the analysis. Rheumatologists who preferred
adalimumab, etanercept, or infliximab as their first choice agent were significantly
different on gender and number of patients with RA seen per week. Rheumatologists
who preferred infliximab as their first choice agent saw more patients with RA per
week compared with rheumatologists who preferred adalimumab or etanercept as the
first choice TNF inhibitor. Also, rheumatologists who preferred infliximab perceived
support for administration of infusion as a major problem compared with those who
either preferred adalimumab or etanercept. Rheumatologists who preferred etanercept
perceived patient compliance with the agent as a major problem compared with those
who preferred adalimumab.
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Table 39. Demographic, practice-related characteristics, and perceived barriers of
rheumatologists who preferred adalimumab, etanercept, or infliximab as their
first choice TNF inhibitor
Characteristics

Adalimumab Etanercept
n=82
n=253

Infliximab
n=53

Stat.

Age, years (Mean+S.D)

51.3+9.2

51.4+10.1

F=0.293

50.6+9.3

Sig.
0.746

χ 2=14.401 0.001*

Gender, n (%)
Males

66 (22.8)

175 (60.3)

49 (16.9)

Females

16 (16.3)

78 (79.6)

4 (4.1)

χ 2=10.333 0.242

Primary Practice Site, n (%)
Hospital-based

4 (23.5)

13 (76.5)

0 (0)

University-affiliated
hospital

9 (13.6)

50 (75.8)

7 (10.6)

Solo-based

27 (27)

58 (58)

15 (15)

Group-based

40 (19.8)

131 (64.9)

31 (15.3)

Other

1 (50)

1 (50)

0 (0)

Number of years in practice as a
rheumatologist (Mean+S.D)
18.4+9.8

17.9+9.6

Number of patients with RA
seen per week (Mean+S.D)

28.4+18.3b

28.3+18.4a

18.4+9.9

F=0.127

0.881

38.2+28.5a,b F=5.494 0.004*

ANOVA: Significant ANOVA’s were investigated with post-hoc Tukey comparisons
a,b: Means with same letters are significantly different.
*
Significant at p< 0.05, S.D = Standard deviation, RA = Rheumatoid arthritis
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Table 39 (contd.). Demographic, practice-related characteristics, and perceived
barriers of rheumatologists who preferred adalimumab, etanercept, or infliximab
as their first choice TNF inhibitor
Adalimumab Etanercept

Infliximab

Stat.

Sig.

Factors

(Mean+S.D)

(Mean+S.D)

(Mean+S.D)

Age of Patient

2.3+1.6

2.3+1.6

2.1+1.5

F=0.538

0.584

Costs to Patients

5.9+1.5

6.1+1.4

5.7+1.6

F=1.868

0.156

Efficacy of TNF inhibitors

2.1+1.3

2.4+1.7

2.1+1.3

F=2.091

0.125

Insurance/Formulary coverage 5.0+1.7

4.9+1.9

4.9+1.9

F=0.356

0.701

Patient Compliance

1.8+1.0a

2.2+1.4a

1.9+1.2

F=5.140 0.006*

Patient Preference

2.1+1.5

2.5+1.4

2.5+1.5

F=2.615

0.074

Route of Administration

2.4+1.4

2.7+1.5

2.8+1.5

F=2.082

0.126

Side Effects

2.8+1.2

2.9+1.4

3.2+1.4

F=2.524

0.081

Support for Administration

1.5+0.8b

1.7+1.3c

2.2+1.5b,c

F=6.861 0.001*

Measured on a 7-point scale where 1 = no problem and 7 = major problem
ANOVA: Significant ANOVA’s were investigated with post-hoc Tukey comparisons
a,b,c: Means with same letters are significantly different.
Significant at p< 0.05
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Discussion for Objective 3
Based on the analysis, the null hypothesis B that there is no difference in
demographic, practice-related characteristics, and perceived barriers to prescribing TNF
inhibitors among rheumatologists who preferred adalimumab, etanercept, or infliximab
as their first choice agent is rejected. Gender and number of patients with RA seen per
week do have an association with prescribing preferences of rheumatologists. More
males compared to female rheumatologists showed preference for these agents.
Rheumatologists who preferred infliximab as their first choice agent saw more patients
with RA per week compared with rheumatologists who preferred adalimumab or
etanercept as the first choice TNF inhibitor. This could be attributed to the difference
in dosing schedule and route of administration of the three drugs (Schwartzman &
Morgan, 2004). Infliximab is administered intravenously (IV) at a dose of 3mg/kg at
weeks 0, 2, and 6, then every 8 weeks thereafter. Both adalimumab and etanercept can
be self-administered subcutaneously (SC). Thus, patients on infliximab require
frequent visits to the rheumatologists to get the infusion.

One of the perceived barriers for prescribing infliximab, although a minor
problem, was the support needed for administering infliximab. Infliximab is generally
administered on an outpatient basis and this requires the use of professionally staffed
clinics and hospital infusion suite. In addition to the basic equipment necessary for
administering the infusion, the possibility of an acute infusion reaction to infliximab
also necessitates the availability of emergency personnel and equipment (Gallup, 2001).
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The compliance with etanercept although perceived as a minor barrier was
significantly different than the other two TNF inhibitor. This perception could be
attributed to a number of factors. It is seen that treatment with assisted IV infusions has
higher compliance rates than self-administered SC injections. Results of a survey of
Canadian patients with RA indicate a preference for IV administration (infliximab)
over an SC regimen (etanercept) (Schwartzman & Morgan, 2004). Patients receiving
etanercept must receive a short training session in self-administered SC injection while,
as mentioned earlier, infliximab is administered on an outpatient basis by trained staff
(Gallup, 2001).

Another major reason for compliance being cited as a perceived barrier could be
due to inequalities in coverage and reimbursement policies. Infliximab is given
intravenously and is covered under medical benefits, which are often unlimited or have
a very high cap (e.g., $ 1,000,000). Self-injectables like etanercept are covered by
pharmacy benefits that are limited by the caps (typically $400-$500 per year for
Medicare patients). In addition, many managed care organizations institute three-tier
plans that require high copay (Gallup, 2001). These reasons could potentially explain
the lower compliance with etanercept perceived by rheumatologists as compared to
infliximab.
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Results for Objective 4
Adalimumab
The most prescribed dose for adalimumab was 40 mg every other week. Nearly
one-fourth of the rheumatologists used this dose in patients with newly diagnosed and
mild RA while a majority of rheumatologists indicated using this dose in moderate RA
(83.7%) and severe RA (74.5%). For patients with severe RA, one-fifth of the
rheumatologists indicated using 40 mg of adalimumab every week.

The laboratory tests routinely ordered by the rheumatologists varied with
respect to the tests ordered and the frequency at which these were ordered. A majority
of the rheumatologists ordered complete blood count (88.2%) and purified protein test
(96.6%). Purified protein test (PPD) was ordered mostly at baseline (82.7%) and a few
(15.7%) ordered the test after a year of follow-up. Antinuclear antibody test (ANA),
chest radiography, and creatinine were monitored by 30 to 60% of rheumatologists
(Table 40).
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Table 40. Laboratory tests ordered for adalimumab and percentage of
rheumatologists ordering the tests during different weeks
Tests

N (%)
0

4

Weeks (%)
6
8

-

1.6

2.3

9.9

7.6

-

ANA

132 (32.5)

52.3

CBC

358 (88.2)

2.5

CXR

205 (50.5)

71.0

Creatinine

247 (61.6)

7.7

PPD

392 (96.6)

82.7

12

24

52

3.9

6.3

20.3

22.6

37.3

5.7

2.5

-

-

-

-

24.0

6.9

-

22.7

32.8

7.7

-

-

-

-

-

-

15.7

ANA - Anti-nuclear antibody, CBC - Complete blood count, CXR - Chest radiograph, PPD - Purified
protein derivative
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Etanercept
The most prescribed dose for etanercept was 50 mg every week for newly
diagnosed (15.3%) and mild RA (14.9%) patients followed by 25 mg twice weekly in
newly diagnosed (13.7%) and mild RA (13.2%) patients. Nearly half of the
rheumatologists reported using etanercept 25 mg twice a week in moderate to severe
patients while 40% of rheumatologists used a dose of 50 mg every week in patients
with moderate to severe RA.

Similar to tests for adalimumab, the laboratory tests routinely ordered for
etanercept varied with respect to the tests ordered and the frequency at which these
were ordered. A majority of the rheumatologists ordered complete blood count
(88.2%) and PPD (96.4%). Purified protein test was ordered mostly at baseline
(82.6%) and a few (15.9%) ordered the test after a year of follow-up. Antinuclear
antibody test (ANA), chest radiography, and creatinine were monitored by 30 to 60%
of rheumatologists (Table 41).
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Table 41. Laboratory tests ordered for etanercept and percentage of
rheumatologists ordering the tests during different weeks
Tests

N (%)
0

4

Weeks (%)
6
8

12

24

ANA

139 (33.6)

53.3

-

1.6

2.3

CBC

365 (88.2)

-

10.7

7.4

22.8

-

11.5

-

CXR

209 (50.5)

70.2

-

-

-

-

-

23.9

Creatinine

255 (61.6)

-

8.3

22.5

32.0

13.4

-

PPD

398 (96.4)

82.6

-

-

-

-

15.9

7.5
-

3.9

9.6

52
20.7

ANA - Anti-nuclear antibody, CBC - Complete blood count, CXR - Chest radiograph, PPD - Purified
protein derivative
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Infliximab
The preferred dose for infliximab was 3 mg/kg in patient population with
varying disease severity. Around 17 % rheumatologists prescribed 3 mg/kg in newly
diagnosed and mild RA patients while 43.4% and 34.2% prescribed 3 mg/kg in
moderate and severe RA, respectively.

Rheumatologists reported using a range of doses for infliximab with almost
93% indicating the use of a minimum dose of 3 mg/kg and 67% reporting a maximum
dose of 5 mg/kg for newly diagnosed patients. In mild patients, 88% rheumatologists
reported using a minimum dose of 3 mg/kg and 73% reported a maximum dose of 5
mg/kg. The 8-week dosing interval for infliximab infusion was universally used by
rheumatologists in newly diagnosed (89.3%) and mild patients (88.5%). In moderate
patients, 81% of rheumatologists used a minimum dose of 3 mg/kg while a maximum
dose of 5 mg/kg was used by 52% rheumatologists and a maximum dose of 10 mg/kg
was used by 19.5% of rheumatologists. Almost three-fourth of the rheumatologists
reported a dosing interval of 8 weeks while 13.2% rheumatologists reported a dosing
interval of 6-8 weeks between infusions.

For severe patients, rheumatologists (64%) used a minimum dose of 3 mg/kg
and 22% rheumatologists used a minimum dose of 5 mg/kg while 30% and 37%
reported using a maximum dose of 5 mg/kg and10 mg/kg, respectively. In severe
patients, rheumatologists reported using a dosing interval of 8-week (55.1%), 6-8
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weeks (15.6%), 6-week (11.4%), and 4-8 weeks (9.9%) indicating an increase in the
frequency of treatment.

The results for laboratory tests ordered and frequency of the tests for infliximab
were similar to that of adalimumab and etanercept. Rheumatologists ordered complete
blood count (89.3%) and PPD (97%). Purified protein test was ordered mostly at
baseline (82.3%) and a few (15.6) ordered the test after a year of follow-up. Like the
PPD test, chest radiograph was ordered by 51.8% rheumatologists with 71.3% ordering
them at baseline and 21.3% after a year of follow-up. Antinuclear antibody test (ANA)
was ordered by 38% of rheumatologists with nearly half of them ordering the test at
baseline (Table 42).
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Table 42. Laboratory tests ordered for infliximab and percentage of
rheumatologists ordering the tests during different weeks
Tests

N (%)
0

4

Weeks (%)
6
8
-

ANA

152 (38)

52.7

-

CBC

357 (89.3)

-

10.2

CXR

207 (51.8)

71.3

-

Creatinine

252 (63)

6.8

PPD

387 (97)

82.3

7.2
-

12

24

52
16.2

5.4

6.8

14.2

31.9

29.1

9.6

-

-

-

-

21.3

11.2

29.2

26.0

12.0

-

-

-

-

-

15.6

9.0

-

ANA - Anti-nuclear antibody, CBC - Complete blood count, CXR - Chest radiograph, PPD - Purified
protein derivative
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Discussion for Objective 4
The survey revealed some interesting points regarding the dosing of the TNF
inhibitors and laboratory tests ordered by the rheumatologists. Dosing guidelines
suggest that adalimumab patients are prescribed a dose of 40 mg every other week,
etanercept patients two doses of 25 mg a week or a new dosage of 50 mg once every
week. The recommended dosing for infliximab is 3 mg/kg of body weight for the first
dose and then at two and six weeks and every eight weeks thereafter. Patients
experiencing inadequate response may increase the dose to 10mg/kg; or may receive
treatment as frequently as every four weeks (Physicians’ Desk Reference, 2002).

The most prescribed dose for adalimumab was 40 mg every other week.
However, in patients who had a severe form of the disease, rheumatologists reported
administering 40 mg every week. For etanercept, both 25 mg twice every week and 50
mg once a week were being administered. Rheumatologists reported using a range of
doses for infliximab from 3mg/kg to 10mg/kg and these doses were administered every
four to eight weeks. A number of studies have shown that there are changes in the
dosing of TNF inhibitors especially with infliximab (Gilbert, Smith, & Ollendorf, 2004;
Harley, Frytak, & Tandon, 2003). Possible explanations for changes in the dosage and
dosing interval include adverse events and safety concerns resulting in decreasing in
dosages, or poor response to therapy with lower dosages resulting in dosage increases
or reduction of dosing intervals (Harley et al., 2003).

There are currently no guidelines available for monitoring patients on TNF
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inhibitors. The only recommended test is the purified protein derivative (PPD), which
is done at pretreatment to monitor for tuberculosis. If the PPD test is positive, chest
radiography is recommended. The results of this study indicate that rheumatologists
are following this recommendation and using PPD monitoring at pretreatment, with
chest radiography if the PPD is positive. Results indicate that only 82% were ordering
PPD and 72% chest radiography, which is recommended if the PPD is positive. Similar
results were reported by Yazici and colleagues (2003). Their study reported that 73%
and 83% rheumatologists ordered PPD tests and 43% and 50% ordered chest
radiography for etanercept and infliximab, respectively.

There are no guidelines for blood test monitoring, however, a majority of
rheumatologists (88-89%) seemed to order complete blood count (CBC) tests for
patients at varying time interval. Percentage of rheumatologists ordering CBC tests
(88-89%) was lower than that reported by Yazici and colleagues (97-98%) (2003).
Also, creatinine tests (61-63%) reported by rheumatologists in this study were lower
than that reported by Yazici and colleagues (88-89%) (2003). Rheumatologists who
did not order tests such as creatinine and anti-nuclear antibody (ANA) may indicate
either a lack of belief on part of the rheumatologists to the utility of these tests or a
belief that all patients do not need these tests. In summary, rheumatologists seem to be
following similar laboratory monitoring practices for all the three TNF inhibitors but
there seems to be no consensus as to how often the tests should be performed. Thus,
there is a need to revisit old monitoring guidelines or implement new monitoring
guidelines for these TNF inhibitors.
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Results for Objective 5
The questionnaire asked the respondents to indicate the monitoring guidelines
they followed when prescribing the three TNF inhibitors to patients with RA. The
responses included ACR guidelines, EULAR guidelines, both ACR and EULAR
guidelines, none, and others. Based on the analysis, the null hypothesis C that
rheumatologists are not following any recommended monitoring guidelines for patients
with RA on adalimumab, etanercept, and infliximab is rejected. Almost 62% reported
following ACR guidelines and 5% reported following both ACR and EULAR. Onequarter of the responding rheumatologists reported not following any monitoring
guidelines for the TNF inhibitors (Table 43).

Discussion for Objective 5
Guidelines for monitoring of potential toxicity caused by DMARDs have been
developed by American College of Rheumatism (ACR Guidelines) and European
League Against Rheumatism (EULAR Guidelines). However, there are no available
guidelines for monitoring TNF inhibitors. It is interesting to note that 62% of the
rheumatologists reported following ACR guidelines to monitor patients on TNF
inhibitors and around 25% did not follow any monitoring guidelines. Since there are
no established guidelines available for TNF inhibitors, it is possible that
rheumatologists who reported following monitoring guidelines continued their practice
based on their experiences with earlier DMARDs, particularly MTX (Yazici et al.,
2003).
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Table 43. Recommended monitoring guidelines followed by rheumatologists
ACR

EULAR

Both

None

Other
N (%)

TNF
inhibitors

N (%)

N (%)

N (%)

Adalimumab 257 (62.2)

1 (0.2)

23 (5.6)

106 (25.7)

26 (6.3)

Etanercept

261 (63.2)

1 (0.2)

22 (5.4)

106 (25.7)

23 (5.5)

Infliximab

254 (61.5)

1 (0.2)

22 (5.3)

108 (26.2)

28 (6.8)

(ACR & EULAR)

TNF - Tumor necrosis factor, ACR - American College of Rheumatology, EULAR - European League
Against Rheumatism
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Results for Objective 6
Rheumatologists who followed ACR monitoring guidelines were compared to
those who reported not following any monitoring guidelines on demographic and
practice-related characteristics. Independent t-tests and Chi-square tests were
conducted for comparisons of these variables. The results of the analysis are presented
in Table 44.

Rheumatologists who followed ACR monitoring guidelines were significantly
different on age, gender, and number of years in practice compared to rheumatologists
who did not follow any monitoring guidelines. Rheumatologists who followed
monitoring guidelines were younger and had practiced as a rheumatologist for fewer
years as compared to those who did not follow any guidelines. A higher proportion of
males followed guidelines more than females.

Rheumatologists who used monitoring guidelines when prescribing each of the
TNF inhibitors were compared to those who did not follow any guidelines on perceived
barriers to prescribing TNF inhibitors. There was no significant difference between the
two groups in all the three TNF inhibitors on perceived barriers to prescribing these
agents.
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Table
able 44. Demographic, practice-related characteristics, and perceived barriers of
rheumatologists who followed monitoring guidelines compared to those who do
not follow any monitoring guidelines
Characteristics

Follow
Guidelines

Don’t Follow Test
Guidelines
Statistic

Significance
P

50.2+9.1

52.9+2.6

t=2.546

0.012*

χ 2=7.223

0.007*

χ 2=7.881

0.096

Age, years (Mean+S.D)
(Mean+
Gender, n (%)
Males

188 (67.1)

92 (32.9)

Females

73 (82)

16 (18)

Primary Practice Site, n (%)
Hospital-based

9 (56.3)

7 (43.8)

University-affiliated 48 (77.4)
hospital

14 (22.6)

Solo-based

60 (61.9)

37 (38.1)

Group-based

142 (74.3)

49 (25.7)

Other

2 (66.7)

1 (33.3)

Number of years in practice as a
rheumatologist (Mean+S.D) 17.5+9.2

20.2+9.8

t=2.467

0.015*

Number of patients with RA
seen per week (Mean+S.D) 30.4+21.1

30.3+19.3

t=-0.061

0.951

*

Significant at p< 0.05, S.D = Standard deviation, RA = Rheumatoid arthritis
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Table 44 (contd.). Demographic, practice-related characteristics, and perceived barriers of rheumatologists who followed
monitoring guidelines compared to those who do not follow any monitoring guidelines
Characteristics

Adalimumab
Follow
Don’t follow
Mean (+SD)
Mean (+SD)

Etanercept
Follow
Don’t follow
Mean (+SD)
Mean (+SD)

Infliximab
Follow
Don’t follow
Mean (+SD)
Mean (+SD)

Age of Patient

2.46 (+1.7)

2.13 (+1.6)

2.30 (+1.6)

2.03 (+1.5)

2.64 (+1.8)

2.31 (+1.6)

Costs to the Patient

5.97 (+1.5)

6.11 (+1.3)

6.02 (+1.4)

6.09 (+1.3)

5.49 (+1.8)

5.37 (+1.9)

Efficacy of TNF
inhibitors

2.58 (+1.5)

2.69 (+1.7)

2.31 (+1.5)

2.60 (+1.7)

2.54 (+1.5)

2.80 (+1.7)

Insurance/Formulary
coverage

5.07 (+1.8)

5.00 (+1.6)

4.87 (+1.9)

4.86 (+1.7)

4.62 (+2.0)

4.32 (+1.9)

Patient compliance

2.17 (+1.3)

2.34 (+1.6)

2.31 (+1.4)

2.33 (+1.6)

2.27 (+1.6)

2.16 (+1.5)

Patient Preference

2.36 (+1.4)

2.53 (+1.6)

2.58 (+1.4)

2.64 (+1.5)

3.05 (+1.5)

2.21 (+1.6)

Route of Administration

2.51 (+1.4)

2.60 (+1.5)

2.64 (+1.4)

2.69 (+1.5)

3.58 (+1.7)

3.62 (+1.7)

Side Effects

2.93 (+1.4)

3.07 (+1.4)

2.73 (+1.4)

2.90 (+1.3)

3.72 (+1.5)

3.88 (+1.4)

Support for Administration

1.72 (+1.3)

1.67 (+1.3)

1.73 (+1.2)

1.68 (+1.3)

2.61 (+1.8)

2.76 (+1.9)

SD = Standard Deviation
Measured on a 7-point scale where 1=no problem and 7=major problem
Independent t-test, significant at p< 0.05

185

Discussion for Objective 6
Based on the analysis, the null hypothesis D that there is no difference in
demographic and practice-related characteristics between rheumatologists who follow
guidelines and those did not follow any guidelines is rejected. The study results
indicated that rheumatologists who followed monitoring guidelines were younger and
had fewer years in practice compared to those who did not follow ant guidelines. This
is consistent with previous reports that showed that younger physicians are more likely
to adhere to guidelines in other disease areas such as hypertension (Fernandes,
Madhavan, Amonkar, Dell, Islam, & Scott, 2003).
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Results for Objective 7
Figure 7 lists the factors that rheumatologists perceived as problematic
regarding the use of specific TNF inhibitors in patients with RA. A repeated measure
ANOVA was conducted for comparisons of these variables. The results of the analysis
are presented in Table 45.

There was no perceived difference seen in the patient compliance with these
agents (F = 0.984, p = 0.322). Age of the patient (F = 4.052, p = 0.045) was perceived
as a minor problem with the perception being the highest for infliximab followed by
adalimumab and etanercept. Efficacy of the TNF inhibitors (F = 4.029, p = 0.049) was
also perceived as a minor problem with etanercept being considered the most
efficacious among the three agents. Costs to the patient (F = 42.612, p = 0.000) and
insurance or formulary coverage (F = 39.799, p = 0.000) were perceived as a major
problem with etanercept and adalimumab being perceived as highly expensive and
lacking insurance coverage as compared with infliximab.

Patient preference for the TNF inhibitor (F = 47.343, p = 0.000) and preference
for route of administration (F = 73.834, p = 0.000) was the highest for adalimumab,
followed by etanercept and infliximab. Side effects of TNF inhibitor (F = 112.247, p =
0.000) was perceived as a major problem for infliximab, followed by adalimumab and
least for etanercept. Finally, support for administering infusions (F= 85.209, p = 0.000)
were perceived more problematic for infliximab than the other two agents.
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Figure 7. Perceived barriers to prescribing TNF inhibitors

2.72+0.11
1.71+0.07
1.71+0.08

Support for administration

3.8+0.09
Side effect

2.88+0.08
3.01+0.09
3.62+0.1
2.71+0.08
2.55+0.09

Route of administration

3.1+0.1

Factors

Patient preference

2.6+0.08
2.38+0.08
2.21+0.09
2.3+0.08
2.21+0.09

Patient compliance

4.62+0.1
4.95+0.11
5.16+0.11

Insurance/Formulary

2.6+0.09
2.47+0.09
2.64+0.09

Efficacy of drug

5.57+0.12
Cost to patient

6.11+0.08
6.12+0.08
2.4+0.9
2.2+0.9
2.4+0.9

Age of patient

1

2

3

4

5

6

Mean+SD
Adalimumab

Etanercept

Infliximab

Measured on a 7-point scale, where 1 = no problem and 7 = major problem
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Table 45. Perceived barriers to prescribing different TNF inhibitors *
Factors

Adalimumab
Mean+SD

Etanercept
Mean+SD

Infliximab
Mean+SD

Age of patient

2.32+0.9a

2.20+0.9b

2.40+0.9a, b

Costs to the patient

6.12+0.8c

6.11+0.8d

5.57+0.11c, d

Efficacy of this TNF
inhibitor

2.64+0.09e

2.47+0.09e

2.60+0.09

Insurance/Formulary
coverage

5.16+0.10f

4.95+0.11f

4.62+0.12f

Patient compliance
with this therapy

2.25+0.08

2.30+0.08

2.21+0.09

Patient preference for
this TNF inhibitor

2.38+0.08g

2.60+0.08g

3.10+0.1g

Route of administration
of this TNF inhibitor

2.55+0.09h

2.71+0.08h

3.62+0.1h

Side effects of this
TNF inhibitor

3.01+0.09i

2.88+0.08i

3.80+0.09i

Support for administering
Infusions

1.71+0.08j

1.71+0.07k

2.72+0.1j, k

* Measured on a 7-point scale where 1 = no problem and 7 = major problem
SD = standard deviation
Repeated Measures of Analysis of Variance with post-hoc Tukey comparisons
a,b,c,d,e,f,g,h,I,j,k,
Means with same letters are significantly different at p<0 .05
TNF = Tumor necrosis Factor
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Discussion for Objective 7
Based on the analysis, the null hypothesis E that there are no significant
differences in rheumatologists’ perception of barriers (insurance coverage, route of
administration, patient compliance, side effects, costs to the patient, age of the patient,
efficacy of the drugs, and support needed for administration of drugs) to prescribing the
three TNF inhibitors is rejected. Two factors (costs to the patient and insurance or
formulary coverage) were perceived as major barriers in prescribing the TNF inhibitors.
Among the three agents, the perception was a little lower for infliximab. The average
wholesale price of these agents for a year of therapy is approximately $16,000
(Kavanaugh et al., 2004). Also, as discussed earlier, infliximab, etanercept, and
adalimumab have different routes of administration, which has resulted in different
coverage and reimbursement policies. Infliximab, which is administered intravenously,
is covered under medical benefits while etanercept and adalimumab are administered
subcutaneously and are covered only under pharmacy benefits. In addition, due to the
tier system of the managed care organizations, patients are required to pay higher copay
or sometimes pay the entire cost of etanercept or adalimumab (Gallup, 2001).

Efficacy of TNF inhibitors, side effects of these agents, and age of patient
eligible for these agents were perceived as less problematic. Etanercept was considered
as most efficacious with less perceived side effects as compared to adalimumab and
infliximab. These TNF inhibitors have been shown to achieve a marked improvement
in outcomes in patients with RA and also found to be well tolerated. There are a few
side effects reported such as injection-and infusion-site reaction and infections. Largest
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clinical experience among the three agents exists with etanercept since it was the first to
be launched in the market. Also, data from clinical trials, practice experience, and postmarketing surveillance reports have shown that etanercept is effective and safe
(Fleischmann & Yocum, 2004).

Rheumatologists perceived patient preference and route of administration as
less problematic in prescribing these agents. Adalimumab was perceived to be least
problematic in terms of patient preference and route of administration as compared to
the other two agents. The patient preference for adalimumab could be high because of
the differences in route of administration of these agents. Adalimumab and etanercept
are self-administered as subcutaneous injections while infliximab is administered as an
infusion. Adalimumab has a dosing schedule of 40 mg every other week as compared
to 25 mg twice a week for etanercept and a loading dose at baseline, two, six and every
eight weeks for infliximab. This might influence better outcomes in patient with RA
although further research is needed to evaluate this possibility.

Finally, support for administering infusions although perceived as a minor
problem, was higher for infliximab as compared to the other two agents. Infliximab is
administered as an infusion on an outpatient basis and requires the use of professional
staff. In addition, it also requires emergency personnel and equipment to monitor any
untoward acute infusion reactions. Etanercept and adalimumab, on the other hand, are
self-administered by patients and do not require additional staff to administer or
monitor patients.
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CHAPTER FIVE
SUMMARY AND CONCLUSIONS
This chapter provides a review of the study findings, draws conclusions,
presents implications of the study findings, lists limitations of each phase of the study,
and provides recommendations for future research.

Phase I
Tumor necrosis factor (TNF) inhibitors offer important treatment options to
patients with RA and are essential to patients that inadequately respond to MTX alone.
With the healthcare expenditures rising due to ageing population and technological
advances, it is becoming important to assess the “value for money” for these new drugs
that are relatively expensive compared to the traditional DMARDs, but then also seem
to provide more health benefits to the patients. A few pharmacoeconomic evaluations
have been conducted with TNF inhibitors in patients with RA who had an inadequate
response to MTX. However, most of the studies have failed to include the withdrawal
rates of patients, adverse effects caused by the TNF inhibitors or a decrease in the
future risk of disability, thereby potentially biasing the cost-effectiveness ratios. Also,
there are no pharmacoeconomic studies that have compared all three TNF inhibitors
(adalimumab, etanercept, and infliximab) and leflunomide.

Thus, the goal of this phase of the study was to conduct an incremental costeffectiveness analysis of TNF inhibitors (adalimumab, etanercept, and infliximab) and
leflunomide used in combination with MTX in the treatment of patients with RA that
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inadequately respond to MTX alone. In particular, the goal was to quantify the cost per
discounted quality-adjusted life year (QALY) gained through the use of etanercept,
adalimumab, infliximab, or leflunomide in combination with MTX compared with the
standard MTX treatment. The method involved modeling clinical pathways, defining
comparators and synthesizing evidence from a range of sources to quantify the model
parameters.

Conclusions for Phase I
The results suggest that the combination of etanercept and MTX should be
considered cost-effective when compared against traditional DMARDs (leflunomide
plus MTX and standard MTX treatment) and the combination of other two TNF
inhibitors with MTX (adalimumab and infliximab) in patients with RA that
inadequately respond to MTX alone. The one-way and probabilistic sensitivity
analyses suggest that this conclusion is relatively robust to the model assumptions
including increased risk of mortality due to RA, consideration of only direct costs,
different estimates of indirect costs or exclusion of hospitalization costs. The results
also suggest that the combination of leflunomide and MTX is the second most costeffective option in patients with RA that inadequately respond to MTX alone. This
treatment was the most cost-effective when the indirect costs were valued at three times
that of the direct costs. In a base-case analysis, adalimumab plus MTX and infliximab
plus MTX cost more and had a higher ICER than leflunomide plus MTX. Therefore,
these options were not cost-effective.

193

Etanercept plus MTX provided more health benefits (15.84 QALYs) and was
more costly than standard MTX treatment, with resulting cost-effectiveness ratios of
$49,724/QALY. The second most cost-effective treatment was leflunomide plus MTX
with an ICER of $52,833/QALY. The lowest cost/QALY for etanercept plus MTX and
leflunomide plus MTX were $30,371/QALY and $43,720/QALY, respectively. The
highest cost/QALY values for etanercept plus MTX and leflunomide plus MTX were
$74,628/QALY and $63,126/QALY, respectively. These ICERs for both the
treatments remained within the acceptable range of $50,000 and $100,000 as compared
to other comparators.

Phase II
Even though infliximab, etanercept, and adalimumab belong to the same class
of drugs, they have distinct clinical, pharmacokinetic, and pharmacodynamic properties
that must be considered when selecting any one of them for therapy. These drugs have
the potential to reduce future disability and cause remission in RA; however, the high
acquisition cost of these agents coupled with intensive monitoring required for
toxicities seem to be the treatment-limiting factors. Since the TNF inhibitors have
recently been introduced in the market, there is not enough data available regarding the
use of these drugs by rheumatologists. Very little information is available regarding
rheumatologists practice patterns, laboratory monitoring practices, and barriers they
perceive in prescribing these agents. This information can only be clarified with the
availability of data from evaluation of physician practice experiences. Thus, the goal of
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phase II of the study was to survey a national sample of rheumatologists and assess
their practice patterns with respect to the use of these three agents.

Conclusions for Phase II
The conclusions of this phase of the study are presented based on the objectives
proposed in the study.

Objective 1: Prescribing patterns for the three TNF inhibitors: adalimumab,
etanercept, and infliximab.
As expected, rheumatologists were prescribing the TNF inhibitors in patients
with moderate to severe RA. An important finding was that some rheumatologists had
broadened the official indication of these agents to patients with early-onset RA. In
patients with severe RA that inadequately responded to MTX alone, rheumatologists
reported using a combination of TNF inhibitor with a traditional DMARD indicating a
preference for combination treatments in patients with severe disease. Another finding
was that a majority of rheumatologists reported switching patients from one TNF
inhibitor to another TNF inhibitor due to lack of efficacy or adverse events of the first
one.

Objective 2: Rheumatologists’ preference for a particular TNF inhibitor.
The null hypothesis aimed to investigate that there is no preference for any
particular TNF inhibitor. The finding of the survey showed a preference for etanercept
followed by adalimumab and infliximab.
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Objective 3: Rheumatologist characteristics and perceived barriers in prescribing
TNF inhibitors and preference for a particular TNF inhibitor.
The null hypothesis aimed to investigate that there is no relationship of
preference for a particular TNF inhibitor and demographic, practice-related
characteristics, and perceived barriers in prescribing TNF inhibitors. The study
revealed that male rheumatologists preferred these agents to females. Also,
rheumatologists who preferred infliximab saw more patients per week compared to
other two TNF inhibitors. Rheumatologists who preferred infliximab perceived the
need for additional support for administration of infliximab compared with etanercept
and adalimumab. Rheumatologists who preferred etanercept perceived patient
compliance as a barrier compared to those who preferred adalimumab. However, both
perceptions were considered as minor problems.

Objective 4: Laboratory monitoring practices and the frequency of tests ordered for
patients on TNF inhibitors.
The complete blood count tests and the purified protein derivative tests were
ordered by a majority of the rheumatologists for all three TNF inhibitors. The antinuclear antibody tests and creatinine tests were ordered by only one-third to half of the
rheumatologists. Also, there was a wide variation in terms of frequency at which these
tests were ordered. The most commonly used doses for adalimumab and etanercept
were 40 mg every other week and 25 mg twice every week, respectively. A range of
doses and dosing intervals were reported with the use of infliximab.
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Objective 5: Recommended monitoring guidelines for patients with RA on adalimumab,
etanercept, and infliximab.
A majority of rheumatologists reported following ACR monitoring guidelines.
Since there are no established monitoring guidelines for TNF inhibitors, it is believed
that rheumatologists were using guidelines based on their past experiences with
traditional DMARDs. Another finding was that one-fourth of the rheumatologists did
not follow any monitoring guidelines for patients who used TNF inhibitors.

Objective 6: Rheumatologist characteristics and perceived barriers in prescribing
TNF inhibitors and monitoring guidelines.
The null hypothesis aimed to investigate that there is no relationship of
adherence to monitoring guidelines and demographic, practice-related characteristics,
and perceived barriers in prescribing TNF inhibitors. Rheumatologists who followed
monitoring guidelines were a little younger and had fewer years of practice. Although
the results were significantly different indicating a difference in age and years of
practice between those who follow guidelines and those who don’t, it only remains to
be seen if a difference of two years is relevant in clinical practice.

Objective 7: Perceived barriers in prescribing TNF inhibitors.
Costs to patients and insurance coverage were perceived as major problems and
patient preference, route of administration, and side effects were perceived as minor
problems. Among the three TNF inhibitors, the perception for costs to patients and
insurance coverage was a little lower for infliximab compared to etanercept and
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adalimumab. For factors like patient preference, route of administration, and side
effects, the perception was lower for infliximab compared to etanercept and
adalimumab.

Implications of Study Findings
The study was undertaken to assess the cost-effectiveness of TNF inhibitors in
patients that inadequately respond to MTX alone. The study also aimed to assess the
prescribing patterns and laboratory monitoring practices of rheumatologists using TNF
inhibitors. The study findings should be useful to decision makers such as payers and
prescribers.

Implications to the Payers
The study results indicate that the combination of etanercept and MTX is the
most cost-effective option in patients with RA that inadequately respond to MTX alone.
Also, the survey results indicate that rheumatologists prefer etanercept to infliximab
and adalimumab for a variety of reasons, including method of administration and
adverse-events profile. Patients with greater disease severity incur high costs and these
new therapies can have long-term savings by preventing functional decline and
subsequent hospitalization and surgery in these patients. Even though the long-term
impact of these agents on joint damage cannot be determined with certainty at present,
a reduced risk of surgery will reduce the demand for orthopedic services. However, the
disparity in reimbursement based on different routes of administration for these
medications underscores the need for investing in long-term positive outcomes through
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aggressive treatment of RA. Managed care organizations need to consider these issues
when making formulary and coverage decisions.

The study findings also indicate that there are no established treatment
guidelines for these agents. Rheumatologists are prescribing these agents to patients in
mild RA and also switching patients from one TNF inhibitor to another without much
evidence available regarding the usefulness of this practice. The practice of switching
may be effective but if not, it may be a waste of time and money. Thus, there is a need
to develop strategies to increase the appropriate prescribing and monitoring of these
agents till sound evidence are available supporting the usefulness of switching TNF
inhibitors or using these agents in patients with early forms of the disease.

Implications to the Prescribers
The use of TNF inhibitors to treat RA has implications for current practices in
rheumatology. The widespread use of etanercept and adalimumab would place a
greater demand on outpatient services. This would include increased involvement of
health care providers like nurses to teach patients to self-administer injections and to
provide disease and drug monitoring services. The widespread use of infliximab will
lead to greater utilization of rheumatology facilities and support staff. Currently there
are no monitoring guidelines available and there is a wide variation in laboratory
monitoring practices among rheumatologists. Thus, interested practitioners,
manufacturers, and policymakers should revisit old monitoring guidelines or perhaps
implement new monitoring guidelines for the use of these newer agents.
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Limitations of the Study
Both phases of the study have some limitations and these are discussed in the
following section. These limitations need to be considered when deriving inferences
from the reported results.

Limitations of Phase I
1. The main limitation relates to available data. An ideal source would have been
a very long-term, randomized study with a large sample size examining the
efficacy and resources utilized by all the therapeutic options in patients with RA
that inadequately respond to MTX alone. In the absence of such a study,
evidence had to be assembled from a range of sources and these sources have
their advantages and disadvantages from a health economic perspective. Thus,
the results of any modeling study need to be treated with some degree of
caution.

2. The base-case analysis in the decision analytic model assumes that the baseline
characteristics of the study patients across RCTs are comparable based on their
close similarities in important baseline demographic and clinical characteristics.
It is a general view that absolute comparability across different treatments can
be established through randomization. Currently, such data does not exist and it
is doubtful whether all the treatment options considered in the analysis would be
evaluated using a single head-to-head randomized controlled clinical trial in the
near future.
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3. The efficacy data for each treatment option except for adalimumab plus MTX
and standard MTX treatment comes from a single respective RCT. Therefore,
there will be generalizability issues with the base-case estimates used in the
Phase I of the study. However, sensitivity analyses were conducted to address
this limitation and the results obtained seemed to be robust at different values of
input parameters.

4. The three TNF inhibitors and leflunomide have different modes of
administration. Since no data is available indicating differing rates of
compliance among the different TNF inhibitors and leflunomide in patients with
RA, the potential impact of compliance was not considered in the model. The
model assumed 100% compliance. This assumption was necessary to fully
quantify the costs and consequences of introducing these agents under ideal
conditions. However, it would be important to see whether the ICERs change
when compliance is introduced in the model.

5. It was assumed that patients who did not respond to the treatments were
switched to palliative care. Currently, there is no data to show the actual
distribution of time a patient spends on each of these drugs. Also, in actual
clinical settings, if the patient fails to respond to one agent, rheumatologists may
switch the patient to a different DMARD or a TNF inhibitor. Thus, a sequential
use of DMARDs could have been a better comparator. Given the complexity of
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treatment regimens, it is very difficult to decide on the sequences of DMARDs
and also the placement of TNF inhibitors in these regimens.

Limitations of Phase II
1. This phase of the study was a mail survey and therefore all the limitations of a
mail survey will be inherent in this study. Some of these limitations include
measurement errors due to respondents not understanding the instructions or
items, and recall bias, which can affect the accuracy of inferences drawn from
the survey responses.

2. Even though the survey instrument has face and content validity, it has not been
otherwise validated.

3. The nonresponse bias analysis revealed differences in some variables such as
age and years in practice between respondents and nonrespondents. Caution
should, therefore, be exercised when extrapolating the findings to the entire
rheumatologist population.

Recommendations for Future Research
The model presented in the study was populated using different data sources
and each of the sources had their own strengths and limitations. The majority of data
came from clinical trials which are conducted under controlled conditions and therefore
do not reflect the real clinical setting. Future studies should try and incorporate data in
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the model from observational study. For example, various TNF registries have been
established all over world. It is too early to get such a data from the registry however,
in the future; these might provide refinement of estimates such as response rates,
withdrawal rates, and long-term disability progression. These data can also be useful in
estimating the compliance of different drugs. Other priorities for future research should
include estimating costs associated with RA incurred by patients and their families,
including a fuller coverage of adverse events of TNF inhibitors and other traditional
DMARDs.

Strategies for treating RA are potentially very complex and could include
combination treatments, triple therapies, or a sequence of drugs. A number of events
such as joint replacement, hospitalization, switching due to lack of efficacy or adverse
events take place in a patient’s lifetime. An advanced modeling technique such as
discrete event simulation can be used to represent such structure and produce a realistic
set of virtual patient histories thereby giving a more accurate estimation.

203

BIBLIOGRAPHY
American College of Rheumatology (ACR) Subcommittee on Rheumatoid Arthritis
Guidelines. (2002). Guidelines for the management of Rheumatoid Arthritis: 2002
Update. Arthritis Rheum.,46 (2),328-346.
Albert, D.A., Aksentijevich, S., Hurst, S., Fries, J.F., & Wolfe, F. (2000). Modeling
therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov
model. J Rheumatol, 27,644-52.
Allaire, S.H., Prashker, M.J., & Meenan, R.F. (1994). The costs of rheumatoid arthritis.
Pharmacoeconomics, 6 ,513-522.
Bansback, N., Brennan, A., & Ghatnekar, O. (2004). The cost-effectiveness of
adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in
Sweden. Ann Rheum Dis; Published Online First [date of publication].
Doi:10.1136/ard.2004.027565.
Bansback, N. J., Regier, D. A., Ara, R., Brennan, A., Shojania, K., Esdaile, J. M. et al.
(2005). An overview of economic evaluations for drugs used in rheumatoid arthritis:
focus on tumour necrosis factor-alpha antagonists. Drugs, 65, 473-496.
Barrett, E.M., Scott, D.G., Wiles, N.J., Symmons, D.P. (2000). The impact of
rheumatoid arthritis on employment status in the early years of disease: a UK
community based study. Rheumatology, 39,1403-9.
Barton, P., Jobanputra, P., Wilson, J., Bryan, S., & Burls, A. (2004). The use of
modeling to evaluate new drugs for patients with a chronic condition: the case of
antibodies against tumor necrosis factor in rheumatoid arthritis. Health Technol Assess,
8, (11), iii,1-91.
Blumenauer, B., Coyle, D., & Tugwell, P. (2002). Pharmacoeconomics of long-term
treatment of rheumatoid arthritis. Expert.Opin.Pharmacother., 3, 417-422.
Brennan, A. & Akehurst, R. (2000). Modelling in Health Economic Evaluation. What is
its place? What is its value? Pharmacoeconomics, 17: 445-459.
Brennan, A., Bansback, N., Conway, P., et al. (2001). Modelling the cost-effectiveness
of etanercept in adults with rheumatoid arthritis in the UK. Arthritis Rheum, 44, Suppl.
9, 157.
Brennan, A., Bansback, N., Reynolds, A., & Conway, P. (2003). Modelling the costeffectiveness of etanercept in adults with rheumatoid arthritis in the UK.
Rheumatology, 42,1-13.
Briggs, A. & Sculpher, M. (1998). An introduction to Markov modelling for economic
evaluation. Pharmacoeconomics, 13, 397-409.
204

Cairns, A.P., & Taggart, A.J. (2002). Anti-tumor necrosis factor therapy for severe
inflammatory arthritis: Two years experience in Northern Ireland. Ulster Med J., 71,
(2),101-105.
Callahan, L. F. (1998). The burden of rheumatoid arthritis: facts and figures. J
Rheumatol Suppl, 53, 8-12.
Centers for Medicare and Medicaid services. Available at:
http://www.cms.hhs.gov/providers/pufdownload/default.asp?. Accessed on February 14,
2005
Chiou, C. F., Wanke, L. K., Reyes, C, et al. (2003). A cost-efficacy comparison of
biologic agents in the treatment of rheumatoid arthritis. Ann Rheum Dis., 62, Suppl. 1,
353.
Choi, H. K., Seeger, J. D., & Kuntz, K. M. (2002). A cost effectiveness analysis of
treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol, 29, 11561165.
Choi, H. K., Seeger, J. D., & Kuntz, K. M. (2000). A cost-effectiveness analysis of
treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis
Rheum., 43, 2316-2327.
Choy, E. H. (2004). Two is better than one? Combination therapy in rheumatoid
arthritis. Rheumatology, 43,1205-1207.
Cimino, W.G., & O’Malley, M. J. (1998). Rheumatoid arthritis of the ankle and hindfoot. Rheum Dis Clin North Am., 24,157-172.
Data TreeAge Software Inc. (2002). Healthcare user’s manual. Massachussetts.
DeLeeuw, E. (1992). Data quality in mail, telephone, face to face surveys. Amsterdam:
TT Publikaties.
Dillman, D. A. (1999). Mail and internet surveys-the tailored design method. 2nd ed.
New York: Wiley and Sons.
Doyle, J. J. (2001). Economic and quality of life impact of rheumatoid arthritis.
Managed Care, 10, (7), 15-18
Drug Topics Red Book. (2004). Fleming, T. (Ed). 108th ed., Medical Economics
Company, Montvale, NJ.
Drummond, M. F., O’Brien, B., Stoddart, G. L., & Torrance, G. W. (1998). Methods
for the economic evaluation of health care programmes. 2nd ed., Oxford, United
Kingdom: Oxford University Press.

205

Emery, P. (2004). Review of health economics modelling in rheumatoid arthritis.
Pharmacoeconomics, 22, 55-69.
Erkan, D., Yazici, Y., Harrison, M. J., & Paget, S. A. (2002). Physician Treatment
preferences in rheumatoid arthritis of differing disease severity and activity: The impact
of cost on First-Line therapy. Arthritis Rheum., 47, (3),285-290.
Fernandes, A., Madhavan, S., Amonkar, M., Dell, D., Islam, S., & Scott, V. (2003).
Evaluating utilization of beta-blockers as secondary prevention for post myocardial
infarction in a Medicaid population. (Doctoral dissertation, West Virginia University,
2003)
Fleischmann, R. & Yocum, D. (2004). Does safety make a difference in selecting the
right TNF antagonist? Arthritis Res. Ther., 6 Suppl 2, S12-S18.
Flendrie, M., Creemers, M. C., Welsing, P. M., den Broeder, A. A., & van Riel, P. L.
(2003). Survival during treatment with tumor necrosis factor blocking agents in
rheumatoid arthritis. Ann Rheum Dis., 62, ii, 30-3.
Gabriel, S. E. (2001). The epidemiology of Rheumatoid Arthritis. Rheum Dis Clin
North Am., 27, (2), 269-281.
Gabriel, S., Tugwell, P., O’Brien, B., Yelin, E., Drummond, M., Ruff, B., et. al. (1999).
Report of the OMERACT Task Force on Economic Evaluation. Outcome Measures in
Rheumatology. J Rheumatol., 27, 203-206.
Gallup, E. (2001). Coverage inequalities of new therapies for rheumatoid arthritis in a
managed care setting. Manag Care Interface,52-58, 69.
Genovese, M. C., Bathon, J. M., Martin, R.W. (2002). Etanercept versus methotrexate
in patients with early rheumatoid arthritis: a two-year radiographic and clinical
outcomes. Arthritis Rheum., 46,1443-50.
Gilbert, T. D., Smith, D., & Ollendorf, D.A. (2004). Patterns of use, dosing, and
economic impact of biologic agent use in patients with rheumatoid arthritis: a
retrospective cohort study. BMC Musculoskelet Disord., 5, 36.
Gold, M. R., Russell, L. B., Siegel, J. E., & Weinstein M. C. (1996). Cost-effectiveness
in health and medicine. New York: Oxford University Press.
Griffiths, R.I., Bar-Din, M., MacLean, C., Sullivan, E. M., Herbert, R. J., Yelin, E. H.
(2001). Patterns of disease modifying antirheumatic drug use, medical resources
consumption, and cost among rheumatoid arthritis patients. Ther Apher., 5, (2),92-104.
Guedes, C. (1999). Mortality in rheumatoid arthritis. Rev Rheum Engl Ed, 66,1895-9.

206

Haraoui, B. (2004). Is there a rationale for switching from one anti-tumor necrosis
factor agent to another? J Rheumatol, 31, 1021-22.
Harley, C.R., Frytak, J. R., & Tandon, N. (2003). Treatment compliance and dosage
administration among rheumatoid arthritis patients receiving infliximab, etanercept, or
methotrexate. Am J Manag Care, 9, 6, S136-S143.
Hochberg, M.C., Tracy, J.K., Holt-Hawkins, M., & Flores, R.H. (2003). Comparison of
efficacy of the tumor necrosis factor α blocking agents adalimumab, etanercept, and
infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann
Rheum Dis., 62, Suppl II, ii 13-ii16.
Homik, J. E., & Suarez-Alamor, M. (2004). An economic approach to health care. Best
Pract Res. Clin Rheumatol.,18, (2),203-218.
Jobanputra, P., Barton, P., Bryan, S., Burls, A. (2002). The effectiveness of infliximab
and etanercept for the treatment of rheumatoid arthritis: a systematic review and
economic evaluation. Health Technol Assess,6, (21),1-110.
Jobanputra, P., Wilson, J., Douglas, K., & Burls, A. (2004). A survey of British
rheumatologists’ DMARD preferences for rheumatoid arthritis. Rheumatology, 43,206210.
Kalton, G. (Ed.). (1987). Introduction to survey sampling. Sage University Paper series
on Quantitative Application in Social Sciences, Series/Number 07-035, Beverly Hills
and London, Sage Pubns.
Kavanaugh, A., Cohen, S., & Cush, J. J. (2004). The evolving use of tumor necrosis
factor inhibitors in rheumatoid arthritis. J Rheumatol, 31, 1881-1884.
Kavanaugh, A., Heudebert, G., Cush, J., & Jain, R. (1996). Cost valuation of novel
therapeutics in rheumatoid arthritis (CENTRA): A decision analysis model. Semin
Arthritis Rheum., 25, (5), 297-307.
Kleinbaum, D. G., Kupper, L. L. & Morgenstern, H. (1982). Epidemiologic research:
Principles and quantitative methods: New York: Van Nostrand Reinhold
Kobelt, G., Jonsson, L., Lindgren, P., Young, A., & Eberhardt, K. (2002). Modeling the
progression of Rheumatoid Arthritis. Arthritis Rheum., 46, (9), 2310-19.
Kobelt, G., Jonsson, L., Young, A., & Eberhardt, K. (2003). The cost effectiveness of
infliximab (Remicade ®) in the treatment of rheumatoid arthritis in Sweden and the UK
based on the ATTRACT study. Rheumatology, 42, 326-335.
Kobelt, G., Lindgren, P., & Young, A. (2002). Modelling the costs and effects of
leflunomide in rheumatoid arthritis. Eur J Health Econ., 3, 180-187.

207

Kremer, J.M. (2001). Rational use of new and existing disease modifying agents in
Rheumatoid Arthritis. Annals of Intern Med, 134, 695-706.
Kremer, J.M, Genovese, M., Cannon, G.W., Caldwell, J., Cush, J., Furst, D.E. et al.
(2004). Combination of leflunomide and methotrexate (MTX) therapy for patients with
active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a
randomized, double-blind, placebo-controlled trial. J Rheumatol., 31, 1521-1531.
Kremer, J.M, Genovese, M., Cannon, G.W., Caldwell, J., Cush, J., Furst, D.E. et al.
(2002). Concomitant leflunomide therapy in patients with active rheumatoid arthritis
despite stable doses of methotrexate. Ann Intern Med.,137, 726-733.
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S.,
et al. (2004). Radiographic, clinical, and functional outcomes of treatment with
adalimumab (a human Anti-Tumor Necrosis Factor Monoclonal Antibody) in patients
with active Rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis
Rheum.,50, (5), 400-1411.
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M. et
al. (2004). Therapeutic effect of the combination of etanercept and methotrexate
compared with each treatment alone in patients with rheumatoid arthritis: double-blind
randomized controlled trial. Lancet, 363, 675-81.
Lan, J., Chou, S., Chen, D., Chen, Y., Hsieh, T., Young, M. (2004). A comparative
study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients
with active rheumatoid arthritis: A 12-week, double-blind, randomized, placebocontrolled study. J Formos Med Asson, 103,618-213.
Lipsky, P. E., van der Heijde, D., Clair, E.W., Furst, D.E., Breedveld, F.C., Kalden,
J.R., et al. (2000). Infliximab and methotrexate in the treatment of rheumatoid arthritis.
New Eng J Med.,343, 1594-602.
Lipsky, P. E., & Kavanaugh, A. (1999). The impact of pharmaco-economic
considerations on the utilization of novel anti-rheumatic therapies. Rheumatology, 38,
Suppl. 2: 41-4.
Louie, S. G., Park, B., & Yoon, H. (2003). Biological Response Modifiers in the
management of rheumatoid arthritis. Am J Health Syst Pharm. 60, 346-55.
Maetzel, A. (2004). Defining therapeutic success in rheumatoid arthritis clinical trials:
from statistical significance to clinical significance. J Rheumatol, 31, 411-412.
Maetzel, A., Bombardier, C., Strand, V., Tugwell, P., & Wells, G. (1998). How
Canadian and US Rheumatologists treat moderate or aggressive Rheumatoid Arthritis:
A Survey. J Rheumatol., 25, 2331-8.

208

Maini, R., St. Claire, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M. et al.
(1999). For the ATTRACT study group. Infliximab (chimeric anti-tumor necrosis
factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients
receiving concomitant methotrexate: a randomized Phase III trial. Lancet, 354, 1932-9.
Malone, D. C., Singh, A., Wanke, L. A., et al. (2003). A cost-efficacy comparison of
adalimumab and etanercept in the treatment of rheumatoid arthritis. Ann Rheum Dis.,
62, Suppl. 1, 537.
Managed Care Lab Fee Schedule. Available at:
http://www.purdue.edu/hr/Benefits/mac.htm. Accessed on February 20, 2005
Meenan, R. F., Yelin, E. H., Henke, C. J., Curtis, D. L., Epstein, W. V. (1978). The
costs of rheumatoid arthritis. A patient oriented study of chronic disease costs. Arthritis
Rheum., 21, 827-833.
Michaud, K., Messer, J., Choi, H. K., & Wolfe, F. (2003). Direct medical costs and
their predictors in patients with rheumatoid arthritis: a three-year study of 7,527
patients. Arthritis Rheum., 48, 2750-2762.
Miller, D., & Homan, S. (1994). Determining transition probabilities. Med Decis
Making, 14, 52-58.
Moots, R., Taggart, A., & Walker, D. (2003). Biologic therapy in clinical practice:
enthusiasm must be tempered by caution. Rheumatology, 42, 614-616.
Moreland, L.W., Cohen, S.B., Baumgartner, S.W., Tindall, E.A., Bulpitt, K., Martin,
R., et al. (2001). Long-term safety and efficacy of etanercept in patients with
rheumatoid arthritis. J Rheumatol, 28, 1238-44.
Muennig, P. (2002). Designing and conducting cost-effectiveness analyses in medicine
and health care. 2nd ed., John Wiley & Sons, Inc.
Nuijten, M. J., Engelfriet, P., Duijn, K., Bruijn, G., Wierz, D., & Koopmanschap, M.
(2001). A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
Pharmacoeconomics, 19, 1051-64.
Physicians’ Desk Reference. (2005). Murray, L. (Ed.). Medical Economics Company,
Inc. Montvale, NJ.
Pope, J. E., Hong, P., & Koehler, B. E. (2002). Prescribing trends in Disease Modifying
Antirheumatic drugs for Rheumatoid Arthritis: A survey of Canadian Rheumatologists.
J Rheumatol., 29, 255-60.
Pinals, R. S. (1987). Survival in rheumatoid arthritis. Arthritis Rheum., 30, 473-5.

209

Pugner, K. M., Scott, D. I., Holmes, J. W., & Hieke, K. (2000). The costs of
rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum., 29, 30520.
Ruff, B. (1999). OMERACT: Economic evaluations and health policy. J Rheumatol.,
26, 2076-7.
Schnabel, A. (2004). Disease modifying Antirheumatic drugs: enhancing efficacy by
combination. Lancet, 363, 670-671.
Schwartzman, S., Fleischmann, R., & Morgan, G. J. (2004). Do anti-TNF agents have
equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther, 6, (suppl 2), S3S11.
Schwartzman, S., & Morgan, G. J. (2004). Does route of administration affect the
outcome of TNF antagonist therapy? Arthritis Res Ther, 6, Suppl 2, S19-S23.
Seymour, H. E., Worsley, A., Smith, J. M., & Thomas, S. H. L. (2001). Anti-TNF
agents for rheumatoid arthritis. Br J Clin Pharmacol., 51, 201:208.
Shaw, J. W., & Zachary, W. M. (2002). Applications of probabilistic sensitivity
analysis in decision analytic modeling. Formulary, 37, 32-40.
Silman, A. J., & Pearson, J. E. (2002). Epidemiology and genetics of rheumatoid
arthritis. Arthritis Res., 4, Suppl 3, S265-S272.
Smolen, J., ven der Heijde, D., Emery, P., et al. (2004). Infliximab inhibits radiographic
joint damage in patients with early rheumatoid arthritis regardless of clinical response
after 54-week treatment. Ann Rheum Dis, 63, Suppl. I, 260.
Sonnenberg, F. A., & Beck, J. R. (1993). Markov models in medical decision-making:
a practical guide. Med Decis Making, 13, 322-38.
Stone, C. E. (1984). The lifetime economic costs of rheumatoid arthritis. J Rheumatol.,
11, 819-827.
Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G. et al.
(1999). Treatment of active rheumatoid arthritis with leflunomide compared with
placebo and methotrexate. Arch Intern Med, 159, 2542-2550.
Terebelo, S. (2003). Rheumatoid arthritis: making the diagnosis – Board review. Clin
Rev., 13 (2), 61
Toussirot, E., & Wendling, D. (2004). The use of TNF-α blocking agents in rheumatoid
arthritis: an overview. Expert Opin Pharmacother, 5, (3), 581-594.

210

Tugwell P. (2000). Pharmacoeconomics of drug therapy for rheumatoid arthritis.
Rheumatology, 39, (suppl. 1), 43-47.
U.S. Census Bureau (Vital Statistics), the Official Statistics, Statistical Abstract of the
United States: 2002.
U.S. Department of Labor. Bureau of Labor Statistics. (http://stats.bls.gov). Accessed on
January, 14, 2005.
van Vollenhoven, R.F. (2004). Switching between biologicals. Clin Exp Rheumatol.,
22, Suppl. 35, S115-121.
van Vollenhoven, R.F., Ernestam, S., Harju, A., Bratt, J., & Klareskog, L. (2003).
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that
the combination is clinically more efficacious. Arthritis Res Ther., 5, R347-R351.
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H.,
Birbara, C. A., et al. (2003). Adalimumab, a fully human anti tumor necrosis factor α
monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking
concomitant methotrexate. Arthritis Rheum., 48, (1), 35-45.
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M.,
Fox, R. I., et al. (1999). A trial of etanercept, a recombinant tumor necrosis factor
receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
N Eng J Med, 340, 253-259.
Weinblatt, M. E., Kremer, J. M., Coblyn, J. S., Maier, A. L., Helfgott, S. M., Morrell,
M. et al. (1999). Pharmacokinetics, safety, and efficacy of combination treatment with
methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis
Rheum., 42, 1322-1328.
Welsing, P. M., Severens, J. L., Hartman, M., van Riel, P. L., & Laan, R. F. (2004).
Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis
factor-blocking agents and leflunomide for treating rheumatoid arthritis in the
Netherlands. Arthritis Rheum., 51, 964-973.
Wolfe, F., Albert, D. A., & Pincus, T. (1998). A survey of United States
Rheumatologists concerning effectiveness of Disease Modifying Antirheumatic Drugs
and Prednisone in the treatment of Rheumatoid Arthritis. Arthritis Care Res., 11, (5),
375-380.
Wolfe, F., Mitchel, D. M., Sibley, J.T., Fries, J. F., Bloch, D. A., Williams, C. A., et al.
(1994). The mortality of rheumatoid arthritis. Arthritis Rheum.,37, 481-94.
Wolfe, F., Rehman, Q., Lane, N. E., & Kremer, J. (2001). Starting a disease modifying
antirheumatic drug or biologic agent in Rheumatoid arthritis: Standards of practice for
RA treatment. J Rheumatol., 28, 1704-11.
211

Wolfe, F., & Zwillich, S. (1998). The long-term outcomes of rheumatoid arthritis. A
23-year prospective longitudinal study of total joint replacement and its predictors in
1,600 patients with rheumatoid arthritis. Arthritis Rheum., 41, 1072-82.
Wong, J. B., Ramey, D. R., & Singh, G. (2001). Long-term morbidity, mortality, and
economics of rheumatoid arthritis. Arthritis Rheum., 44, (12), 2746-2749.
Wong, J. B., Singh, G., & Kavanaugh, A. (2002). Estimating cost-effectiveness of 54
weeks of Infliximab for Rheumatoid Arthritis. Am J Med., 113, 400-408.
Wong, J.B. (2004). Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp
Rheumatol., 22, Suppl. 35, S65-S70.
Yazici, Y. & Erkan, D. (2004). Do etanercept-naive patients with rheumatoid arthritis
respond better to infliximab than patients for whom etanercept has failed? Ann Rheum
Dis., 63, 607-608.
Yazici, Y., Erkan, D., & Paget, S. A. (2003). Monitoring by rheumatologists for
Methotrexate-, Etanercept-, Infliximab-, and Anakinra-associated adverse events.
Arthritis Rheum., 48, (10), 2769-2772.
Yelin, E., & Wanke, L. A. (1999). An assessment of the annual and long-term direct
costs of rheumatoid arthritis: the impact of poor function and functional decline.
Arthritis Rheum, 42, 1209-1218.
Zentilin, P., Seriolo, B., Dulbecco, P., Caratto, E., Iiritano, E., Fasciolo, D., et al.
(2002). Eradication of Helicobacter pylori may reduce disease severity in rheumatoid
arthritis. Aliment Pharmacol Ther, 16 ,1291-1299.

212

APPENDIX A: FIRST COVER LETTER
Date: October 10, 2004
Dear Physician:
We are writing to seek your opinions on an important class of drugs that you
use in your practice. Tumor Necrosis Factor (TNF) inhibitors such as adalimumab,
etanercept, and infliximab, have advanced the treatment of Rheumatoid Arthritis.
Clinical trials with these drugs have shown that they may be more effective than
traditional agents because of their ability to prevent or control joint damage as well as
diminish pain. However, these drugs have been only recently introduced in the market,
and there are numerous questions regarding their appropriate dosage, monitoring
schedules, and target population.
The objective of the current research study is to assess the current treatment
practices of rheumatologists who use TNF inhibitors in patients with Rheumatoid
Arthritis. This research study is part of a doctoral (Ph.D.) dissertation project and is
being undertaken and funded by the West Virginia University School of Pharmacy.
Information obtained from this research study will be useful in determining common
practices and issues associated with the use of TNF inhibitors.
Your name was randomly selected from a national list of rheumatologists. We
hope that you will participate by completing the attached questionnaire that asks about
your current treatment practices and experiences using TNF inhibitors in patients with
Rheumatoid Arthritis. The approximate time to complete the questionnaire is 5-10
minutes. To assure confidentiality, your responses will be coded and your name will
not appear in any data analysis or research reports. Therefore, we assure you of as
much confidentiality as legally possible. Your participation in this research study is
voluntary. You do not need to answer all questions even though we would prefer that
you do.
Your response will provide valuable information and is critical to the success of
the research study. Please return the completed survey in the enclosed postage-paid
business reply envelope.
If you have any questions or concerns, please do not hesitate to contact Khalid
Kamal at (304) 293-1442 or Dr. Suresh Madhavan at (304) 293-1652 at the West
Virginia University School of Pharmacy.
Thank you.
Sincerely,
Khalid Kamal, M.S.
Ph.D. Candidate

Suresh Madhavan, Ph.D.
Professor and Chairperson

Attachment
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APPENDIX B: SECOND COVER LETTER
November 15, 2004
Dear Physician:
About two weeks ago, we sent you a survey asking you about your current
treatment practices and experiences using Tumor Necrosis Factor (TNF) inhibitors in
patients with Rheumatoid Arthritis. If you have already completed and returned the
survey, we thank you for your time and participation. If you have not completed the
survey, we request you to kindly do so.
We understand that you are busy or may not have received the initial survey.
However, your views are extremely important to us, and the information obtained from
this research study would be very useful in determining common practices and issues
associated with the use of TNF inhibitors. Therefore, we are again sending you this
survey and would appreciate it if you will take a few minutes to complete the survey
and return it in the postage-paid business reply envelope.
This research study is part of a doctoral (Ph.D.) dissertation project and is being
undertaken and funded by the West Virginia University School of Pharmacy. To assure
confidentiality, your responses will be coded and your name will not appear in any data
analysis or research reports. Therefore, we assure you of as much confidentiality as
legally possible. Your participation in this research study is voluntary. You do not need
to answer all questions even though we would prefer that you do.
If you have any questions or concerns, please do not hesitate to contact Khalid
Kamal at (304) 293-1442 or Dr. Suresh Madhavan at (304) 293-1652 at the West
Virginia University School of Pharmacy.
Thank you.
Sincerely,
Khalid Kamal, M.S.
Ph.D. Candidate

Suresh Madhavan, Ph.D.
Professor and Chairperson

Attachment
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APPENDIX C: STUDY SURVEY
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Current Treatment Practices using Tumor Necrosis Factor Inhibitors in
Rheumatoid Arthritis
INSTRUCTIONS: The first section of the questionnaire gathers prescribing information on specific Tumor
Necrosis Factor (TNF) inhibitors [adalimumab (Humira®), etanercept (Enbrel®), and infliximab (Remicade®)]
for patients with Rheumatoid Arthritis (RA). Please answer the questions carefully. All responses will be
kept confidential.

Section A
1. In what patient population do you normally use the following TNF inhibitor/s: adalimumab
(Humira®), etanercept (Enbrel®), and infliximab (Remicade®): (Please check all that apply)

TNF inhibitors

Newly Diagnosed

Adalimumab (Humira®)
Etanercept (Enbrel®)
Infliximab (Remicade®)





2. I do not use TNF inhibitors



Patient Population
Mild RA
Moderate RA








Severe RA




(If you have checked this box, please go to Section C)

3. In patients diagnosed with Rheumatoid Arthritis in whom you determine a TNF inhibitor is necessary,
which TNF inhibitor are you most likely to prescribe? (Please rank in the order of preference with 1
being your first choice)
TNF Inhibitor
Rank
Adalimumab (Humira®)
Etanercept (Enbrel®)
Infliximab (Remicade®)

________
________
________

4. In patients who have severe RA and who have failed to respond to methotrexate, please indicate how
you would use a TNF inhibitor: (Please check all that apply)




TNF inhibitor alone
 TNF inhibitor and one other DMARD
TNF inhibitor and 2 other DMARDs  No TNF inhibitor
Other treatment or approach (please specify) _______________

5. a. In your practice, have you ever switched any patient from one TNF inhibitor to a different TNF
inhibitor due to inadequate response or side effects?
 No

 Yes

b. If yes, please indicate in general, your reason(s) for switching______________________________
_________________________________________________________________________________
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INSTRUCTIONS: The following questions are regarding the use of [adalimumab (Humira®), etanercept
(Enbrel®), and infliximab (Remicade®)] in your practice. Please answer the questions carefully. All responses will
be kept confidential.
Section B
1. The following questions are regarding the use of Adalimumab (Humira®)
a. Please indicate the typical dose and frequency of dosing of adalimumab (Humira®) that you use for
patients with RA in your practice.
Dose for newly diagnosed RA
Dose for mild RA
Dose for moderate RA
Dose for severe RA

____________
____________
____________
____________

mg every_________ week
mg every_________ week
mg every _________ week
mg every _________ week

b. Which laboratory tests do you routinely order for adalimumab (Humira®) and how frequently do you
order these tests? (Please check all that apply)
Tests
Antinuclear Antibody test (ANA)
Complete blood cell count (CBC)
Chest radiography
Creatinine
Purified protein derivative (PPD)

Tests ordered

How frequently?
Every
Every
Every
Every
Every







________ week(s)
________ week(s)
________ week(s)
________ week(s)
________ week(s)

2. The following questions are regarding the use of Etanercept (Enbrel®)
a. Please indicate the typical dose and frequency of dosing of etanercept (Enbrel®) that you use for
patients with RA in your practice.
Dose for newly diagnosed RA
Dose for mild RA
Dose for moderate RA
Dose for severe RA

____________
____________
____________
____________

mg every_________ week
mg every_________ week
mg every _________ week
mg every _________ week

b. Which laboratory tests do you routinely order for etanercept (Enbrel®) and how frequently do you
order these tests? (Please check all that apply)
Tests
Antinuclear Antibody test (ANA)
Complete blood cell count (CBC)
Chest radiography
Creatinine
Purified protein derivative (PPD)

Tests ordered






How frequently?
Every
Every
Every
Every
Every

________ week(s)
________ week(s)
________ week(s)
________ week(s)
________ week(s)

3. The following questions are regarding the use of Infliximab (Remicade®)
a. Please indicate the typical dose and frequency of dosing of infliximab (Remicade®) that you use for
patients with RA in your practice.
Dose for newly diagnosed RA
Dose for mild RA
Dose for moderate RA
Dose for severe RA

____________
____________
____________
____________

mg every_________ week
mg every_________ week
mg every _________ week
mg every _________ week
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b. Which laboratory tests do you routinely order for infliximab (Remicade®) and how frequently do you
order these tests? (Please check all that apply)
Antinuclear Antibody test (ANA)
Complete blood cell count (CBC)
Chest radiography
Creatinine
Purified protein derivative (PPD)

Every
Every
Every
Every
Every







________ week(s)
________ week(s)
________ week(s)
________ week(s)
________ week(s)

4. Please indicate the extent to which you feel each of the following factors are problematic to using
specific TNF inhibitors in patients with Rheumatoid Arthritis. Circle the number on the continuum
between 1 and 7 (1=no problem and 7=major problem) that best describes your opinion for each
specific TNF inhibitor.
Adalimumab (Humira®)
Major
Problem

Etanercept (Enbrel®)
No
Problem

Major
Problem

Infliximab (Remicade®)

Factors

No
Problem

No
Problem

Major
Problem

Age of patient

1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7

Costs to the patient

1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7

Efficacy of this TNF
inhibitor in your
experience

1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7

Insurance / Formulary
coverage

1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7

Patient compliance
with this therapy

1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7

Patient preference for
this TNF inhibitor

1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7

Route of administration
of this TNF inhibitor

1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7

Side-effects of this
TNF inhibitor

1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7

Support for administering
infusions
1 2 3 4 5 6 7

1 2 3 4 5 6 7

1 2 3 4 5 6 7
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INSTRUCTIONS: This section of the questionnaire gathers information about you and your practice.

Section C
1. Age _________Years
2. Gender:



Male



Female

3. Number of years in practice as a rheumatologist: ______________ Years
4. Your primary practice site is:


Hospital based



Others, please specify _________________



University-affiliated Hospital



Solo, Office-based



Group, office-based

5. Average number of RA patients seen per week _____________
6. Average number of prescriptions written per week for each drug:
Adalimumab (Humira®)
Etanercept (Enbrel®)
Infliximab (Remicade®)

________
________
________

7. Please indicate which of the following monitoring guidelines you follow for patients with RA on
adalimumab (Humira®), etanercept (Enbrel®), or infliximab (Remicade®)?
ACR
Adalimumab (Humira®)
Etanercept (Enbrel®)
Infliximab (Remicade®)





EULAR ACR & EULAR









None

Other
(Please specify)





COMMENTS
If there is anything else that you would like to tell us, please use this space to provide your comments.

****THANK YOU FOR YOUR TIME AND ASSISTANCE!****
Please return the completed survey in the enclosed business reply envelope.
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APPENDIX D: NON-RESPONSE SURVEY
Current Treatment Practices Using TNF Inhibitors in Rheumatoid Arthritis:
Non-Response Survey
Dear Physician:
During the past two months you may have received two or three mailings of a questionnaire
asking you about your current treatment practices and experiences using Tumor Necrosis
Factor (TNF) inhibitors in patients with Rheumatoid Arthritis. We realize that you have been
very busy and have chosen not to answer the survey. Since your views are extremely important
to us, we would like to know your reason for not responding to this survey and some key
information for the research study.
This research study is part of a doctoral (Ph.D.) dissertation project and is being undertaken and
funded by the West Virginia University School of Pharmacy. Your participation in this research
study is voluntary. You do not need to answer all questions even though we would prefer that
you do. Your responses will be coded, and your name will not appear in any data analysis or
research reports. Therefore, we assure you of as much confidentiality as legally possible.
Please answer the few questions below and mail it to us in the postage-paid business reply
envelope. If you have any questions or concerns, please do not hesitate to contact us at (304)
293-1442 or (304) 293-1652.
Sincerely,

Khalid Kamal, M.S.
Ph.D. Candidate

Suresh Madhavan, Ph.D.
Professor and Chairperson

Q1. I did not respond to the survey because:

I did not receive it
Forgot the survey
I did not have enough time to complete it
The survey was misplaced
Survey was biased
Topic was irrelevant

I do not respond to mail surveys
The survey was too long
The survey was confusing
I am not interested in such studies
No incentive to complete it
Other reasons (Please
specify):_________
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Q2. In what patient population do you normally use the following TNF inhibitor/s:
adalimumab (Humira®), etanercept (Enbrel®), and infliximab (Remicade®): (Please check
all that apply)
Patient Population
TNF inhibitors
Newly Diagnosed Mild RA Moderate RA
Adalimumab (Humira®)




Severe RA


Etanercept (Enbrel®)









Infliximab (Remicade®)









Q3. I do not use TNF inhibitors



Q4. Demographics:
1. Age _________Years
2. Gender:

 Male

 Female

3. Number of years in practice as a rheumatologist: ______________ Years
4. Your primary practice site is:

 Hospital based

 University-affiliated Hospital

 Solo, Office-based

 Group, office-based  Others, please specify _________________
6. Average number of RA patients seen per week _____________
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